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Coeliac disease is a common small intestinal disorder affecting approximately 1% 
of the Northern European population. It is caused by an inappropriate immune response to 
dietary gluten found in wheat, rye, barley and, for a small minority of patients, oats. There 
is mounting evidence to suggest that the immune response of coeliac disease is not purely 
driven by gluten-sensitive T lymphocytes but also by an innate immune response mediated 
through interleukin-15. 
Dietary gluten comprises of two major protein fractions, gliadins and glutenins. 
Considerable research has been carried out on the immunostimulatory components in wheat 
gliadin. Glutenins, newly discovered to be toxic to coeliac individuals, have limited 
evidence describing their immunostimulatory potential in coeliac disease. Glutenins can be 
further differentiated by their molecular weight into low and high molecular weight 
fractions. Small intestinal T-cell studies suggest that an in vitro response to certain high 
molecular weight glutenin proteins may occur in some, but not all, coeliac individuals. 
There is even less evidence available concerning the coeliac disease toxicity of low 
molecular weight glutenin proteins. The stimulating epitopes within these proteins are not 
fully understood.  
This thesis describes the immunostimulatory potential of peptides contained in high 
molecular weight glutenins, glut 04 p721-735, and in low molecular weight glutenins, glt 
156 p44-59, that have been implicated in a small number of coeliac individuals. The 
adaptive immune response to these peptides has been measured by proliferation assays 
using gluten-sensitive small intestinal lymphocytes and measurement of their interferon-γ 
secretion. The innate immune response has been assessed by morphometric measurement of 
small intestinal biopsies following overnight incubation with these peptides, followed by 
interleukin-15 assessment via secretion into the tissue culture supernatant. 
A number of attempts have been made to raise monoclonal antibodies to these 
peptides. A variety of immunisation schedules have been attempted in host mice. A number 
of cell fusion experiments have been performed without success. The possible reasons for 
this lack of success are discussed. 
Results generated by in vitro studies of coeliac small intestinal explants and isolated 
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Chapter 1: Introduction 
 
 
Coeliac disease (CD) is also known as Coeliac Sprue or gluten-sensitive enteropathy. It is a 
common small intestinal disorder caused by an inappropriate immune response to dietary 
gluten. Ingestion of wheat, rye or barley proteins in susceptible individuals triggers an 
inflammatory response particularly in the proximal small intestinal mucosa causing damage 
to the villous architecture. In a small minority of patients this also happens with oat 
proteins. The disease manifests itself as a generalised malabsorption which typically 
presents as weight loss, diarrhoea or disorders associated with specific nutrient deficiencies 
such as anaemia or osteoporosis. However, since the advent of highly sensitive serological 
screening tests, less well defined forms of the disease are being increasingly recognised. 
Treatment is the life long, complete avoidance of gluten from the diet. 
 
1.1  History of Coeliac Disease 
One of the first descriptions of coeliac disease came from Areteus the Cappadocian who 
lived in the 2
nd
 Century AD. He described the characteristic stool and noticed that it was 
more common in women than in men, and that children could also be affected (Adams 
1856). However, one of the first modern documented descriptions of coeliac disease was a 
report written by the paediatrician, Samuel Gee in 1888 entitled “On the Coeliac Affection” 
after a lecture at Great Ormond Street Hospital. The report included a particularly elaborate 
description of the appearance of the stools from a patient suffering from “the coeliac 
affliction”. Interestingly, the author speculated that the cause of the disease was probably 
diet-related. It was noted that if the diet was the cause however, this did not explain how in 
a family of children all raised the same way only one child would suffer from the disease. 
He observed the symptomatic improvement of a child who was “fed upon a quart of the 
best Dutch mussels daily” but who relapsed when the season for mussels was over. It is not 
clear whether this diet consisted solely of mussels, but presumably the child’s improvement 
was as a result of the absence of dietary gluten, although this was not understood at the 
time. An avoidance of starch, amongst other foods, was recommended. In 1924, an 
American physician named Dr Hass recommended a diet restricting the use of 
carbohydrates, except ripe bananas, and fat, which was known as “the banana diet”. This 
27 
diet was used extensively until the gluten-free diet was introduced. In Britain during the 
Second World War, coeliac children were allocated rations of dried bananas as a 
supplement. However, the cause was not realised until the early 1950s during the flour 
shortages in the Second World War when a Dutch physician, Dicke, noticed that the 
condition of many of his coeliac patients improved. His subsequent experiments lead to 
identification of wheat and related cereals as being the trigger for CD (Dicke 1953a and b).  
 
1.2  Epidemiology 
Early estimations of the prevalence of CD indicated that it was an uncommon disorder. 
This has now changed due to the advent of improved serological testing and endoscopic 
evaluation. Approximately 1% of the UK population has been reported (West 2003) where 
previously it was thought to affect 1:8000 in England and Wales in the 1950s (Fasano 
2001). Coeliac disease has been found in many countries now across the world (Cook 2000, 
Gandolfi 2000, Gomez 2001, Hovell 2001, Imanzadeh 2005, Sood 2006, Ben Hariz 2007, 
Oliveira 2007, Abu-Zekry 2008, Mustalahi 2010, Wu 2010, Alarida 2011, Dalgic 2011, 
Xin-Qiong 20011). There is no data at present in sub-Saharan Africa although the highest 
prevalence of coeliac disease is to be found in the Sahrawi population of Arab-Berber 
origin living in Algeria (Catassi 1999). High levels of consanguinity, high frequencies of 
HLA-DQ2 and heavy gluten ingestion are potential explanations. Coeliac disease is known 
to be rare in Afro-Caribean individuals (Brar 2006). 
 
1.3  Clinical Features of coeliac disease 
1.3.1 Classical coeliac disease 
The clinical manifestations of coeliac disease vary greatly and although this was perceived 
as a purely paediatric disease, the diagnosis is increasingly being made in adult life.  
In adults, CD can manifest as a variety of symptoms presenting to almost any hospital 
department. The presenting symptoms may be varied including gastrointestinal, metabolic, 
neurological or psychological. The most common presenting gastrointestinal symptom is 
diarrhoea which can be continuous, intermittent or alternated with periods of constipation. 
It may be accompanied by weight loss, bloating, anorexia or abdominal pain. Isolated 
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increase in serum aminotransferase level caused by mild, non-progressive liver 
inflammation is also a common presentation (Rubio-Tapia 2007). 
Approximately 50% of coeliac patients do not have clinically significant diarrhoea and 
present with less severe symptoms such as lassitude, weakness or weight loss. Anaemia is a 
frequent finding in coeliac disease and may be the presenting feature (Halfdanarson 2007). 
Microcytic anaemia, secondary to iron deficiency anaemia is highly prevalent and is 
frequently the sole manifestation of the disease; oral iron supplementation will prove 
useless in these cases. Macrocytic anaemia may occur as a result of folate or B12 deficiency. 
This deficiency was previously thought to be unusual in CD because B12 is absorbed in the 
terminal ileum, the distal part of the small intestine, and coeliac pathology primarily occurs 
proximally. Studies have reported low serum vitamin B12 levels in untreated patients 
(Dahele 2001). Low calcium and vitamin D absorption may give rise to osteomalacia and 
bone pain, with an increasing risk of developing osteoporosis. 
1.3.2  Silent and latent coeliac disease 
The true prevalence of CD within a population is difficult to estimate as many affected 
individuals will not display any symptoms; the disease is therefore undetected. These 
patients are said to have a “silent” form of the disease- these individuals have positive 
coeliac serology with an abnormal small intestinal mucosa. “Latent” coeliac disease is a 
poorly understood condition where individuals are found to have positive serology but 
normal small bowel biopsy whilst on a gluten-containing diet. Latent coeliac patients do 
not display any symptoms but they may have had some symptoms in the past or may 
develop them in later life. 
These cases of CD, often undetected, make up a large part of what is now frequently 
described as the “coeliac iceberg”, with clinically diagnosed cases forming only the tip 
(Catassi 1994) see Figure 1.1 The coeliac iceberg. This concept was emphasised by a 
multicentre, screening study undertaken in Italy, where it was found that for every 
diagnosed coeliac patient seven went undiagnosed. Those were subsequently confirmed by 
biopsy to have the disease (Catassi 1996). Screening relatives of individuals with coeliac 






































1.4  Pathogenesis of coeliac disease  
The pathophysiology of coeliac disease is not fully understood, but what is known is 
summarised in Figure 1.2 and below. 
1.4.1 T-cells in lamina propria 
Coeliac disease occurs in genetically susceptible individuals in possession of particular 
human leucocyte antigen (HLA) class II molecules with approximately 95% of patients 
expressing human leucocyte antigen (HLA) -DQ2 and the remainder HLA-DQ8 (Sollid 
1993). The HLA-DQ2 or DQ8 molecule is responsible for antigen recognition (Sollid 
2002). Digested gluten peptides enter the lamina propria of the small intestine either 
through the enterocytes or paracellularly (Zimmer 2010), where they must bind to HLA 
molecules on dendritic antigen-presenting cells enabling the peptides to be presented to T-
cells. The HLA molecules have a peptide binding groove in which there are discrete 
binding pockets, found in positions 1, 4, 6, 7 and 9, which can accommodate amino acid 
side chains. HLA-DQ2 and DQ8 have a preference for binding peptides with negatively 
charged anchor residues; HLA-DQ2 at positions 4, 6 or 7 (Johansen 1996, van de Wal 
1996) and HLA-DQ8 at positions 1 and 9 (Kwok 1996, Suri 2005). Figure 1.3 is a 
diagrammatic representation of the binding of an HLA-DQ2 molecule to a γ-gliadin epitope 
that has undergone selective deamidation (Arentz-Hansen 2002). 
Gluten proteins contain 30-35% glutamine and 10-15% prolamine residues. Gluten, as a 
result, contains very few negatively charged amino acids. These proteins undergo a process 
of partial selective deamidation where certain glutamine residues are converted to glutamic 
acid, mediated by tissue transglutaminase-2 (tTG2) (Molberg 1998). The presence of many 
proline residues, resistant to digestive enzymes, ensure that many immunostimulatory QXP 
motifs survive digestion in fragments comprising of 20-40 amino acid peptides (Shan 
2002), increasing the Immunogenicity of the peptide. This allows peptides large enough for 
T-cell recognition to be presented. 
Gluten-sensitive T helper cells proliferate in response to presentation of the antigen and 
release interferon-γ (IFN-γ) (Nilsen 1995, Troncone 1998). This expands cytotoxic T-cells 
in the lamina propria. IFN-γ also stimulates fibroblasts to release matrix metalloproteases 
(Daum 1999) which degrade the extracellular matrix, and also stimulates disease-specific 
plasma cells to produce anti-tissue transglutaminase antibodies which are initially released 
into the lamina propria (Sollid 1997). It is these enzyme antibodies in the blood stream that 
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can be quantified to screen for coeliac disease as a prelude to referral for diagnostic 
endoscopy and distal duodenal biopsy, to permit histological evaluation of the small 
intestinal mucosa.  
1.4.2  Intra-epithelial lymphocytes  
Intra-epithelial lymphocytes (IELs) are localised between intestinal epithelial cells and are 
thought to play an important role in immune surveillance of the epithelium. They are an 
abundant and heterogeneous population of T cells that are upregulated in coeliac disease. 
They are specialised CD8 positive lymphocytes which can respond to antigens via a T-cell 
receptor, or natural killer (NK) cell receptors. The NK cell receptors NKG2D and CD94 are 
thought to kill enterocytes via MICA and HLA-E ligands expressed on the surface of 
enterocytes under stress, whereas NKG2A is thought to be protective through activation of 
TGF-β (Braud 1998). The role of IELs in the pathogenesis of coeliac disease is not fully 
understood however, they may represent the starting process of coeliac disease (Mäki 
2003).  
In the normal small intestine, IELs are normally comprised of approximately 75% CD8
+
T-
cell receptor (TCR) αβ+ and 15% TCR γδ+ cells (Jarry 1990). There is an expansion of both 
subsets in active coeliac disease (Kutlu 1993), possibly as a result of raised interleukin-15 
expressed and secreted by stressed enterocytes (Maiuri 2000 and 2003, Mention 2003, Hüe 
2004, Malamut 2010). These IELs are enriched with cytolytic proteins (Ciccocioppo 2001, 
Di Sabatino 2001, Oberhuber 1996). They produce large amounts of IFN-γ (Olaussen 2002) 
that are thought to contribute to the villous atrophy found in untreated coeliac disease. 
Following initiation of a gluten-free diet, there is recovery of the villous architecture with 
the numbers of CD8
+TCRαβ+ IELs returning to normal. In contrast the numbers of TCRγδ+ 
IELs remain high for many years afterwards (Kutlu 1993, Bhagat 2008). Current opinion 
suggests that CD8
+TCRαβ+ IELs exert a deleterious effect on epithelial cells that can be   
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Figure 1.2: Summary of key events in the pathogenesis of coeliac disease 
 
1. Gluten peptides, derived from luminal digestion, enter the lamina propria 
2. Selective deamidation of specific glutamine residues by tTG 
3. Dendritic cells present peptides bound to DQ2 
4 Recognition of peptide and proliferation by gluten-sensitiveT helper cells 
5. Cytokine production recruits and stimulates effector cells 
6. CD8
+
 cytotoxic T-cell population expands in lamina propria and epithelium 
7. Fibroblasts secrete matrix metalloproteinases which degrade the extracellular matrix 
8. Disease-specific antibody production by plasma cells  





Figure 1.3 Diagrammatic representation of the interaction between the DQ2 molecule 
peptide binding groove and an epitope from γ-gliadin. 
 
Key anchor points are at positions 1, 4, 6, 7 and 9 with negative charges preferred at 
positions 4, 6 and 7. E is the deamidated glutamine residues to glutamic acid. 
antagonized by TCRγδ+ IELs and that this regulatory function may be overwhelmed in 
active coeliac disease (Bhagat 2008). Indeed their persistence in coeliac patients on a GFD 
and the lack of elevation in patients with other small bowel enteropathies suggest a specific 
relationship between the pathogenesis of coeliac disease and TCRγδ+ IELs (Spencer 1989). 
The interaction between IELs’ natural killer cell receptor NKG2D with MICA, its ligand 
expressed on enterocytes under stress ensures that a toxic cascade of intracellular processes 
terminally damage the enterocyte. It is thought that MICA expression on the enterocytes is 
induced by gliadin, or its p31-49 peptide (see section 1.11.1) via IL-15 (Hüe 2004).Within 
these enterocytes, exosomes containing granzyme and perforin are released which 
ultimately destroy the enterocyte (Hüe 2004).  
TCRαβ+ CD8+ IELs represent an effector T-cell subset that mediates enterocyte cell 
destruction ultimately leading to villous atrophy in coeliac disease. The basis for this 
destruction is the recognition of stress ligands expressed on the surface of enterocytes. 
Whether this killing is mediated mainly by the natural killer receptors or whether activating 
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natural killer receptors lowers the activation threshold of the TCR allowing IELs to 
recognise the low-affinity self –antigens expressed by enterocytes remains unanswered. 
The role of TCRγδ+ IELs in the pathogenesis of coeliac disease is also unclear. There are 
no studies at present to conclude definitively that they play no decisive role, have a 
protective role or contribute to the pathogenesis of coeliac disease.  
In order for IELs to kill epithelial cells they need changes in the epithelium resulting in 
upregulation of IL-15 and non classical MHC class I molecules that are recognised by 
natural killer receptors as well as activation and expansion of HLA DQ2 or DQ8 restricted 
gluten-sensitive CD4+ T-cells in the lamina propria producing IL-21 and IFN-γ with other 
as yet undetermined factors.  
The relationship between normal IELs in coeliac disease and those found in refractory 
coeliac disease is very poorly understood. IELs in type 1 refractory coeliac disease (RCD) 
express TCR on their surface whereas in type 2 RCD IELs lack surface TCRs, see section 
1.7.1. The reason for this as well as the cause is not known and perhaps may represent 
another disease process leading to a more aggressive disease course. What is interesting is 
that the genome-wide association searches (see section 1.8) have not found epithelial 
specific genes associated with coeliac disease, unlike other inflammory disorders such as 
asthma (Zhang 2012). 
1.4.3 Interleukin-15 
Interleukin-15 (IL-15) is emerging as an important cytokine in regulating the IEL response 
in coeliac disease and refractory coeliac disease (RCD), see section 1.7.1. It is able to 
stimulate two natural killer cell receptors, CD94 and NKG2D, on IELs which are 
upregulated in active CD (Jabri 2000, Hue 2004, Meresse 2004) as well as MICA on the 
surface of enterocytes (Hüe 2004). IL-15 is up-regulated by enterocytes and lamina propria 
monocytes in active CD and RCD, see section 1.7.5. IL-15 drives the differentiation, 
functional maturation and survival of natural killer CD8
+
 T-cells, in the lamina propria, and 
CD8
+TCRαβ+ IELs (Mention 2003, Di Sabatino 2006). In active CD and RCD enterocyte-
derived IL-15 may activate IELs by two possible mechanisms: as a soluble cytokine (Di 
Sabatino 2006) or more likely, as a membrane-bound cytokine on the surface of enterocytes 
(Mention 2003, Bergamashi 2008).  
Interleukin-15 serves several functions in the epithelium of CD patients. Due to its potent 
anti-apoptotic effect observed at low concentrations (10 times less than those required for 
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proliferation), IL-15 stimulates the survival of IELs in uncomplicated CD even more 
efficiently than that of clonal pre-malignant IELs in RCD. This provides a rationale for 
their massive accumulation despite a modest proliferation rate (Mention 2003, Di Sabatino 
2006). It is also emerging as a driver for epithelial damage. Ex-vivo, IL-15 stimulates 
various effector functions from IELs from either active CD or RCD individuals. Notably, 
IL-15 stimulates IEL secretion of IFN-γ and their granzyme/perforin-dependant 
cytotoxicity against enterocyte lines (Mention 2003, Di Sabatino 2006). In addition, 
neutralising anti-IL-15 antibody inhibits the production of IFN-γ and epithelial apoptosis in 
organ culture from active CD (Mauiri 2000, Benahmed 2007, Fina 2007), attesting to the 
important contribution of IL-15 to mucosal damage. Furthermore, it may promote the 
activation of gliadin-specific IELs in mice (Oh 2004). IL-15 has also been shown to 
stimulate the spontaneous killing of enterocyte lines by IELs from active CD as well as 
RCD, where the T-cell receptor is lacking. This suggests that additional receptors may also 
be involved in the killing of enterocytes (Mention 2003, Di Sabatino 2006). Recent work 
also indicates that IL-15 may function in this regard by orchestrating the interactions 
between NK receptors on IELs and their ligands on epithelial cells without involving the T-
cell receptor (Meresse 2009). 
1.4.4 Dendritic cells 
Little is known about the role of dendritic cells in coeliac disease. Dendritic cells are 
messenger cells with a rapid turnover. They help regulate the intestinal immune respose to 
the many foreign antigens they come across. Murine CD103+ dendritic cells have been 
shown to induce gut-homing receptors on responding T cells and their differentiation to 
FoxP3+ regulatory cells in vitro. Induction of regulatory T cells requires TGF-β and 
convertion of retinal to retinoic acid by CD103+ dendritic cells. A recent study in mice, 
which had been engineered to express IL-15 in their intestinal mucosa, demonstrated an 
inflammatory immune response rather than tolerance towards gluten after co-administration 
of retinotic acid acting via dendritic cells (De Paolo 2011).  
Another more recent study suggests that the phenotypic role of dendritic cells can be altered 
by the concentration of tissue transglutaminase 2 (TTG2) (Dalleywater 2012). At lower 
concentrations the dendritic cells were able to sample gluten antigens whereas at higher 
TTG2 concentrations they were able to present antigen to T-cells more effectively. 
 
36 
1.4.5 Potential ideas in the pathogenesis of coeliac disease 
This would suggest that there are two mechanisms involved in the pathogenesis of coeliac 
that may be interlinked. What is not clear is the link between the epithelial and IEL 
response and the adaptive anti-gluten response. There is an adaptive T-cell response 
predominantly in the lamina propria as well as the innate response potentially driven by IL-
15 and IEL enterocyte interaction. It is perhaps this response that is the initiator of the 
pathological process with the adaptive T-cell response maintaining the inflammation. 
Pathological changes in the mucosa of coeliac individuals start to occur one hour after 
ingestion of gluten (Ciclitira 1984, Maiuri 1996) which is too early for an activated T-cell 
response. Tissue transglutaminase is an intracellular enzyme that requires active secretion 
into the lamina propria to deamidate gluten peptides. The more peptides are deamidated the 
greater the available antigens for presentation to T-cells. It may be that the innate response, 
dominated by IELs and enterocytes, initiates the inflammatory cycle that is maintained by 
the adaptive T-cell response. Further understanding of the pathogenesis will allow potential 
treatments to be designed. 
 
1.5  Diagnosis of coeliac disease 
1.5.1  Immunological markers and screening 
Serum IgA and IgG antibodies against gliadin, reticulin, endomysium (components of 
connective tissue), tissue transglutaminase and deamidated gliadin peptides are detectable 
in individuals with CD. Screening for serological markers is initially used for individuals 
who are at increased risk of CD: patients with non-specific symptoms; those with a family 
history of CD or patients with an associated condition such as Type 1 diabetes mellitus.  
Serum anti-endomysial antibody (EMA) is measured by incubating sections of monkey 
oesophagus or human umbilical cord with serum from an untreated coeliac patient and is 
standardised in Europe. Anti-endomysial antibodies present in the serum will react with the 
connective tissue antigens which can be detected by a fluoresceinated secondary antibody. 
IgA EMAs are reported to be the most reliable serological test for CD with a sensitivity of 
approximately 90% and a specificity of 99% (Stern 2000). False positive results are 
unlikely, however, the results can be subjective as they depend on the interpretation of the 
observer as to whether or not the staining is positive or not. The expertise in this technique 
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is being lost due to time constraints in modern immunology laboratories. The slightly lower 
sensitivity of EMA probably reflects the high prevalence of selective IgA deficiency among 
coeliac patients. Approximately 2-3% of coeliac patients are IgA deficient (Cataldo 1998) 
which can produce false negative EMA results. For this reason, it is recommended that 
serum IgA levels be measured in those individuals at a higher risk of CD, those with 
symptoms or with a family history. IgA deficient individuals should be screened using an 
IgG-EMA.  
Prior to use of EMAs, measurements of serum anti-gliadin antibodies (AGA) were used to 
detect CD. However the test for AGA is less sensitive and specific and can give a positive 
result in non-coeliac individuals with conditions such as gastroenteritis, inflammatory 
bowel disease and cow’s milk protein intolerance (Uibo 1993). 
In 1997, Dieterich and colleagues identified tissue transglutaminase (tTG) as being the 
autoantigen against which anti-endomysial antibodies are directed. Consequently, an IgA 
anti-tTG ELISA was developed which utilised a purified extract of guinea pig liver. This 
assay was reported to be cheap, easy to perform, less time consuming and less subject to 
inter-observer variation than the IgA EMA (Dieterich 1998). The diagnostic efficiency of 
the antibody screening tests currently available was compared in a multi-centre study (Stern 
2000). The anti-tTG IgA ELISA was found to be less specific than the IgA EMA test (95% 
compared to 99%) but more sensitive (93% compared to 90%). An anti-tTG assay that 
employs human recombinant tTG as the coating antigen is more specific than the guinea 
pig liver ELISA (Tonutti 2003, Lewis 2006). 
Antibodies to deamidated gliadin peptides (DGP) have been shown to be of diagnostic 
value (Volta 2010). However, a meta-analysis comparing the performance of DGP test with 
the tTG test, the current standard, suggested that the tTG test outperforms the DGP test 
(Lewis 2010a). Where this test may be useful is in assessing gluten intake on a gluten-free 
diet. Monzani et al (2011) demonstrated both IgA and IgG anti DGP assays showed higher 
sensitivity than anti-tTG IgA and AGA IgA in monitoring compliance with GFD in 
children with coeliac disease, but anti DGP IgA paired with IgG seemed to perform better. 
They did not outperform anti-tTG IgA for CD screening. 
A combination of IgA tTG and IgG DGP may increase sensitivity for screening coeliac 
patients as it picks up IgA deficient patients. 
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1.5.2  Histology 
The coeliac lesion predominantly affects the proximal small intestine with lessening 
damage occurring towards the distal small intestine. The pathology spans a spectrum of 
severity that has been classified into five stages by Marsh (1992): the pre-infiltrative, 
infiltrative, hyperplastic, destructive and hypoplastic (atrophic) lesions. These were 
subsequently modified by Oberhuber (1999) to be able to use the classification for 
diagnostic purposes. The classification is summarised in table 1.1. The parameters assessed 
in the diagnosis of coeliac disease on mucosal small intestinal biopsy specimens include 
villous or crypt architectural changes as well as lamina propria cell density and intra-
epithelial lymphocyte (IEL) cell counts.  





Type 2 Type 3a Type 3b Type 3c 
IEL/100 
enterocytes 
<40 >40 >40 >40 >40 >40 
Crypts 
 
normal normal hypertrophic hypertrophic hypertrophic hypertrophic 







These features form a continuum with normal mucosal architecture at one end and the 
classical flat lesion at the other end, which may take many years to develop. A comparison 
of normal duodenal mucosal biopsy with Marsh 3c duodenal mucosal biopsy is seen in 
Figure 1.2. Marsh 0 is a normal small intestinal biopsy. Marsh 1 is an increase in IELs 
counted per 100 enterocytes, the first and most sensitive index of the effects of gluten on 
the mucosa. Infiltration of gluten-dependent lymphocytes into the lamina propria is also 
seen. However, it is not pathognomonic for coeliac disease as they may be raised in 
infections for example. Marsh 1 is often seen in dermatitis herpetiformis (see section 1.7.8), 
in treated coeliac disease, and in family members of those affected by coeliac disease. 
Marsh 2 is an infiltrative lesion where there is an increase in crypt length as well as raised 
IELs. The crypt epithelia are infiltrated by lymphocytes. It is not often seen in the diagnosis 
of coeliac disease. 
Marsh 3 is the destructive lesion Marsh described. It is divided into three different 
subgroups depending on the degree of villous atrophy. These lesions are the classical 
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“diagnostic” lesions of coeliac disease, before the advent of serology and newer genetic 
screening. Mitotic activity within the crypt is substantially increased and the time taken for 
cells to migrate from the crypt to the surface is reduced from between three and five days to 
between one and two days. Consequently, surface epithelial cells are immature and the 
surface enterocyte height is reduced. All type 3 lesions have raised IELs and an increase in 
crypt depth. Marsh 3a is characterised by mild villous flattening; Marsh 3b is characterised 
by marked villous flattening, and Marsh 3c is characterised by a flat mucosa. All are 
evidence of an advanced cell-mediated mucosal immune response which occurs in 
untreated coeliac disease, whether silent or classical. However, villous atrophy is not 
pathognomonic for coeliac disease as it can occur in the context of other disorders such as 
cow’s milk allergy, giardiasis, rotavirus infection and autoimmune enteropathy (Freeman 
2004). 
Type 4 is a very rare hypoplastic lesion which is characterised by a flat mucosa but normal 
crypt depth and normal IEL count. It is probably a historic lesion seen in severely 
emaciated small children and most likely signifies malnutrition parallel findings in 
kwashiorkor (Brunser 1970). 
 
1.5.3  ESPGHAN criteria for diagnosis of Coeliac Disease 
The required criteria for a diagnosis of CD were first proposed by the European Society of 
Paediatric Gastroenterology and Nutrition (ESPGHAN) in 1970 (Meeuwisse 1970). The 
original statement proposed that a diagnosis should be based on three criteria: 
i. Structurally abnormal jejunal mucosa when taking a gluten-containing diet 
ii. Clear improvement of villous structure when taking a gluten-free diet 
iii. Deterioration of the mucosa as a result of a gluten challenge. 
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Figure 1.4 Histological changes of coeliac disease 
Marsh 0     Marsh 3c 
 
H+E stain second part of duodenum low power (x100) courtesy of Dr Chang, St Thomas 
Hospital  
A patient underwent a minimum of three endoscopies for a definite diagnosis of CD. The 
criteria were revised in 1990 (Walker-Smith 1990) after it was found that many 
gastroenterologists were not recommending a gluten challenge and a third biopsy. The 
revised criteria continue to emphasise that an initial biopsy is paramount. Histological 
examination showing the characteristic abnormalities, that is, lymphocytic infiltration, 
villous atrophy and crypt hyperplasia, on a gluten-containing diet provides the first step 
towards a diagnosis. In children under the age of 2 a gluten re-challenge and small 
intestinal biopsy is still required for the diagnosis of coeliac disease. 
A definite symptomatic improvement within a few weeks of commencing a strict gluten-
free diet would be consistent with a diagnosis of CD. A second biopsy may be carried out 3 
to 6 months after commencement of the diet to confirm that there has been histological 
improvement as well as symptomatic relief (NICE guidelines 2009 CG86).If there is a 
symptomatic improvement but no histological recovery the GFD should be verified and 
continued and a further biopsy taken after three months. It has been shown that complete 






no histological response or symptomatic improvement it is recommended that patient 
compliance to a gluten-free diet should be examined. 
Those patients who do not respond to a strict diet may have refractory sprue, ulcerative 
jejunitis or intestinal lymphoma (see sections 1.7.5, 1.7.6, 1.7.7). A third endoscopy after 
gluten challenge is no longer a compulsory diagnostic step. It may be required however at a 
later date if the original diagnosis of coeliac disease is brought into question. 
However, at present a consultation process is underway to further revise these ESPGHAN 
criteria in view of more accurate serological tests and knowledge of genetic risk factors. 
Only 12% of paediatric gastroenterologists, who responded to a postal survey, adhered to 
the current ESPGHAN guidelines (Ribes-Koninckx 2011). The main transgression was the 
omission of gluten re-challenge in the under 2 age group. The algorithm proposed by the 
ESPGHAN working group on the diagnosis of coeliac disease is complicated. It aims to 
reduce the need for endoscopy which requires anaesthesia in the paediatric cohort. The 
authors propose that children who have classical symptoms of coeliac disease, with HLA-
DQ2 or -DQ8, the genetic predisposition, and strongly positive serology should not 
undergo endoscopic evaluation of the small intestine. Those who have the genetic 
predisposition and equivocal serology should proceed to a biopsy of the small intestine, as 
in those patients in whom the diagnosis in unclear. The new proposed algorithm includes 
the use of genetic screening, a test that is currently not widely used in routine practice 
(Husby 2011). 
 
1.6  Treatment 
1.6.1  Gluten-Free Diet 
Once a diagnosis of CD has been established, patients are advised to start a lifelong gluten-
free diet (GFD). This involves the exclusion from the diet of any cereal that contains wheat 
gluten and prolamins from rye and barley or its derivatives, such as malt, or hybrid wheat 
varieties, such as spelt. The place of exclusion of oats from a gluten-free diet remains 
controversial, see section 1.6.1.1. A typical gluten-containing diet contains an estimated 10-
20 grams of gluten, derived from multiple sources and therefore a GFD necessitates a 
calculated avoidance of many foods. A strict gluten-free diet is low in dietary fibre and 
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folate, niacin and vitamin B12 (Thompson 2005, Thompson 2000, Thompson 1999). 
Complying with a gluten-free diet is difficult for a number of reasons:  
1. Gluten may contaminate food during harvesting, food preparation or processing 
(Ellis 2008b, Hernando 2008) 
2. Gluten-free products are more expensive than gluten containing products and may 
be more difficult to source (Singh 2011) 
3. Dietary compliance is poor particularly in adolescents (Fabiani 2000) 
4. There is no agreed consensus on the minimal amount of gluten permitted in food: in 
Australia “no detectable gluten” is <5mg/kg (Australia and New Zealand Food 
Standards Code 2003) whereas in Europe “gluten–free” is <20mg/kg (Codex Stan 
118 1979 amended 2008) 
5.  A wide variety of gluten sensitivities exist between patients: 50% of patients 
experience symptoms with an acute challenge whilst 50% do not 
6. To improve palatability, many gluten-free products contain purified wheat starch 
which invariably contains residual gluten (Ellis 2008b) 
7. A gluten-free diet does not resolve the problems associated with the rare 
complication of refractory coeliac disease, see section 1.7.5 
Patients not adhering to a gluten-free diet are predisposed to numerous sequelae such as 
short stature (Bonamico 1992), nutritional deficiencies, early osteoporosis, secondary 
autoimmune disorders (West 2004, Lewis 2010b), malignancies (Holmes 1989), infertility 
and poorer outcome of pregnancy (Freeman 2010). However, a gluten-free diet has few 
side effects.  
Naturally gluten–free cereals include rice, millet, maize and sorghum (reviewed in Ellis 
2002). Quinoa, an Andean grain from Peru has many benefits for a gluten-free diet as it is 
the only plant to have all essential amino acids as well as being high in minerals and 
vitamins however, quinoa has similar prolamin content to wheat (Vega-Gálvez 2010). A 
recent study demonstrated that not all cultivars of quinoa are safe for coeliacs to eat as 
evidenced by T-cell activation (Zevalos 2012). 
Products labelled as gluten-free have to adhere to strict permissible levels of gluten in 
Europe (Codex Stan 118 1979). This standard was amended in 2008 to reduce permissible 
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level of gluten in gluten-free foods. The change was ratified in January 2009, however, 
manufacturers had until January 2012 to comply. Foods labelled as “gluten-free” must now 
contain no more than 20mg/kg of gluten whereas foods labelled as “very low gluten” can 
contain between 21 to 100mg/kg. 
1.6.1.1 Oats in gluten-free diet 
Oats are more distantly related to wheat (more details in section 1.9.1) and are thought to be 
less toxic to coeliac patients. Several studies suggest that oats are safe for coeliac patients to 
eat (Janatuinen 1995, Janatuinen 2002, Koskinen 2009), however, there are high drop out 
rates in both the Janatuinen studies in the oats group of patients. Janatuinen in his five year 
follow up study (2002) only had 23 out of the original recruited 35 coeliac patients left, and 
in his study in 1995 there was a 10% drop out rate in the group eating oats. Many 
commercially available oat products are contaminated with wheat, rye or barley (Thompson 
2004). Studies from Norway suggest that in a small minority of patients oats are toxic 
(Lundin 2003, Arentz-Hansen 2004). These studies are with oats that are known to be free 
from gluten contamination that are produced specially for coeliac patients in fields where 
no harmful cereals are grown. The oats are processed in a separate production line and 
repeated testing using ELISA kits have shown that the oats are free from contamination. In 
19 coeliac patients recruited for Lundin’s study, one was found to develop new villous 
atrophy, the blistering rash of dermatitis herpetiformis, associated with coeliac disease, and 
clinically active coeliac disease. Subsequently Arentz-Hansen (2004) found two further 
patients who deteriorated after they started eating oats following changes to the national 
recommendations. Biopsies from these two patients were taken and challenged with oats 
resulting in avenin reactive T-cells. These cell lines were also tested with wheat and found 
to stimulate the T-cells but through different epitopes.  
1.6.2 Nutrient replacement 
Nutritional deficiencies should recede on commencement of GFD but dietary supplements 
may be necessary. Recovery from anaemia can take between 6 and 12 months as intestinal 
mucosa reverts to normal (Annibale 2001). After a diagnosis of CD patients should 
undergo a dual-emission x-ray absorptiometry (DXA) scan to assess bone mineral density 
(BMD). Patients found to have a low BMD should be advised to strictly adhere to a GFD, 
to avoid smoking and excessive alcohol intake, and take calcium and vitamin D 
supplements (BSG Guidelines 2007).  
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1.6.3 Novel therapies 
A greater understanding of the pathogenesis of coeliac disease has allowed alternative 
treatments to be designed to act either as an adjuvant to a gluten-free diet, allowing for 
minor transgressions, or replace it altogether through potential blocking of various 
postulated mechanisms (reviewed in Donnelly 2011). The options include: 
1. Modifying wheat in an attempt to reduce the toxic gluten epitope content 
2. Degrading gluten to smaller peptides using enzymes, not able to be presented to 
gluten-sensitive T-cells, either in vivo or in vitro 
3. Targeting tight junction proteins to ensure that they do not allow gluten to pass 
through 
4. Tissue transglutaminase 2 blockade to reduce the deamidated peptides presented to 
gluten-sensitive T-cells 
5. Reducing HLA-DQ peptide presentation to gluten-sensitive T-cells by amino acid 
substitution of gluten T-cell stimulatory sequences 
6. Immune system modification either by naturally occurring gluten peptide 
sequences or helminth infection 
7. Targeting inflammatory cytokines with biological therapies, such as anti-IL15 
8. Vaccination with gluten peptides in order to induce immune tolerance 
9. Intra-nasal administration of T-cell immunostimulatory gluten epitopes to induce 
tolerance 
Many of the options above are a long way off from market as they are in the early stages of 
development and testing in animal or human subjects. However, this is a rapidly expanding 
market driven, in part, by the wish of coeliac individuals for an alternative to a gluten-free 
diet. The main drawback facing researchers is that a gluten-free diet has few side effects. 
Therefore, for a treatment to be recommended in the treatment of coeliac disease, it has to 
have an acceptable low number of side effects. A greater understanding of the pathogenesis 
of coeliac disease will help increase the potential solutions to this. 
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1.7 Complications and associations of Coeliac Disease 
There are many complications associated with coeliac disease. The most common is non-
responsive coeliac disease where individuals with coeliac disease fail to improve on a 
gluten-free diet. A recent study (Dewar 2012) demonstrated by far the most common cause 
was continued gluten ingestion by the individual, whether it was inadvertently or 
deliberately. Other causes of continued symptoms were of small bowel bacterial 
overgrowth, microscopic colitis, concomitant inflammatory bowel disease and lactase 
deficiency, often with more than one reason being found for continued symptoms. 
Females with coeliac disease have a higher incidence of unexplained infertility (Collin 
1996), and have lower birth weight infants (Norgard 1999, Ludvigsson 2001). 
There is also an established link with other autoimmune diseases such as type 1 diabetes 
mellitus (Schuppan 2000, Neuhausen 2008), sharing similar genetic variants (Smyth 2009).  
Neurological symptoms may also be experienced by coeliac individuals, mainly ataxia and 
peripheral neuropathy (Hadjivassiliou 1996, 2006, 2008a). A recently identified tissue 
transglutaminase 6 may be the cause of these symptoms (Hadjivassiliou 2008b). 
Dermatitis herpetiformis is a gluten-sensitive skin disorder which is associated with skin 
deposition of anti-tissue transglutaminase 3 antibodies (Zone 2011). Few patients suffer 
malabsorption but some do have abnormal small intestinal histology. The treatment 
involves a gluten-free diet as well as dapsone, the dose of which may be decreased after 
initiation of a GFD. 
The risk of both enteropathy associated T-cell lymphoma (EATL) and small intestinal 
adenocarcinoma are elevated, the latter manyfold. A wealth of collected data exists as the 
incidence of cancer is one of the leading causes of concerns for coeliac patients as well as 
their gastroenterologists (Cellier 2000, Askling 2002, Catassi 2002, Green 2003. Howdle 
2003, Rampertab 2003, Green 2004, West 2004, Smedby 2005, Mearin 2006). The risk of 
developing these rare cancers occurs with coeliac disease as opposed to silent or latent 
forms of the disease (Elfström 2011). 
1.7.1 Refractory Coeliac Disease 
A rare complication of coeliac disease is refractory coeliac disease (RCD), when clinical 
symptoms and histological changes persist or recur after a good response to a gluten-free 
diet and after other causes of villous atrophy having been excluded. Intestinal mucosal 
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recovery on commencement of a GFD can take up to two-years (Grefte 1988) and it may 
therefore be necessary to delay a diagnosis of refractory coeliac disease until at least one-
year on a GFD. 
Refractory coeliac disease can be classified according to the immunophenotype of intra-
epithelial lymphocytes. Abnormal clonal lymphocytes with loss of surface markers CD8 
and CD3 occur in type 2 RCD whereas in type I RCD the majority of lymphocytes have 
normal surface markers and T-cell receptors are polyclonal (Cellier 2000). Differentiation 
between the different types of refractory coeliac disease is important as the reported five-
year survival rate varies between 40-58% for type 2 RCD (Mauriño 2006, Al-Toma 2007, 
Malamut 2009, Rubio-Tapia 2009), and 93% in type 1 RCD (Malamut 2009). The main 
cause of death in type 2 RCD is progression to an enteropathy associated lymphoma 
(EATL) with a five-year survival rate of 8-20% (Gale 2000, Al-Toma 2007) as well as 
progressive malnutrition. 
Little is known about the pathophysiology of RCD due to the scarcity of these patients in 
clinical practice making it difficult to conduct randomised controlled trials and tailor 
treatment. 
1.8  Genetics 
Coeliac disease has a strong genetic component. At present the most important genetic 
association with coeliac disease are the HLA-DQ2 and-DQ8 haplotypes (Sollid 1989, 
Karell 2003). The vast majority of coeliac individuals have the HLA-DQ2 haplotype with 
approximately 5% of coeliacs being HLA-DQ8. This difference in haplotypes may affect 
disease presentation and subsequent course (Biagi 2011). HLA-DQ molecules are 
responsible for antigen presentation, and therefore, it is not surprising that they have the 
strongest genetic link to coeliac disease. However, whilst HLA-DQ molecules are 
necessary for coeliac disease, they are not sufficient to cause it. Approximately 30% of 
healthy individuals in the Western population express these haplotypes (Sollid 1989) and 
yet do not develop coeliac disease; therefore, other genetic or environmental factors must 
be involved. 
Genome-wide linkage studies aim to identify broad genomic regions which contain 
predisposing variants for the disease in question. They rely on comparing large sample 
sizes of healthy controls with the target disease group trying to find genes that are more 
frequently associated with the disease group. There have been 5 genome-wide association 
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studies (GWAS) which have added new genes associated with coeliac disease (van Heel 
2007, Hunt 2008, Smyth 2009, Coenen 2009, Garner 2009, Dibois 2010). The main 
function of these genes concern co-stimulation or co-inhibition of T and B-cells, T-cell 
development in thymus, cytokine and chemocytokine signalling as well as the detection of 
viral DNA, although the latter had relatively weak statistical significance. These findings 
implicated primary alterations in the immune response rather than the intestinal epithelial 
barrier or digestive enzymes, as was previously considered. It is still not clear how genetic 
change alters biological function, however, it is allowing research to be targeted to the 
genes involved and increase knowledge of pathogenesis of coeliac disease. Interestingly 
none of these genes relate to IELs, see section 1.4.2. The findings of the GWAS studies are 
summarised in Table 1.2. 
 
1.9  Cereal chemistry 
1.9.1 Taxonomy 
Cereals are species of grasses (gramineae) which are classified into four subfamilies. See 
Figure 1.5. Wheat (triticum) is a member of the triticeae tribe, of the pooideae subfamily. 
Within the triticeae tribe a number of species exists: one of the most widely grown species 
of wheat is triticum aestivum, used in bread making. Oats are slightly removed from wheat, 
rye and barley, being a member of the avenae tribe. The cereals are largely classified 
according to the structure of their seed-storage proteins; this may partially explain the 
observed differences in the disease-activating properties of oats and wheat. 
1.9.2 Gluten  
The environmental trigger for CD is dietary gluten in genetically susceptible patients. 
Gluten can be further subdivided into two major protein subclasses according to their 
solubility in alcohol and aqueous solutions. These subclasses consist of gliadins, soluble in 
40-70% ethanol and glutenins which are large, polymeric molecules insoluble in both 
alcohol and aqueous solutions. Glutenins help trap carbon dioxide in the fermentation 
process to enable the bread to rise while gliadin helps trap water to give bread its elasticity. 
Frazer in 1959 digested wheat gluten into six fractions using pepsin and trypsin. Frazer’s 
Fraction III (FFIII) is now widely used in coeliac research as it is soluble in buffered saline 
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solution and contains both gliadins and glutenins. A summary of the preparation is shown 
below in Figure 1.6. 
Table 1.2 New genes implicated in coeliac disease from the genome-wide association 
studies 







IL2 T-cell activation and proliferation 
IL21 Enhancement of B, T, NK cell 
proliferation and IFN-γ production 
Hunt 2008 1643 coeliacs 
3406 controls 
CCR3 Recruitment of effector immune cells to 
site of inflammation 
IL12A Induction IFN-γ secreting Th1 cells 
IL18RAP Mature IL18 induces T-cell IFN-γ 
synthesis, RAP expressed in un-
stimulated T and NK cells 
LPP Unknown. Highly expressed in small 
intestine 
RGS1 Regulation of chemocytokine receptor 
in B-cell activation and proliferations. 
Expressed in IELs in coeliac disease 
SH2B3 Regulates T-cell receptor, growth factor 
and cytokine receptor-mediated 
signalling in leukocyte and myeloid cell 
homeostasis 
TAGAP Expressed in activated T-cells, 
unknown role in immune function 




CTLA4 Expressed on the surface of helper T-
cells, transmits inhibitory signals to T-
cells 
CCR5 Loss of expression of chemocytokine 
receptors 
PTPN2 Regulation of cell growth, 
differentiation, mitotic cycle and 
oncogenic transformation 
IL7R critical role in the V(D)J recombination 
during lymphocyte development, 
controls accessibility of TCR gamma 
locus 
PRKCQ Controls cellular signalling in NF-κB 
pathway 
CD226 mediates cellular adhesion to other cells 
bearing its ligands 
UBASH3A Negatively regulates T-cell signalling 




Table 1.2 New genes implicated in coeliac disease from the genome-wide association 
studies continued  
Study Size of 
sample 
Gene Action 





PTPN22 Regulates T-cell signalling 
TNFAIP3 Inhibition of NF-κB activation and 
TNF-mediated apoptosis 
REL Important role in survival and 
proliferation 
PFKFB3/PRKCQ Controls cellular signalling in NF-κB 
pathway 
Garner 2009 906 coeliacs 
3819 controls 
ITGA4 Cell adhesion, migration and activation 
of immune cells 
Dubois 2010 4533 coeliacs 
10750 
controls 
BACH2 Promotes oxidative cell death 
CCR4 Regulation of cell trafficking of various 
types of leukocytes 
CD80 Controls strength and nature of the 
response to T or B-cell receptor 
activation by antigens 
CIITA-SOCS1-
CLEC16A 
Transcriptional co-factor in HLA class 
II positive cell lines 
ICOSLG Controls strength and nature of the 
response to T or B-cell receptor 
activation by antigens 
ZMIZ1 Regulation of the activity of various 
transcription factors 
ETS1 Key player in thymic CD8
+
 lineage 
differentiation, promotes RUNX3 
expression 
RUNX3 Master regulator of CD8
+
 T lymphocyte 
development in the thymus 
THEMIS Positive and negative T-cell selection 
during late thymic development 
MMEL1/TNFRSF14 Widespread functions in peripheral 
leucocytes and promoting thymocyte 
apoptosis 
Genes in grey do not quite reach statistical significance however are implicated in the 
pathogenesis 
The gliadins and glutenins can be further subdivided into groups according to their 
molecular weight as shown in Figure 1.7. The gliadins are well described as toxic (Dicke 
1953a,b, van de Kamer 1953, Sturgess 1994, Shidrawi 1995, Anderson 2000, Arentz-
Hansen 2000, Ellis 2003, Fraser 2003, Martucci 2003, Mazzarella 2003). However, the 
glutenins have only recently been extracted in a pure form (Keck 1995). Prior to this the 
glutenins were assumed to be non-toxic. Any observed toxicity was thought to be due to 






Figure 1.5: Cereal taxonomy of the grass family (Gramineae) 
Family       Gramineae 
 
 
Subfamily     Fesucoideae   Panicoideae 
 
 
Tribe    Triticeae  Aveneae Tripsaceae Oryzeae 
 
 
Subtribe  Triticineae 
 
 
Genus   Triticum Secale    Hordeum Avena  Oryza          Zea 
 
 
Species Wheat Rye    Barley Oats  Rice      Maize
  







Figure 1.6 Frazer’s enzymatic fractionation of gluten 
  GLUTEN 
    Pepsin pH 1.8, 4hrs, 37°C 
 
  Fraction I 
    Adjustment to pH 7.8 
    Trypsin 4hrs, 37°C 
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Fraction IV   Fraction III 
(insoluble, 25% by weight) (soluble, 75% by weight) 
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Undialysable residue    Dialysate 
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Figure 1.7 Wheat protein classification 
              Gluten 
 
  Gliadins      Glutenins 
 
ω gliadin α/β gliadin γ gliadin  LMW glutenins HMW glutenins 
MMW peptide   LMW peptide    HMW peptide 
 
We now know that the glutenins are toxic (van de Wal 1999, Vader 2002a, Molberg 2003, 
Dewar 2006, Ellis 2006). Vader tested small intestinal T-cell clones of children with 
coeliac disease with an array of proteins and peptides, including low molecular weight 
(LMW) glutenin. Four out of 16 T-cell clones from children were sensitive to the LMW 
glutenin. Van de Wal tested different 18 amino acid peptide sequences spanning the entire 
HMW glutenin molecule with a T-cell clone from an HLA-DQ8 positive paediatric coeliac 
patient and was able to demonstrate the minimal epitope required for optimal T-cell 
stimulation was residues 724-734, QGYYPTSPQQS. However the drawback in both these 
studies is that the reaction with T-cell clones is too specific and unlikely to represent the 
mass action of T-cells present in the gut. Dewar demonstrated the toxicity of a mixture of 
chemically purified HMW glutenins by demonstrating in vitro stimulation of T-cell lines in 
11 of 17 coeliac patients. He also performed in vivo challenges in 3 patients with coeliac 
disease taking small intestinal biopsies every hour for six consecutive hours after 
instillation of the HMW glutenin into the duodenum. All patients developed significant 
change in intestinal morphology after 4hrs. We still know little about the toxicity of the 
HMW subunits known as Dx5, Bx7, By9 and Dy10. Molberg’s group (2003) managed to 
stimulate 5 out of 12 human leucocyte antigen (HLA)-DQ2 T-cell lines when testing 
recombinant Dy10 and 3 out of 12 HLA-DQ2 T-cell lines with recombinant Dx5. Our 
group demonstrated the toxicity of recombinant Dx5 and Dy10 fractions by in vitro and in 
vivo testing (Ellis 2006). Four out of 13 small intestinal T-cell lines were stimulated by Dx5 
and 3 out of 11 T-cell lines were stimulated by Dy10. Both coeliac patients in the in vivo 
studies were found to react however, only one patient was tested with each fraction. 
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Tye-Din (2010) has recently extended the evidence for immunostimulatory T-cell epitopes 
in wheat, rye and barley. In his study he tested a large number of potential T-cell epitopes 
against activated peripheral blood lymphocytes in HLA-DQ2 positive coeliac individuals 
following a five-day oral gluten challenge prior to venesection. The T-cell response to these 
epitopes was measured by interferon-γ ELISpot test. He found that the T-cell response 
differed between coeliac individuals, as well as depending on the gluten challenge cereal, 
wheat, rye or barley. The strongest immune response, as evidenced by IFN-γ secretion, was 
from the 33-mer α2-gliadin p56-88. However, the universal response, the most widespread 
T-cells activation, was from ω-gliadin. Tye-Din’s work suggested that the glutenins were 
not major T-cell epitopes in HLA-DQ2 restricted patients. However, when T-cells did 
respond they secreted large amounts of IFN-γ. 
Classically gluten referred to the storage proteins in wheat gliadins. Rye and barley have 
similar toxic peptide sequences to gliadin, although less toxicity work has been done as it is 
assumed that they would also be toxic (Vader 2003). Vader used T-cell lines and clones 
from 8 different patients with coeliac disease to test 11 amino acid peptides from a 
selection of epitopes from rye and barley similar but not identical to the equivalent region 
in gliadin. He found that seven of eleven peptides were recognised by gluten-specific T-
cells lines or clones from coeliac patients. No further work has been done to extend or 
improve these results to date. Now the term gluten is commonly used to refer to the 
immunostimulatory proteins in wheat, rye and barley 
1.9.3 Role of Cereals in bread making 
It is the unique protein composition of wheat that makes it suitable for baking leavened 
bread. It is thought that the prolamins become rearranged during the kneading process, and 
strong non-covalent bonds form the gluten network. The gluten network and starch 
granules then serve to trap the carbon dioxide produced by yeast fermentation during bread 
making (Shewry 1992). The suitability of a wheat flour for bread making is largely 
determined by its composite glutenin proteins. The structure of the glutenin polymers, the 
types of glutenin subunits present and the ratio of high: low molecular weight subunits are 
the major factors contributing to the overall quality of the glutenin protein. The correct 
balance of viscosity and elasticity is essential and it is the glutenins that are responsible for 
the elastic properties of the dough (reviewed in Anjum 2007). Rye and barley do not have 
the equivalent gluten protein content as wheat and are therefore not suitable for bread 
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making. Barley is mainly used for malt in the production of beer and whisky. Rye is used 
for making crispbreads, rye breads and is also used in whisky. 
 
1.10 Methods for assessing the toxicity of gluten fractions and peptides 
There are animal models available for coeliac disease, although these have inherent 
problems. Irish setter dogs have a gluten-sensitive diarrhoeal illness with similar 
histological lesions (Batt 1984). However, the lack of anti-gliadin and anti-tTG2 antibodies 
and major histocompatability complex (MHC) class II linkage with disease precludes their 
use as a model for coeliac disease. Captive rhesus macaque monkeys’ chow contains gluten 
with a minority exhibiting chronic diarrhoea, stomach distension and a blistering rash, 
similar clinical symptoms to coeliac disease. Juvenile macaques seem prone to elevated 
anti-gliadin antibodies with similar histological lesions in their duodenums, as seen in 
humans with coeliac disease, which improve on a gluten-free diet (Bethune 2008). 
However, a Mamu class II association with simian gluten-sensitive enteropathy, while 
under investigation (Mazumdar 2010), is yet to be found, as is an immune response directed 
towards the tissue transglutaminase 2 in this disease. 
The current toxicity testing in coeliac disease therefore uses human tissue. The testing can 
be further subdivided into in vitro methods and in vivo methods.  
1.10.1 In vitro 
1.10.1.1 Organ culture of small intestinal biopsy 
Browning and Trier first described a method where small intestinal biopsies were cultured 
successfully using an in vitro organ culture system (Browning 1969). This was 
subsequently extended to investigate changes in small intestinal biopsies from patients with 
untreated coeliac disease (Trier 1970, Falchuk 1974) and the parameters used to assess the 
biopsies were refined to use mean enterocyte cell height (Howdle 1984). Figure 1.8 
explains these terms. This method has now been used by a number of other researchers in 
assessing the toxicity of gluten fractions (Howdle 1984, de Ritis 1988, Przemioslo 1995, 
Shidrawi 1995, Maiuri 1996, Biagi 1999, Beckett 1999, Martucci 2003, Mazzarella 2003). 
Interestingly, Maiuri (2003) demonstrated that A-gliadin 31-43 was not able to stimulate 
gluten-sensitive T-cells but did produce a positive result in organ culture implying that 
coeliac disease is not purely driven by T-cells and that innate immunity may also be 
involved. A point that will be discussed later in this thesis. 
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1.10.1.2 Small intestinal T-cell culture 
Gliadin specific T-cells were first isolated from coeliac small intestinal biopsies by Lundin 
in 1993 and grown in culture with cyclical antigenic stimulation. T-cell lines are groups of 
unselected cells that have only been stimulated a maximum of three times whereas clones 
are T-cells grown from a single cell. They therefore lack the mass T-cell action of the gut 
immune system. These cells can then be used for a transformation or proliferation assay.  
This assay is used to assess gluten-specific T-cell proliferation in response to the candidate 
peptide presented by inactivated antigen-presenting cells (APC), usually irradiated 
peripheral blood mononuclear cells, and compared with a negative control of T-cells with 
APC. Positive controls of T-cells with APC presenting gluten and T-cells with 
phytohaemagglutinin-L (PHA) alone are also used. PHA is a plant lectin that triggers 
lymphocyte agglutination and proliferation.  
A stimulation index (SI) can then be calculated after overnight incubation with tritiated 
thymidine (
3
H-thymidine) by dividing the mean count per minute of the T-cells with APC 
and antigen by the mean counts per minute of the T-cells with APC alone. A SI greater than 
2 is positive and demonstrates toxicity of the protein or peptide tested. This method has 
been used to identify the toxic epitopes in gliadin by many researchers (Anderson 2000, 
Arentz-Hansen 2000, Ellis 2003, Dewar 2006) and continues to be the most widely used 





Figure 1.8 Parameters used to assess histological changes of coeliac disease mucosal 
sections  
 











1.10.2 In vivo 
1.10.2.1 Small intestinal in vivo challenge of gluten 
The gold standard for toxicity testing in coeliac disease is in vivo gluten challenge as this is 
the most reliable and relevant method for testing gluten fractions and candidate peptides. 
Treated coeliac volunteers are sedated and a hydraulic biopsy tube, with a cannula taped to 
the side, is placed in the second part of the duodenum under x-ray guidance. An exact 
amount of candidate peptide can then be infused directly into the small intestine and 
sequential biopsies can be taken. This method has been used to confirm the toxicity of α-, 
β-, γ- and ω-gliadin fractions (Ciclitira 1984) as well as A-gliadin 31-49 (Sturgess 1994), α-
gliadin 57-68 (Fraser 2003) and HMW-glutenin (Dewar 2006). It is an invasive method of 
testing which requires an experienced physician and relies on the goodwill of the patient. 
However, it allows a correlation with the T-cell data. This is not widely used as the capsule, 
hydraulic pump and spare parts required are no longer manufactured.  
1.10.2.2 Other in vivo 
In the search for less invasive in vivo methods for testing toxicity of gliadin peptides, other 
methods have been devised. The rectal mucosa of coeliac patients has been shown to have 
some of the pathological features of the small intestinal mucosa therefore rectal infusion 
poses an alternative method which has been used by some researchers (Loft 1990, Ensari 
1993). However Loft reported non specific increases in intraepithelial lymphocytes in a few 
control patients, and patients tend to find it unacceptable (Ellis 2000). 
Oral gluten challenge by injection of peptides into the buccal mucosa is relatively non 
invasive and some people find it more acceptable (Ellis 2000). It has been used by a group 
in Finland to confirm the toxicity of A-gliadin 31-49 (Lähteenoja 2000a, b). 
 
1.11  Disease activating epitopes identified to date 
The immunostimulatory potential of α-, γ- and ω-type gliadins was confirmed using in vivo 
challenge studies (Ciclitira 1984). Since then a great deal of research has gone into 
identifying the precise regions of gliadin which may be responsible for triggering the 
disease. One of the earliest studies that attempted to characterise toxic gluten epitopes in 
CD was of de Ritis et al (1988). Using chemical and enzymatic methods to digest A-
gliadin, several peptide fragments were produced. By studying the morphological recovery 
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of paediatric biopsy specimens after 48 hours of culture in medium with and without A-
gliadin, peptides corresponding to amino acids 1-127, 128-246, 1-55,1-30 and 31-55 were 
found to be toxic in vitro.  
A great deal of attention has focussed on a region of A-gliadin corresponding to amino 
acids 31-49. Recognition of this peptide by an HLA-DQ2 restricted peripheral blood T-cell 
clone provided evidence of its potential immunogenicity (Gjertsen 1994). Further studies 
using small intestinal organ culture showed that this peptide was immunostimulatory to the 
coeliac small intestine in vitro (Shidrawi 1995). A similar peptide (A-gliadin, amino acids 
31-43) induced anti-endomysial antibody production from treated coeliac biopsy specimens 
but not controls (Picarelli 1999). Biagi (1999) abolished the in vitro immunostimulatory 
effects of A-gliadin 31-49 by changing a single amino acid. Perhaps the most significant 
evidence for a role of A-gliadin 31-49 in disease pathogenesis arose from the in vivo 
challenge study of Sturgess et al (1994). Infusion of 200mg of A-gliadin peptide into the 
duodenum of treated coeliac patients caused a significant decrease in villous height: crypt 
depth ratio and in the enterocyte cell height, with a parallel increase in the intraepithelial 
cell counts in all 4 patients tested. A control peptide, corresponding to A-gliadin 3-21, had 
no histological effects. Subsequent analysis of the biopsies from the Sturgess study used in-
situ hybridisation to show that exposure to 31-49 caused an increase in the expression of 
IFN-γ mRNA (Kontakou 1995). This provided robust evidence that the observed 
histological effects were as a result of activated gliadin-specific T-cells. 
Other studies investigating the immunostimulatory potential of this peptide reported 
conflicting results. The binding affinity of peptide 31-49 for HLA-DQ2 is only moderate 
(Johansen 1996, Shidrawi 1998) and only one T-cell clone from peripheral blood has been 
identified (Gjertsen 1994). Arentz-Hansen et al (2000) found that polyclonal, small 
intestinal T-cell lines from 6 patients did not respond to a series of native or deamidated 
peptides corresponding to A-gliadin 1-58. However, Maiuri et al (2003) demonstrated that 
A-gliadin 31-43 was able to induce damage to small intestinal biopsies in organ culture, 
mediated by interleukin-15, while failing to stimulate gliadin sensitive T-cells. This 
suggested that a more complex pathologic situation where the innate immune response was 
also implicated along with gluten-sensitive T-cells in the histological deterioration of the 
small intestine in response to gluten peptides. 
One of the most significant findings to date was the identification of two HLA-DQ2 
restricted T-cell stimulatory α-gliadin peptides corresponding to amino acids 62-75 of α2-
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gliadin and 57-68 of α9-gliadin (Arentz-Hansen 2000). Twelve out of seventeen polyclonal 
T-cell lines had proliferative responses to peptide 57-68, eleven responded to peptide 62-
75. In each case deamidation was found to enhance T-cell proliferation. Peptides not 
containing the α2 and α9 epitopes failed to stimulate gliadin-specific T-cell lines. It was 
proposed that the T-cell response in HLA-DQ2 restricted patients is primarily focused on 
these two immunodominant gliadin epitopes. This theory was supported by similar findings 
by Anderson et al (2000) who investigated peripheral blood T-cell responses to a panel of 
pooled A-gliadin peptides following a five-day oral gluten challenge. A peptide 
corresponding to amino acids 57-73 elicited T-cell responses in eleven out of twelve 
patients but not in controls.  
The significance of these overlapping T-cell epitopes in disease pathogenesis was 
highlighted by Shan et al (2002). They identified a physiologically stable 33-mer peptide, 
corresponding to amino acids 57-89 of α2-gliadin, which included the epitopes identified 
previously by Arentz-Hansen et al (2000) and Anderson et al (2000). Not only was this 
peptide highly immunogenic, but it was also found to be resistant to digestion by gastric, 
pancreatic and small intestinal brush border enzymes. This could suggest that a build up of 
the peptide occurs in the lumen of the small intestine, providing enough time for tTG 
deamidation and thereby increasing recognition of the peptide by specific T-cells. Vader et 
al (2002a) identified an additional 6 T-cell stimulatory peptides which suggested that the T-
cell response in CD was not directed against a small number of gliadin epitopes. T-cell 
lines isolated from paediatric coeliac patients each responded to between one and four 
gluten peptides, representing sequences from both the gliadin and glutenin fractions. They 
also found that some children responded to gluten peptides in their native, non-deamidated 
form. The wide range of gluten peptides recognised by T-cells in young patients lead the 
authors to suggest that epitope focussing may occur as the disease develops. They 
postulated that in the early stages of the disease, T-cells recognise a wide range of 
immunogenic epitopes. As mucosal damage occurs, tTG is released causing deamidation of 
peptides thereby enhancing the T-cell response and the strength of the HLA-DQ2 binding. 
The gluten-specific response progressively focuses on those peptides with the strongest 
binding affinity for HLA-DQ2 and T-cell stimulatory capacity. 
Sjöström et al (1998) identified a T-cell stimulatory peptide corresponding to amino acids 
134-153 of γ-gliadin confirming the disease activating properties of the γ-gliadins. An 
additional three γ-gliadin epitopes and an α-gliadin epitope was identified by Arentz-
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Hansen et al (2002) using recombinant proteins. During the course of these experiments the 
authors observed that there were a high proportion of glutamine and proline residues within 
the stimulatory epitopes. By mapping the numbers of these residues along the length of the 
α- and γ-gliadin proteins, a clear correlation was observed between proline content and 
regions containing stimulatory epitopes. The authors speculated the possible reasons for 
this. The majority of mammalian peptidases are unable to cleave peptide bonds either side 
of a proline residue. The more proline residues within a protein or peptide, the less it will 
be subjected to enzymatic digestion. Furthermore, the spacing between proline and 
glutamine residues has been shown to influence sequences targeted by tTG (Vader 2002b). 
Sequences preferable for tTG deamidation such as QXP, where X is any amino acid, were 
frequently found in regions containing T-cell epitopes. 
Tye-Din et al (2010) increased the evidence for potential candidate epitopes in wheat, rye 
and barley in HLA-DQ2 restricted individuals. They used peripheral blood lymphocytes 
taken after a five-day oral gluten challenge using the relevant cereal to be tested for IFN-γ 
enzyme-linked immunosorbent spot (ELISPOT) testing. They tested oligopeptides, 20 
amino acids in length, 37 in wheat, including 4 HMW glutenin oligopeptides and one 
LMW glutenin oligopeptide, 30 in barley and 29 in rye. They demonstrated that the T-cell 
response in vitro depends on the cereal used in the gluten challenge. A hierarchy of 
peptides was created and those with high IFN-γ secretion were tested with T-cell clones 
from the small intestine. They showed that there were two responses: the most active 
peptides as well as the peptides with the widest response in the individuals tested. They 
further demonstrated that the 33-mer HLA-DQ2 immunodominant peptide (Shan 2002) 
triggered the highest secretion of IFN-γ, however, ω-gliadin peptides triggered a lower 
immune response in a wider selection of coeliac patients. They confirmed previous 
conclusions that the immune response of each coeliac individual is heterogeneous (Vader 
2002a) but were able to demonstrate that T-cell clones from individuals challenged with 
any gluten cereal reacted to two epitopes of ω-gliadin. 
Studies investigating the HLA-DQ8 restricted gliadin epitopes are few as only a small 
proportion of coeliac individuals carry this tissue type. Van de Wal et al have identified two 
HLA-DQ8 restricted T-cell stimulatory epitopes within the gliadins and glutenins (1998, 
1999). More recently the same group investigated the effects of the identified HLA-DQ8 
restricted gliadin epitope on small intestinal organ culture specimens from HLA-DQ8
+
 
individuals. Immune activation and FAS expression in response to this peptide was 
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detected in six out of six HLA-DQ8
+
 individuals but not in HLA-DQ2
+ 
individuals 
(Mazzarella 2003). The authors concluded that the peptide was probably an 
immunodominant HLA-DQ8 epitope. However the peptide was only tested in six patients 
and was not tested with any gliadin specific T-cell lines or clones. Table 1.3 summarises 
the immunostimulatory epitopes to date. 
Table 1.3 Immunostimulatory evidence for epitopes 
Name Stimulating Amino Acid 
sequence (epitope) 
Reference 
α2 gliadin 62-75 





Anderson 2000  
Arentz- Hansen 2000  
Vader 2002a 
Ellis 2003  
Fraser 2003  
A-Gliadin 31-43 
Innate response peptide 
LGQQQPFPPQQPY Shridawi 1994 (p31-49) 
Sturgess 1994 






QYPSGQGSFQPSQQNPQA Mazzarella 2003  
A-gliadin 51-70 SQQPYLQLQPFPQPQLPYSQ Martucci 2003  
α20-gliadin  PQPFRPQQPYPQPQPQ Vader 2003 
γ30-gliadin 222-236 VQGQGIIPQQPAOL Vader 2002a 
γ1-gliadin PQQPQQSFPQQQRPF Vader 2003  
γ 2-gliadin QQPFPQQPQQPFPQ Vader 2003  
HMW glutenins Not known, possibly 
GQQGYYPTSPQQS 
Van de Wal 1999  
Vader 2002a  
Molberg 2003 
Dewar 2006  




1.12  Choice of peptides and immunogens for the present study 
The HMW glutenin glut 04 (QGQQGYYPTSPQQSG) peptide 721-735 (HMW glut04) 
was chosen due to evidence using T-cell clone work (van de Wal 1999) as well as T-cell 
line and monoclonal antibody work (Mitea 2008). It is also contained in the HMW protein 
subunit Dy10. Van de Wal took the entire HMW glutenin molecule and divided it into 
overlapping peptides, 18 amino acids long. He then tested these peptides with a gluten-
sensitive HLA-DQ8 restricted T-cell clone from a single child. The letters in bold highlight 
the optimal stimulating epitope for the clone in van de Wal’s study. Mitea found that the 
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minimum stimulating epitope that monoclonal antibodies recognised was QGQQGYYP, 
which differed slightly to the minimum stimulating epitope that T-cells recognised, 
QGYYPTSPQ. In this study, the peptide containing Mitea’s minimum stimulating epitopes 
for both B and T-cells which also had a high activation count in van de Wal’s research was 
chosen, QGQQGYYPTSPQQSG. This peptide configuration had the second highest 
activity in van de Wal’s work was used as, according to protein chemists from GenScript, 
this was the more stable peptide to make. During the course of this thesis Tye-Din (2011) 
published his work using ELISpot testing of activated peripheral blood mononuclear cells. 
He tested a variety of HMW peptides and the peptide labelled W24 in his study contained 
the HMW glutenin peptide used in this thesis. 
Work done previously in our laboratory, raising monoclonal antibodies against peptides of 
HMW glutenin highlighted some problems (Šuligoj 2011). In order overcome these 
problems, use of multiple antigenic peptides (MAP) as the immunogen had been suggested 
by the MRC laboratory in Cambridge. These are large molecules with a central, inert core 
of branched poly-lysine residues to which the peptide of interest is attached, either 4 or 8 
times depending on the size of peptide used, (Posnet 1989) which collectively affords 
molecular mass large enough to trigger an immune response (see section 6.1). However the 
peptide used in HMW glut04 MAP had to be changed as the chemists from Cambridge 
Peptides making the MAP, considered the original peptide, QGQQGYYPTSPQQSG, 
would form ring structures in MAP format and would be difficult to make. The peptide 
QPGQGQQGYYPTSPQ was used as a compromise, having the 5
th
 highest activity in van 
de Wal’s work. 
The LMW glutenin peptide (LMW glt156) 44-59 PPFSQQQQSPFSQQQQ was chosen, the 
glutamines underlined requiring deamidation. The choice was determined by 
transformation assays using T-cell clones in children (Vader 2002a). In this study, Vader 
tested a number of different peptides and protein fragments, some were known to be 
immunostimulatory while others were novel. Vader tested two novel LMW glutenin 
peptides LMW glt156 and LMW glt17. The LMW glutenin peptide chosen for the studies in 
this thesis had the highest stimulation index and was able to stimulate more childrens’ T-
cell clones than the other LMW glutenin peptide tested. The numbers were small however, 
with only 4 out of 16 T-cell clones stimulated for LMW glt156 versus 3 out of 16 for the 
other LMW glutenin fragment glt17. There were no problems with the manufacture of MAP 




Van de Wal (1999) and Vader (2002a) have identified potential HLA DQ8 coeliac 
immunostimulatory epitopes in children in both high molecular weight and low molecular 
weight glutenins by testing against gluten-sensitive T-cell clones. Neither of these epitopes 
has been tested in T-cell lines or in small intestinal organ culture. 
I wish to further assess the immunostimulatory potential of high molecular weight glutenin 
glut04 and low molecular weight glutenin156 in coeliac individuals and type 2 refractory 
coeliac individuals by 
I. Transformation assays of gluten-sensitive T-cell lines with candidate epitopes 
II. Measurement of interferon-γ secretion in the transformation assays 
III. Morphometric assessment of coeliac duodenal biopsies incubated with candidate 
epitopes 
IV. Measurement of interleukin-15 secretion from these biopsies 
The null hypothesis of these studies is that both the KHW glut04 and LMW glt156 glutenin 
peptides do not stimulate gluten-sensitive T-cells isolated from the mucosa of coeliac 
patients. They will also not damage the biopsy of coeliac and type 2 refractory coeliac 
patients when placed overnight in organ culture sytem. 
I wish to raise monoclonal antibodies against these two peptides with a view to producing 
improved methods of gluten measurement. 
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The patients used in this study were either treated coeliac disease on a gluten-free diet or 
untreated coeliac disease therefore still on their gluten-containing diet. For the organ 
culture group, patients with type 2 refractory coeliac disease were also included. Treated 
patients were diagnosed following the revised ESPGAN criteria (Walker-Smith 1990) and 
were attending endoscopy as part of their ongoing clinical management. Untreated coeliac 
patients were undergoing endoscopy for suspected coeliac disease either with symptoms or 
with positive serology. These patients were only included if the histology confirmed the 
diagnosis of coeliac disease, otherwise these patients were used as negative controls. The 
diagnosis of type 2 refractory coeliac disease was confirmed if the patients had no other 
cause of villous atrophy identified, were on a gluten-free diet with negative coeliac 
serology, and had clonality of their intra-epithelial T- cell receptor (Cellier 2000). 
Ethical approval was obtained for all experiments (LREC 05/Q0702/167) and every patient 
gave their written, informed consent prior to the procedure. 
 
2.2 Prolamins 
2.2.1 Enzymatic digestion of whole gluten 
Small intestinal T-cells are normally presented with digested gluten peptides by antigen-
presenting cells in the gut (Lundin 1993). In order to replicate this spectrum of gluten 
peptides, industrial gluten was digested with pepsin and trypsin for use in the restimulation 
of small intestinal T-cell lines and positive controls in both the T-cell studies and small 
intestinal organ culture studies. The following modified method of Frazer’s original method 
(Frazer 1959, Bolte 1996) was used at 37°C: 
1. 1 gram of industrial gluten was dissolved in 50ml 0.1M hydrochloric acid and the 
pH adjusted to 2. 
2. 4000U pepsin-coated agarose beads from porcine gastric mucosa (P0609, Sigma) 
was added and incubated for 2 hours stirring with a magnetic stirrer. 
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3. To remove the pepsin, the mix was centrifuged for 20 minutes at 2000 revolutions 
per minute (rpm) (500g). 
4. The pH of the supernatant was adjusted to 7.8 with 1M sodium hydroxide 
5. 25U of trypsin-coated agarose beads (T1763, Sigma) was added and incubated for 2 
hours at 37°C stirring with a magnetic stirrer. 
6. The mix was centrifuged for 20 minutes at 2000rpm (500g) to remove the trypsin.  
7. 1M hydrochloric acid was added to adjust the pH of the supernatant to 7.0. 
8. The pepsin trypsin digest was dried in a glass petri dish at 37°C, scraped off and 
stored at room temperature. 
 
2.2.2 Antigen preparation 
Two groups have reported that deamidation of peptides is crucial for T-cell recognition of 
peptides (Arentz-Hansen 2000, Anderson 2000). This can be achieved in vitro by pre-
incubating peptides with tissue transglutaminase (tTG). For the T-cell studies all gluten 
fractions and control proteins were pre-treated with tTG prior to incubation with the 
antigen-presenting cells (APC) in the transformation assay. This included PT gluten and 
Frazer’s fraction III (FFIII). The method used was as follows: 
400µg/ml of antigen and calcium chloride (CaCl2, C3881, Sigma), to a final concentration 
of 1mM in phosphate-buffered saline (PBS, P4417, Sigma), were incubated with 100 µg/ml 
guinea pig liver tissue transglutaminase (T3598, Sigma) for 4 hours at 37ºC. 
The mix was then irradiated for 30minutes to sterilise it. 
For tTG treatment of synthetic peptides the following recipe was used: 
500µg/ml peptide and CaCl2 to a final concentration of 1mM in PBS were incubated with 
100µg/ml guinea pig tissue transglutaminase for 4 hours at 37ºC. 
The mix was irradiated for 30 minutes to sterilise it. 
FFIII and PT gluten were not tTG pre-treated for the organ culture experiments as 
deamidation has been shown to occur by endogenous tTG within the mucosal tissue in 
culture (Molberg 2001). 
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2.3 Small intestinal biopsy organ culture 
The organ culture system used in my study differs only slightly from the original method 
described by Browning and Trier in 1970. Organ culture medium, containing either a test 
glutenin peptide (200μg/ml) or a control protein (1mg/ml), was prepared two hours prior to 
obtaining the biopsies and drawn up into 2ml syringes. Culture medium preparations were 
kept at 37ºC until required. Sterile Falcon organ culture dishes (353037, VWR) were 
prepared in advance: 1ml of sterile distilled water was added to the outer well, a sterile 
stainless steel wire grid was placed over the central well and the dishes kept at 37 ºC until 
required.  
Duodenal biopsies were taken using an Olympus GIF H260 endoscope and radial jaw large 
cap with needle biopsy forceps in the second part of the duodenum. Biopsies for routine 
histology were taken first. Biopsies used for the culture experiments were immediately 
placed in warmed (37 ºC) medium which was kept warmed in the hands of the 
experimenter. These were quickly transported back to the laboratory while being kept at 
37ºC. 
One or two biopsies were carefully arranged on each wire grid so that the villi were 
uppermost. Harvested duodenal biopsies have a tendency to “curl up” with the villi pointing 
outwards which helps establish the correct orientation of tissue. The grid was placed over 
the central well of the organ culture dish and pre-warmed culture medium, with or without 
the test peptides, was slowly injected into the central well until it was drawn over the tissue 
by capillary action. Excess medium was drawn back into the syringe so as not to 
completely submerge the tissue, leaving between 0.5 and 1ml of medium in the central well 
so that the biopsies are in contact with two thirds of the medium. See figure 2.1 for a cross 
section representation of this. 
The culture dish lid was replaced and the system placed within a sealed chamber. A gas 
mixture of 95% O2/ 5% CO2 was allowed to flow through the chamber for one minute prior 
to sealing the chamber. The chamber was sealed and gas was further introduced until a 
pressure of 2psi was reached. The time period between excision of small intestine and 
placement in the organ culture chamber was approximately 10 minutes. The culture system 
was incubated for 18-20 hours at 37ºC. 
Culture dishes were removed from the sealed chamber the following day. Culture medium 
was aspirated from the central well, the volume measured and kept at -20°C until required 
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for cytokine analysis (see section 2.5). The wire grids with the biopsy material were placed 
onto blotting paper allowing the excess medium to be removed. Biopsies were placed on 
aluminium foil to be weighed and then fixed in 10% formal saline (see appendix II) for 48 
hours. The biopsies were embedded in paraffin wax, sectioned and stained with 
haematoxylin and eosin (640401 and 640385, Clin-Tech) described in section 2.6, and anti-
IL-15 (AF315, R+D Systems), as covered in section 2.5. 
 







2.4 T-cell studies 
2.4.1 Isolating peripheral blood mononuclear cells from blood 
After giving their written, informed consent, 50ml of blood was collected from patients at 
endoscopy. Blood was taken in a sterile syringe and transferred to a sterile Falcon 50ml 
tube (352098, SLS) containing 100µl heparin (1000U/ml, LEO Laboratories) and mixed 
thoroughly. The protocol used for separating the mononuclear cells as follows: 
1. Bloods was centrifuged at 3000rpm (1200g) for 10 minutes. 
2. The plasma “supernatant” was removed, leaving the white cell interface layer intact. 
3. The remaining cell mixture was gently mixed and 10ml was transferred to a 50ml 
Falcon tube 
4. 28ml Rosewell Park Memorial Institute (RPMI) medium (E15-840, PAA) was 
added and mixed thoroughly 
5. The RPMI/blood mix was carefully under-laid with 10ml Lymphoprep (1114545, 
Axis-Shield PoC) 
6. The mix was centrifuged at 3000rpm (1200g) for 20minutes. 
Biopsies on grid 
Culture 
dish 
Water Culture medium 
with test peptide 
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7. White cells contained in the grey “buffy coat” under laying the pink RPMI layer 
were collected using a squeezing pipette and transferred to a 50ml Falcon tube, see 
figure 2.2. 
8. The white cell mix was centrifuged at 2000rpm (500g) for 15 minutes 
9. The supernatant was carefully poured off. 
10. The resulting cell pellet was loosened and resuspended in autologous plasma 
medium (ASM). 
11. The peripheral blood mononuclear cells (PBMC) were carefully frozen down for 
future use (see method for freezing/thawing cells, section 2.4.7). 










RPMI Roswell Park Memorial medium 
 
2.4.2 Obtaining autologous plasma for culture medium 
Plasma was heated at 56 ºC for 35 minutes to inactivate complement proteins and then 
centrifuged at 3000rpm (1200g) for 10 minutes. The plasma supernatant was collected to 




“Buffy coat” containing white blood cells 
Erythrocyte layer 
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2.4.3 Isolating T-cells from in vitro prolamin-challenged duodenal biopsies 
The establishment of small intestinal T-cell lines in vitro was based on methods from 
Molberg et al (2000). Duodenal biopsies were obtained from both untreated and treated 
coeliac patients using the organ culture method as described earlier in section 2.3. Four to 
six biopsies were set up on a single stainless steel grid in the organ culture system and 
cultured overnight at 37 ºC in organ culture medium (see appendix 2 for recipe) containing 
either FFIII or PT gluten (5mg/ml), as the resulting T-cell line was to be tested for 
reactivity to glutenin peptides. Following overnight incubation, biopsies were finely 
minced with two sterile scalpel blades. The minced biopsy material was run through a 
70µm filter (352350, SLS) to remove non-degradable material and epithelial cells. This was 
labelled as the debris fraction and resuspended in autologous serum medium after washing 
twice in 10ml ASM warmed to 37 ºC and centrifuging at 1500rpm (300g) for 7 minutes. 
The filtered cells as well as the liquid from the organ culture plate were labelled as the SIL 
fraction, resuspended in 10ml autologous serum medium and washed twice by centrifuging 
at 1500rpm (300g) for 7 minutes. The supernatant was discarded and the cell pellet was 
resuspended in 1ml autologous serum medium with 1x10
6
 irradiated (22 gray) autologous 
PBMC and 10U/ml human, recombinant interleukin-2 (IL-2, I2644, Sigma) in one well of a 
48 well plate (353078, SLS). 
 
2.4.4 Maintenance of T-cell lines in culture 
10 U/ml IL-2 was added to the T-cell culture on day one, and at three day intervals 
subsequently. Medium was refreshed every 2-3 days depending on cell growth rate. This 
involved carefully removing 1ml of medium and replacing it with fresh ASM and IL-2 at 
10U/ml, ensuring that the cell layer at the bottom of the well was not disturbed. On day 
seven the culture was restimulated as follows: 1x10
6
 autologous, irradiated autologous 
PBMC were incubated for 18 hours with the stimulating antigen, either PT gluten or FFIII 
(100µg). Unless otherwise stated it can be assumed that all whole gluten antigens such as 
PT gluten or FFIII are pre-treated with tTG. T-cells were counted and were resuspended in 
1ml of medium containing pre-pulsed PBMC in a ratio of 1:1. The cell line was thereafter 
maintained on a weekly stimulation cycle by feeding with IL-2 (10U/ml) every 3-4 days 
after refreshing the medium. 
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RPMI medium contains a bicarbonate buffer and phenol red indicator, the correct colour for 
the medium is bright orange indicating a pH of 7.2. A pink colour indicates a raised pH 
which suggests there is insufficient CO2; yellow medium is an indicator of acid production 
as a result of rapid cell growth and suggests the culture needs feeding. 
To avoid overcrowding when cells were growing rapidly, cell suspensions were split by 
transferring either half or a third of the cell suspension to a new well. This was then made 
up to the volume with fresh ASM and IL-2 was added. 
2.4.5 T-cell proliferation assay 
For the T-cell proliferation assays, autologous PBMC were used as antigen-presenting cells 
(APC): either fresh PBMC or thawed from cold storage. The PBMC were counted using a 
haemocytometer and sufficient cells isolated to allow 5x10
4
 cells per well. Cells were 
suspended in autologous serum medium at 50µl/well. To prevent APCs proliferating in 
response to antigen, PBMC were irradiated. A dose of 22 grey was found to be sufficient to 
prevent cell growth (Molberg 2000). Irradiated cells were added to a 96 well U-bottomed 
plate (353077, Nunc). Each condition was tested in triplicate, or duplicates if cell numbers 
were low. 
In order to assess the cell viability, a test of T-cells with phytohaemagglutinin (PHA) as 
well as non-irradiated APCs with PHA were included. Phytohaemagglutinin is a potent 
stimulator of lymphocyte cell division. A test of T-cells with APC alone was included in 
each assay as a baseline. A negative protein was not included in the assay as previous work 
done in the laboratory demonstrated no T-cell response raised against ovalbumin (Ellis 
2003). 
APC were incubated with antigen at 37ºC; the incubation time depended on the size of the 
antigen. For small peptides, 4 hours was considered sufficient to ensure the antigen was 
completely taken up and processed by the APCs. A more complex antigen such as PT 
gluten or FFIII required 18 hours (Molberg 2000). Each test was performed in triplicate; 
when there were insufficient cells for triplicate tests, duplicate tests were performed. Whole 
proteins (FFIII, PT gluten) were used at a final concentration of 100µg/ml. Peptides were 
used at a final concentration of 10µg/ml (unless otherwise specified). 
T-cell lines to be tested for antigen reactivity were counted using a haemocytometer and 
adequate numbers removed to allow 5x10
4
 cells per well, the total number of Tcells 
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required for the transformation assays was 1.08x10
6
 to allow for wastage. The cell lines 
were not used after 3 weeks in culture to minimise the risk of a particular T-cell clone 
dominating the cell lines. Cells were centrifuged (1500rpm (300g) for 7 mins), resuspended 
in medium and added to the pre-pulsed APC. The well total volume was made up to 200µl/ 
well before incubation at 37ºC for 48 hours, although 18 hours was considered sufficient if 
the colour of the medium was indicative of a rapid proliferation response. Tritiated 
thymidine (
3
H; Amersham) was added at 1µCu/well (37,000Bq/well) in 20µl medium and 
the assay incubated at 37ºC for a further 18 hours. Prior to the addition of 
3
H, 100μl from 
each well was carefully aspirated, combined for each test condition and stored at -20°C for 
interferon-γ analysis by ELISA (see section 2.5.1). Fresh ASM was replaced. Plates were 
harvested using a Tomtec Cell Harvester (Receptor Technologies Ltd) and 
3
H-thymidine 
incorporation into the nuclei of proliferating cells was measured using a Wallac 1450 
MicroBeta Plus liquid scintillation counter (PerkinElmer). Stimulation indices (SI) for each 
antigen were calculated by dividing the mean counts per minute (CPM) for the T-cells plus 
APC plus test antigen by the CPM for T-cells plus APC alone. 
2.4.6 Freezing of cells for liquid nitrogen storage 
Cells to be frozen were centrifuged, resuspended in fresh medium and cooled on ice. To 
prevent rupture of cell membranes, ice cold 20% dimethyl sulphoxide (DMSO, D2650, 
Sigma), in autologous plasma medium, was added drop-wise to the cold cells until a final 
concentration of 10% was reached. 1ml aliquots of the cell mixture were frozen in Nunc 
cryotubes (368632, VWR)to -20ºC overnight and then to -70 ºC the following day for at 
least two hours before transferring to liquid nitrogen for indefinite frozen storage. 
When required, cryotubes were removed from liquid nitrogen and thawed rapidly under 
running cold tap water. One ml of of ice-cold RPMI medium was added very slowly 
dropwise with continual shaking, followed by a further 9ml more rapidly with continual 
shaking to dilute the DMSO. The cell solution was centrifuged at 1500rpm (300g) for 7 
minutes and the resulting cell pellet resuspended with 11ml RPMI medium to be further 
centrifuged at 1500rpm (300g) for 7 minutes. The cell pellet was resuspended in ASM. 
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2.5 Cytokine analysis 
2.5.1 Interferon-γ ELISA 
Supernatants from the proliferation assays were analysed for interferon-γ (IFN-γ) 
production using a non-competitive (sandwich) enzyme-linked immunosorbant assay 
(ELISA). A hundred microlitres from each well was removed, and replaced with fresh 
ASM, prior to the addition of tritium in the proliferation assay (see section 2.4.5). The 
supernatants from each of the test peptides were combined in order to facilitate 
measurement. A commercial kit (DY285, R+D Systems) was used to measure IFN-γ 
concentration using the methodology described here. 
The IFN-γ ELISA employed human recombinant IFN-γ as a standard and two antibodies: a 
mouse anti-human IFN-γ capture antibody and a biotinlyated goat anti-human IFN-γ 
detection antibody. All analyses were carried out on the same day and the lowest sensitivity 
of the assay was 7pg/ml.The protocol is described in brief below; all steps were carried out 
at room temperature and all products were supplied in the kit apart from bovine serum 
albumin (BSA, A7030, Sigma) and phosphate-buffered saline (PBS, P4417, Sigma).  
1. A 96 well microtitre plate (430341, SLS) was coated with 100μl capture antibody 
2. The plate was sealed and incubated overnight 
3. The plate was blocked with 400μl 1% w/v BSA in PBS for an hour 
4. 100μl of sample or standard was added and incubated for 2 hours  
5. 100μl of detection antibody was added and incubated for 2 hours 
6. 100μl of Streptavidin-HRP was added and incubated for 20 minutes in the dark 
7. 100μl of substrate solution was added (1:1 mix of hydrogen peroxide and 
tetramethylbenzidine, DY999 R+D Systems) 
8. 50μl of stop solution was added (supplied in the kit) 
The plate was washed thrice with PBS/1%v/v Tween 20 (T9039, Sigma) after steps 2-6. 
Positive control was supplied in the kit as human recombinant IFN-γ and used to generate a 
standard curve for each plate. A negative control of ASM only was used. The optical 
density of each sample was determined using an ELISA reader (Biotec ELx800) with the 
wavelength set at 450nm. Using the standard curve obtained, the concentration of cytokine 
in each sample was calculated. Figure 2.1 is an example of the standard curve obtained. The 
net secretion of interferon-γ was calculated by subtracting the concentration obtained from 
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a well containing ASM only from the concentration measured in the combined supernatents 
from each well.  
 
Figure 2.3 A typical standard curve from the low sensitivity IFN-γ ELISA 
 
2.5.2 High sensitivity interleukin-15 ELISA 
The level of interleukin-15 (IL-15) secretion from small intestinal organ culture 
experiments was known to be low therefore an assay with a higher sensitivity was used for 
these experiments. A commercial kit was used (DY1500, R+D Systems). All the analyses 
were carried out on the same day with the lowest sensitivity of the kit detecting 3.9pg/ml. 
The IL-15 high sensitivity ELISA plate already came pre-coated with mouse monoclonal 
antibody against human IL-15 and employed two antibodies: a standard of recombinant 
humanised IL-15 and a detection antibody of mouse anti-human IL-15. All reagents, apart 
from PBS (P4417, Sigma), were supplied in the kit, the protocol in brief, was as follows, all 
steps were carried out at room temperature: 
1. A seven point standard curve was prepared by doubling dilutions from 250pg/ml 
solution of IL-15 in organ culture medium 
2. 100μl per well of either standard or sample was added to the pre-coated microplate 
and incubated for 3 hours 
3. 200μl of Streptavidin-HRP was added to each well and incubated for 45 minutes 
4. 200μl of substrate reagent (1:1 mix of hydrogen peroxide and tetramethylbenzidine, 
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5. 50μl of stop solution (2M sulphuric acid) was added to each well  
The plate was washed with wash buffer (PBS/1%v/v Tween 20) four times after steps 2 and 
3.  
Positive control was supplied in the kit as recombinant humanised IL-15 and used to 
generate a standard curve for each plate. A negative control of ASM only was used. The 
optical density of each sample was determined using an ELISA reader (Biotec ELx800) 
with the wavelength set at 450nm. Using the standard curve obtained, the concentration of 
cytokine in each sample was calculated as picograms secreted per weight of tissue after the 
concentration of ASM was subtracted from each value obtained from the standard curve. 
 
2.6 Histological assessment of formalin-fixed, paraffin-embedded coeliac small 
intestinal tissue sections 
2.6.1 Fixing of tissue in formalin 
Tissue that has been fixed in 10% v/v formal saline has better preservation of morphology 
than frozen sections. After overnight incubation with either the control proteins or the 
candidate peptides (see section 2.3), biopsies were weighed on aluminium foil, placed villi 
uppermost on 0.45µm cellulose nitrate membrane filter (FDC-860-132G, Whatman Fisher 
Scientific) and submerged in 20ml of 10% formalin. They were incubated at room 
temperature for 48 hours before embedding in paraffin wax for sectioning, see section 2.6.2 
below. 
2.6.2 Embedding of tissue in paraffin wax 
Paraffin wax is immiscible with water therefore tissue must be dehydrated before the 
molten wax is added. The biopsies were wrapped in filter paper and placed in labelled 
embedding cassettes with stainless steel covers. These cassettes were then placed in graded 
ethanol baths at room temperature. The small intestinal biopsies were immersed in 400ml 
70% v/v 74OP ethanol, followed by 400ml 95% v/v 74OP ethanol and then in 400ml 100% 
v/v 74OP ethanol each time for a minute. Finally the biopsies were immersed in three 
different 400ml xylene baths for a minute each. The biopsies on the membrane were then 
angled at 45° to the bottom of base moulds where molten paraffin at 58°C was added and 
left to set on a cold plate using Paraffin Embedding Machine (LS-100+ Embedding Center, 
Bio-Equip) in St Thomas Hospital Histopathology department. 
75 
2.6.3 Cutting of sections onto slides 
Sections were cut to 4µm on a Leitz microtome and floated in a water bath onto glass 
slides. Tissue adherence to the slides was enhanced by using SuperFrost Ultra Plus 
adhesion slides (631-0099, VWR). The sections were then baked overnight onto the slides 
at 60°C.  
2.6.4 De-waxing of tissue sections 
Paraffin was removed prior to staining by heating to melt the wax and immersing cut small 
intestine tissue sections in xylene and graded ethanols. Sections were heated to 60°C for 
15-30 minutes on a slide warmer, until the wax melted. The slides were then immersed in 
three sequential 400ml baths of xylene for a minute each at room temperature. Slides were 
placed in graded ethanol baths for a minute each, starting at 400ml of 100% v/v 74OP 
ethanol and then 400ml 95% v/v 74OP ethanol and 400ml 70% v/v 74OP ethanol. Slides 
were immersed in a 1l basin in running tap water for 5 minutes. 
2.6.5 Hematoxylin and eosin staining 
Small intestinal tissue sections were stained for morphometric assessment of enterocyte cell 
height using Mayer’s Haemalum (640401, Clin-Tech) and 1% w/v Eosin (640385, Clin-
Tech). Slides were de-waxed as per section 2.5.4. Unless otherwise stated all steps were 
carried out at room temperature. Tap water in London is weakly alkaline and therefore used 
instead of a weakly alkaline solution in this protocol: 
1. Slides were placed in 400 ml Mayer’s Haemalum for 5 minutes 
2. They were then placed in running tap water for 5 minutes to “blue” the nuclei 
3. The slides were than placed in 400ml 1% v/v acid alcohol (see appendix II) for 3 
seconds to help differentiate the nuclei. Acid alcohol was made the day of use for 
best results. 
4. They were then placed in running tap water for a further 5 minutes to “blue” the 
nuclei 
5. The sections were examined under a microscope to assess the density of nuclear 
staining. If over-stained steps 4 and 5 were repeated, if under-stained then steps 1-5 
were repeated until satisfactory staining was achieved. This was seen as dark blue 
nuclei seen in the sections with little cytoplasmic staining. 
6. Slides were placed in 400ml 1% w/v Eosin for 2 minutes 
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7. These were washed in running tap water for 30 seconds 
8. The slides were examined for correct nuclear and cytoplasmic staining under a 
microscope before dehydrating as per section 2.5.2. 
9. Sections were covered with a coverslip and DPX, a neutral mounting medium 
(610301, Clin-Tech) and dried overnight at room temperature. 
2.6.6 Immunohistochemistry 
An indirect immune-peroxidase method was used to detect interleukin-15 (IL-15) within 
the formalin-fixed paraffin-embedded sections of small intestine. This method uses the high 
affinity of avidin for biotin. A primary antibody was applied to the tissue sections which 
recognise IL-15. A secondary biotintylated antibody binds to this primary antibody 
following which enzyme-labelled avidin binds to the biotin. The enzyme used in these 
experiments, horseradish peroxidise, is developed by a chromogen, 3,3’ diaminobenzidine 
tetrachloride (DAB), to give a brown colouration. The strong affinity of avidin for biotin 
and the mild biotintylation process make the avidin-biotin methods more sensitive than 
other direct and indirect methods (Hsu et al 1981).  
Formalin fixation of tissues conceals antigen binding sites by altering the tertiary structure 
of proteins. Microwaving formalin fixed sections in a citrate buffer rescues binding sites for 
antibodies previously considered unsuitable for use in routinely processed material (Shi et 
al 1991). The method works by disrupting cross links in the polypeptide backbone induced 
by formalin. The metal salts used in the buffer further unfold the protein tertiary structure 
by the dissociation of hydrogen bonds allowing antigens to be recognised by a specific 
antibody (Norton 1993). A potential problem with the microwaving step is loss of 
adherence of tissue sections to the glass slides hence the use of SuperFrost Ultra Plus 
adhesion slides (631-0099, VWR).  
2.6.6.1 Microwave processing of tissue sections 
Slides were immersed in 400ml pre-warmed (37 ºC) 0.01M tri-sodium citrate solution 
(pH6.0) on a glass rack in a microwave proof container. They were then microwaved at 700 
watts for 10 minutes, in two timed sections of 5 minutes with replenishment of buffer to 
prevent slides from drying out. The length of time required for microwaving was calculated 
in preliminary experiments since this varies between tissues. The length of time was also 
confirmed with immunohistochemistry technicians at St Thomas Histopathology 
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department who also agreed with the timings. After microwaving, the slides were taken out 
of the sodium citrate solution and placed directly into warm PBS (37ºC) prior to staining.  
2.6.6.2 Avidin-Biotin-Complex staining method of small intestinal sections 
All steps were carried out at room temperature and the tissue sections were not allowed to 
dry out. A commercial kit for anti-goat horseradish peroxidise-DAB cell and tissue staining 
(CTS008, R+D Systems) and human IL-15 antigen affinity purified polyclonal goat 
antibody (AF315, R+D Systems) was used according to the manufacturer’s instructions and 
dropper bottles supplied:  
Endogenous peroxide activity was blocked to prevent non-specific background staining by 
covering the sections with 2 drops of 3% hydrogen peroxide for 5 minutes at room 
temperature. This was then rinsed with 2ml PBS and gently washed with 2ml PBS for 5 
minutes in case the tissue sections were loosened by hydrogen peroxide. To prevent non-
specific binding of secondary antibody the sections were incubated with 2 drops of goat 
serum blocking reagent for 15 minutes. Slides were drained and excess serum was carefully 
wiped off.  
The sections were incubated with 2 drops of avidin blocking reagent (CTS008, R+D 
Systems part 865009) for 15 minutes. They were then rinsed with 2ml PBS, drained and 
excess buffer carefully wiped off. Two drops of biotin blocking reagent (CTS008, R+D 
Systems part 865008) were added. The slides were incubated for 15 minutes, then rinsed 
with 2ml PBS, drained and excess buffer carefully wiped off. The sections were incubated 
with human IL-15 antigen affinity purified monoclonal antibody at 7μg/ml. This had been 
pre-determined by titration until cellular staining was preserved with little background 
staining. The sections were rinsed and then washed three times in 2ml PBS for 15 minutes 
per wash. Slides were drained and excess buffer carefully wiped off. One to three drops of 
biotintylated secondary antibody was incubated with the section for 45 minutes. The slides 
were then rinsed, washed 3 times with 2ml PBS for 15 minutes per wash, drained and 
excess buffer carefully wiped off. Two drops of high sensitivity streptavidin-horseradish 
peroxidase were incubated for 30 minutes. The sections were rinsed, washed three times 
with 2ml PBS for 2 minutes per wash, drained and excess buffer carefully wiped off. Two 
drops of DAB chromogen solution were added to cover the entire sample and incubated for 
7-20 minutes. The colour development was monitored under a light microscope to ensure 
proper intensity of staining. The slides were rinsed with distilled water and washed in fresh 
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distilled water for 5 minutes. The slides were mounted with DPX (610301, Clin-Tech) and 
dried overnight at room temperature. 
2.7 Monoclonal antibody production 
2.7.1 Animals 
An animal project licence number 70/5688 and a personal licence number 70/21925 was 
obtained by attending modules 1-5 of the Home Office Personal Licensing Course. All 
animal work was done under the Home Office severity grading of “mild”.  
A breeding pair of Balb-C mice were obtained from a designated breeding establishment 
(Harlan) and bred. The standard rodent diet contains gluten and previous work has shown 
that better antibody responses are obtained in animals that are not consuming gluten (Ellis 
1998). A gluten-free diet from birth ensures the mice are antigen naïve and therefore the 
mother of the litter, when suckling, was on a gluten free diet and the pups were weaned 
onto a gluten-free diet (dextrose (off) TD.95148, Harlan).  
2.7.2 Conjugation of peptides to tuberculin purified protein 
The tuberculin purified protein available (PPD, 2T.U/0.1ml, 12-817-01, Statens Serum 
Institut), which is also used for mantoux testing, contains glycerol and preservatives. As a 
purified tuberculin protein derivative (PPD) is required for conjugation to smaller peptides 
the following method was used to clean the PPD, conjugate it to the relevant peptide and 
precipitate the conjugated peptide in order to use it in immunisation schedule in section 
2.7.3.  
As PPD is light sensitive the steps were protected from daylight by either wrapping the 
beaker in foil or performing the experiments in a dark cupboard. The PPD was added to 
dialysis tubing (molecular weight cutoff 1000 Daltons, D7884, Sigma) and dialysed at 
room temperature against three 400ml changes of PBS for 45 minutes to remove glycerol. 
The volume of PPD suspension was measured and four times that volume were added of -
70°C acetone. After an hour of incubation at -70°C, this mixture was centrifuged at 
3000rpm (1200g) for ten minutes and the pellet was allowed to air dry before being 
weighed. A molar ratio of 2:1 of PPD:peptide was calculated and was dissolved in PBS to 
give a final concentration of 2mg/ml of PPD. Fresh, grade 1 gluteraldehyde (G5882, 
Sigma) was added to this volume to give a final concentration of 0.05% and incubated for 
18 hours at room temperature.  
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After the overnight incubation, ammonium chloride (A4514, Sigma) was added to give a 
final concentration of 0.1M and stirred for 30 minutes at room temperature. The final 
volume was measured and four volumes of -70°C acetone was added. This was incubated at 
-70°C for an hour before centrifugation at 3000rpm (1200g) for ten minutes. The pellet was 
air dried before diluting to a concentration of 1mg/ml in normal saline.  
2.7.3 Immunisation schedule 
Mice, once adult, were immunised in groups of three for each immunogen. They were 
given subcutaneous injections of multiple antigenic peptides (MAPs) 100μl per mouse 
(3mg/ml in 0.9% saline) emulsified in a 1:1 v/v ratio with complete Freund’s adjuvant 
(CFA, 642851, MP Biomedicals). This was followed a month later by 100μl per mouse 
MAP (3mg/ml in 0.9% saline) emulsified in a 1:1 ration with incomplete Freund’s adjuvant 
(IFA, 642861, MP Biomedicals) subcutaneously. A tail bleed was performed 10-14 days 
afterwards to assess the antibody response, see section 2.7.4 and 2.7.5 below. Two to ten 
weeks after the tail bleed, animals with a good antibody response were given an 
intravenous injection into the tail of 50µg peptide dissolved in 100µl normal saline. Mice 
were sacrificed three to five days later and used for fusion experiments to create 
hybridomas, covered in sections below.  
If mice were being immunised with tuberculin-purified protein derivative conjugates of the 
peptides then prior sensitisation to the tuberculin protein was required. This was achieved 
by a 100μl subcutaneous injection of tuberculin protein used for BCG vaccine (0.2-0.8 
million bacteria made in 1ml Diluted Sauton SSI, both Statens Serum Institut) 2 weeks 
prior to the immunisation schedule. The animals were immunised following the same 
protocol as for the MAPs.  
2.7.4 Mouse tail bleed  
Ten to fourteen days after the incomplete Freund’s Ajuvant subcutaneous injection the mice 
were venesected by a tail bled to assess the antibody response the immunogen. Prior to this, 
if required, the mice underwent ear notching by the animal house staff to ensure easy 
identification of individual mice.  
Mice in their cages, with ready access to water, were placed in an incubator at 40°C for half 
an hour to allow vasodilation. Each mouse in turn was placed in a restrainer device with the 
tail left free. The distal third of the tail was cut at a 45° angle to the skin with a sterile 
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scalpel. A few drops of blood were collected in 1.5ml Ependorf centrifuge tubes and the 
tails blotted with soft gauze to ensure haemostasis. The Ependorf tubes were centrifuged at 
13000rpm (10,000g) for 5 minutes using a bench-top centrifuge (MSE MicroCentaur). The 
serum was collected and diluted 1:100 v/v in 0.9% saline for ease of use in ELISA and 
stored until further analysis at -20°C.  
2.7.5  Tail bleed analysis of antibody response to immunogen 
Blank ELISA plates (430341, Nunc) were coated overnight at 4°C initially with 100μl 
Fraser’s Fraction III 25μg/ml in carbonate buffer and subsequently 100μl pepsin trypsin 
digested (PT) industrial gluten 25μg/ml in 60% ethanol as well as 100μl PT recombinant 
Dy10, a HMW glutenin protein subunit containing HMW glut04, at a concentration of 
3.8μg/ml in carbonate buffer, or 100μl MAP LMW glt156 at a concentration of 50μg/ml in 
60% ethanol. The plates were washed three times with 250μl PBS/0.05% Tween 20 (P9416 
Sigma) and blocked with 200μl 1% bovine serum albumin (A7030, Sigma) for an hour at 
37°C. The plates were washed three times with 250μl PBS (P4417, Sigma) /0.05% Tween 
20 and covered and stored at -20°C if not being used immediately. 
Negative control serum was from Balb-C mice at the time of cull, having previously been 
immunised with HLA DQ8 immunodominant peptide and found not to have mounted a 
serological response. The resultant optical density from the serum was multiplied by a 
factor of 2 in order to have a negative optical density result. Positive control for HMW 
glut04 was serum of mice previously successfully immunised with recombinant HMW 
Dy10 by Dewar (2009) as part of his MD thesis. 
The coating concentrations had been worked out in earlier experiments, not shown in this 
thesis. Serum from the first group of mice immunised in Chapter 5 was tested at different 
coating concentrations ranging from 6.25μg/ml to 100μg/ml. The proteins were diluted in 
carbonate buffer, PBS and 60% ethanol each used at these different concentrations. The 
optimum coating antigen concentration was able to detect the samples and the positive 
control of previously immunised Dy10 immunised mouse serum as well as having a low 
background optical density. 
The protocol is described in brief below; all steps were carried out at 37°C:  
1. 100μl of sample or control serum was added and underwent doubling dilutions 
before incubated for 45 minutes 
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2. Anti-mouse IgG-alkaline phosphatase antibody produced in rabbit was added (1 in 
2000, A4312, Sigma) and incubated for 45 minutes  
3. 100μl of alkaline phosphatise yellow (pNPP) liquid substrate (P7998, Sigma) was 
added and incubated in the dark for 20-30 minutes. 
The plate was washed with PBS/0.05% v/v Tween 20 (T9039, Sigma) after step 1 and 2. 
The optical density of each sample was determined using an ELISA reader (Biotec 
ELx800) with the wavelength set at 405nm.  
A positive titre was taken as a result greater than 1:6400 as previous experiments done by 
the laboratory group have shown that this titre is required for successful hybridoma 
formation (Ellis 1989). 
2.7.6 Splenocyte harvesting 
Mice that had a good serological response to the immunogen were given an intravenous 
injection of the candidate peptide (50μg dissolved in 100μl 0.9% saline) 2 to 10 weeks after 
the tail bleed. Three to five days after the intravenous injection the mice were culled by 
cervical dislocation. Spleens were blunt dissected from the cadaver after drenching the fur 
with 100% v/v 74OP ethanol to sterilise. They were immediately placed in 5ml double 
strength antibiotic medium (appendix II) for 30 minutes. The spleens were rinsed twice in 
5ml single strength antibiotic medium (appendix II) before resuspending in 2ml single 
strength antibiotic medium and disrupted using a manual tissue homogeniser to remove the 
splenic capsule. The liquid was centrifuged at 1500rpm (300g) for ten minutes. Five 
millilitres of red blood cell lysing buffer (R7757, Sigma) was mixed with the dry pellet to 
remove the erythrocytes from the splenocytes and under-layered with 2ml foetal calf serum 
(FCS). This was centrifuged at 15000rpm (300g) for 10 minutes and the pellet was 
resuspended in 5ml serum-free medium. At least three washes with 15ml RPMI was 
required to remove the FCS. This was deemed clean when no bubbles were visible on 
gentle agitation of the centrifuge tube. 
During the stage of blunt dissection, serum was also obtained by opening the thoracic 
cavity, transecting the heart and collecting the pooled blood before it had a chance to clot 
using a small syringe, with subsequent centrifugation at 13000rpm (10,000g) for 5 minutes 
using a benchtop centrifuge (MSE MicroCentaur) and discarding the clot. Serum was then 
frozen at -20 ºC for use in screening hybridomas and as a positive control for future 
screening experiments.  
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2.7.7 Fusion of splenocyte-myeloma hybridomas 
Splenocytes cannot be maintained in culture. If they are fused with cancer cells, myeloma 
in this case (P3X63Ag8.653, Health Protection Agency Culture Collections), they produce 
hybridoma cells that have the immortal qualities of the cancer cell with the antibody 
production properties of the splenocyte.  
An average mouse spleen was assumed to have 1x10
8
cells. The optimal ratio of splenocytes 
to myeloma cells is 2-10:1 therefore the number of myeloma cells required per spleen is in 
the range of 1-10x10
7
. A 1% aliquot of the myeloma cells were kept in a separate well to 
use as an unfused myeloma cell control well. Splenocytes were added to serum-free 
myeloma cells and the pellet was dried by centrifugation at 15000rpm (300g) for 10 
minutes and then carefully removing all medium. These cells were agitated to loosen the 
pellet before the addition of polyethylene glycol.  
Polyethylene glycol (P7181, Sigma) was used to reduce surface tension allowing the 
membranes to fuse. After 2 minutes on ice, the fusion process was terminated by gentle 
addition of 1ml of medium with constant shaking and further slow addition of 9ml 
complete medium and centrifugation at 15000rpm (300g) for 10 minutes. This process was 
repeated to remove all traces of PEG as this inhibits cell proliferation. The cell pellet was 
then resuspended in 100ml hypoxanthine aminopterin and thymidine (HAT) medium 
(H0262, Sigma) (appendix II) and plated into four 24 flat bottomed well plate (Nunc) with 
one well dedicated to the control, unfused myeloma cells. Each well was then topped up 
with more HAT medium to 2ml. 
2.7.8 Hybridoma culture 
Cells were screened after 5-7 days. After fusion the selection of viable cells in culture are 
as follows, unfused cells, myeloma cells fused to myeloma cells, splenocytes fused to 
splenocytes and the hybridomas. Splenocytes normally die within 5-7 days in medium 
whereas myeloma cells proliferate rapidly. Hybridoma cells are vulnerable after the first 
few days of fusion and can be overwhelmed by the myelomas cells. To ensure this did not 
happen HAT medium is used.  
Cells produce DNA by either de-novo pathways or by salvage pathways, using preformed 
bases in either HAT or hypoxanthine thymidine (HT, H0137, Sigma) medium. Aminopterin 
is a folic acid analogue which inhibits the enzyme dihydrofolate reductase, critical in the 
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de-novo synthesis of DNA. Therefore in HAT medium, cells can only survive if they are 
able to utilize the salvage pathways for DNA synthesis with the preformed bases provided 
by thymidine and hypoxanthine in the medium. Splenocytes are able to provide the salvage 
pathway and therefore in the HAT medium only the hybridoma cells are able to survive.  
Once the myeloma cells in the control well are dead it was assumed that the unfused 
myeloma cells in the hybridoma cultures are also dead and the medium was changed to HT 
medium (appendix II). This allowed the hybridomas to grow more rapidly. Two millilitres 
of the HAT medium is gently removed and replaced with 2ml of HT medium. 
2.7.9 Screening of hybridoma colonies 
Once the hybridoma colonies were of sufficient size the supernatant was carefully removed 
so as not to disturb the colony. This was screened by ELISA for the presence of antibodies 
using the following protocol: 
1. 100μl of supernatant from the well the hybridoma colonies were grown in was 
added to 20μl Hepes (H0887, Sigma)  
2. ELISA plates were coated with PT Dy10 3.8μg/ml in carbonate buffer for HMW 
glut04 hybridoma colonies or LMW glt156 MAP 50μg/ml in 60% ethanol for LMW 
glt156 colonies and incubated overnight at 4°C. 
3. They were blocked with 1% BSA (A7030, Sigma) at 37°C for an hour. 
4. 50μl of supernatant was added to the ELISA plate and incubated for 45 minutes at 
37°C 
5. Anti-mouse IgG-alkaline phosphatase antibody produced in rabbit was added (1 in 
1000, A4312, Sigma) or Anti-mouse IgM-alkaline phosphatase antibody produced 
in goat (1 in 1000, A9688, Sigma) and incubated for 45 minutes at 37°C 
6. 100μl of alkaline phosphatise yellow (pNPP) liquid substrate (P7998, Sigma) was 
added and incubated in the dark for 20-30 minutes. 
The plate was washed with PBS/1%v/v Tween 20 three times after steps 2-6. The optical 
density of each sample was determined using an ELISA reader (Biotec ELx800) with the 
wavelength set at 405nm.  
2.7.10 Immunoglobulin precipitation 
The supernatant from the hybridoma colony was collected in order to precipitate the 
antibodies in suspension. This allowed the antibodies to be purified and concentrated. 
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Precipitation works on the principle that the solubility of the antibodies in the medium is 
altered when a saturated solution of ammonium sulphate (A4915, Sigma) is added to the 
medium allowing them to come out of solution and be collected by centrifugation. The 
following method was used to extract the antibodies from the hybridoma supernatant. 
The starting volume of supernatant was measured and noted for each sample. An equal 
volume of saturated ammonium sulphate solution was added dropwise while mixing with a 
magnetic stirrer. The solution was left for a minimum of 6 hours in the fridge and then 
centrifuged at 3000rpm (1200g) for 30 minutes. The pellet was resuspended in PBS at a 
tenth of its original supernatant volume. This was then added to dialysis tubing (molecular 
weight cut off 12500 Daltons, D9402, Sigma) and dialysed against 3 changes of PBS for 
1hr each time to remove excess salts.  
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Chapter 3: Immunogenicity of glutenins in adaptive immunity 
 
3.1 Introduction and aims 
Until recent years, glutenins could not be extracted in pure form without gliadin 
contamination.They were therefore erroneously assumed not to stimulate the small 
intestines of coeliac patients. However, work from van de Wal (1999), Vader (2002a), 
Molberg (2003), Dewar (2006) and Ellis (2006) suggests that glutenins are 
immunostimulatory in coeliac disease. The epitopes contributing to this response are not 
yet known. 
Van de Wal et al tested different peptide sequences, 18 amino acids in length, spanning the 
entire high molecular weight glutenin (HMWG) molecule with a single T-cell clone from a 
paediatric human leucocyte antigen (HLA)-DQ8 restricted coeliac patient. The group was 
able to demonstrate that the minimal epitope required for optimal T-cell stimulation was 
residues 724-734, QGYYPTSPQQS. Vader et al tested T-cell clones of children with 
coeliac disease with an array of proteins and peptides; some were already known to be toxic 
whilst others, including the peptide low molecular weight glutenin 156 (LMW glt156), were 
novel. These clones were grown from twenty-five children newly diagnosed with coeliac 
disease producing twenty-eight T-cell lines, only four of which were gluten-sensitive after a 
week in culture. These four gluten-sensitive T-cell lines were cloned and used in his 
experiments. Four out of sixteen T-cell clones from these children were sensitive to LMW 
glutenin 156. None of the 4 adult coeliac T-cell lines from small intestinal biopsies reacted 
to this peptide. The drawback in both these studies is that the reaction with T-cell clones is 
too specific and unlikely to represent the mass action of T-cells present in the gut (see 
section 1.4). 
We still know little about the toxicity of the HMW subunits known as 1Dx5, 1Bx7, 1By9 
and 1Dy10. Dewar et al demonstrated the immunostimulatory potential of HMW glutenins 
by demonstrating in vitro stimulation of T-cell lines in eleven of seventeen coeliac patients 
with a mixture of chemically purified Dx5, Bx7, By9 and Dy10 sub-units of HMW glutenin 
(see section 1.9.2). They also performed in vivo challenges in three patients with coeliac 
disease taking small intestinal biopsies every hour for six consecutive hours after 
instillation of the chemically purified HMW glutenin into the duodenum (Dewar 2009). All 
86 
patients developed significant change in intestinal morphology after 4hrs. Molberg et al 
(2003) managed to stimulate 5 out of 12 HLA-DQ2 restricted small intestinal T-cell lines 
when testing recombinant 1Dy10 and 3 out of 12 HLA-DQ2 restricted small intestinal T-
cell lines with recombinant 1Dx5. The toxicity of recombinant 1Dx5 and 1Dy10 fraction of 
HMWG was further demonstrated in vitro where 3 out of 14 and 3 out of 11 small intestinal 
T-cell lines were stimulated respectively (Ellis 2006), and in vivo in studies mentioned 
earlier with chemically purified fractions (Dewar 2006) and recombinant proteins (Ellis 
2006), see section 1.12. 
Tye-Din et al (2010) made significant progress inunravelling potential immunostimulatory 
epitopes using peripheral blood lymphocytes in adults. However, the research only included 
individuals who were HLA-DQ2 positive and excluded HLA-DQ8 positive individuals (see 
section 1.11). The group tested a large peptide library covering wheat gliadins and 
glutenins, rye and barley peptide epitopes with oligopeptides 20 amino acids in length 
following a five-day oral gluten challenge. In his initial screening of peptides he found that 
both the HMWG and LMWG peptides did not produce large IFN-γ T-cell responses as 
tested by enzyme-linked immunosorbent spot (ELISPOT). Therefore, the group further 
tested only one LMWG oligopeptide and 4 HMWG oligopeptides. In Tye-Din’s study, in 
the majority of adult patients tested, the peripheral blood lymphocytes failed to produce 
interferon-γ. Peripheral blood responses to gluten in CD are thought to be less relevant to 
the CD pathology than small intestinal T-cell responses. This is highlighted by the fact that 
some non-coeliac individuals have been shown to produce a blood T-cell response to 
gluten. Furthermore, responses to peripheral blood lymphocytes can be restricted not only 
by the disease-associated HLA-DQ2 molecule but are also restricted by HLA-DP and 
HLA-DR (Gjertsen 1994). 
The aim of this study was to assess the adaptive immune system response to two glutenin 
candidate immunostimulatory epitopes, HMW glut04 and LMW glt156. These peptides were 
assessed by proliferation assays using T-cell lines grown from small intestinal biopsies 
from coeliac individuals and interferon-γ secretion from these T-cells. The HMW glut04 
peptide is contained within the Dy10 subunit of HMW glutenin protein and is also found in 
the HMW glutenin peptide W24 in the Tye-Din study (2011). The LMW glt156 peptide 
was not reported in Tye-Din’s study. The null hypothesis in these experiments is that 
coeliac small intestinal T-cell lines are not simulated by the candidate epitopes HMW glut04 
and LMW glt156. 
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3.2 Methods used 
3.2.1 T-cell studies 
Small intestinal T-cells were isolated and cultured initially against Frazer’s Fraction III 
(FFIII) and subsequently against peptic-tryptic digest of whole gluten (both antigens 
5mg/ml) as described earlier in section 2.3, 2.4.1, 2.4.2 and 2.4.3. The culturing antigen 
was changed as a result of the animal screening experiments for immunisation of peptides 
which found a poor response as tested with FFIII as the ELISA coating antigen compared 
with either the HMW glutenin subunit Dy10 or the multiple antigenic peptide (see section 
5.4). A peptic-tryptic digest of whole gluten was felt to be more representative of the 
spectrum of gluten peptides presented to the small intestine in a gluten challenge. 
The lines underwent weekly antigen restimulation and maintenance with IL-2, see section 
2.4.4. A proliferation assay was set up to determine gluten specificity and the proliferative 
response to the peptides as described earlier in section 2.4.5. Phytohaemagglutinin (PHA) 
was used to assess the cell viability in the assay with tests of T-cells alone and APCs alone, 
either fresh or thawed but not irradiated. The negative control in the experiment was the T-
cells in culture alone with PBMCs to act as the antigen-presenting cells. The positive 
control used in the assay was intitially FFIII and subsequently changed to a peptic-tryptic 
digest of industrial whole gluten. This was taken as a marker that the T-cells had retained 
their antigen specificity. Timing of the testing was dependant on sufficient T-cell numbers 
being achieved (1.08x10
6
 T-cells). T-cell lines were not used after three antigen 
restimulation as it is accepted that this was less likely to be a polyclonal T-cell line. 
3.2.2 Interferon-γ analysis 
T-cell secretion of interferon-γ in the assay supernatants was measured by ELISA using a 
commercial kit, according to the manufacturer’s instructions (R+D systems, Minneapolis, 
USA). This method has been described in section 2.5.1. 
3.2.3 Statistics 
GraphPad Prism 5.0 was used for statistical analysis. A one-way repeated measurement 
ANOVA with Dunnett’s multiple comparison test was used to compare the means of the 
each candidate group against the control group of T+APC. This was not possible for the 
non-coeliac control group as there were only two patients analysed. 
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3.3 Peptides 
The rationale for choosing the peptides in this study has already been explained in section 
1.12 and in the introduction to this chapter, section 3.1. HMW glut04 peptide is contained 
in the HMW protein subunit Dy10 and in the HMW glutenin peptide W24 (Tye-Din 2011). 
The following peptides were made commercially by GenScript (New Jersey, USA) with the 
minimum stimulating T-cell epitope in bold and the underlined glutamine residues a target 
for deamidation to glutamic acid:  
Amino acids 721-735 of HMW glutenin, HMW glutenin04 (HMW glut04) 
        QGQQGYYPTSPQQSG 
Amino acids 44-59 of LMW glutenin LMW glutenin156 (LMW glt156) 
        PPFSQQQQSPFSQQQQ 
 
3.4 Patients used in T-cell studies 
Most cell lines used in this study were freshly grown from patients with a diagnosis of 
coeliac disease (SD patient codes). A few frozen cell lines were also used (JE patient codes) 
with their frozen peripheral blood mononuclear cells and stored serum. These cell lines 
were known to be Frazer’s Fraction III (FFIII) sensitive having been used in previous 
manuscripts (Ellis 2005, Dewar 2006). They had been stored in liquid nitrogen for between 
7-9 years and had serum stored at -20°C. When these cell lines were defrosted, they were 
grown against either FFIII or peptic- tryptic digest of gluten (PT gluten) for a week (see 
section 2.4.4) before being used in a proliferation assay (see section 2.4.5). Unfortunately, 
there was limited data from the HLA status of these patients as it was not routine practice in 
the unit at that time to measure this. Two cell lines were grown from patients who were not 
coeliac in order to compare responses to the glutenin peptides. 
The demographic details of the patients used in this study are shown in Tables 3.1 for cells 
grown against FFIII and 3.2 for cells grown against petic-tryptic digest of whole gluten. 
The length of time a patient had coeliac disease was taken as the time from their first 
diagnostic small intestinal biopsy to the time for the study small intestinal biopsy. There are 











Table 3.1 Demographic details of patients whose T-cells were grown against Frazer’s 
Fraction III 







SD17 22 M DQ2 4 months nil 
SD18 35 F DQ2.5 1 year nil 
JE2 NA NA NA NA NA 
SD20 22 F DQ8  1 year nil 
SD21 47 F NA 17 years 
Bowel 
cancer 
JE6 NA NA NA NA NA 
JE8 NA NA NA NA NA 
JE9 NA NA NA NA NA 
JE10 NA NA NA NA NA 
SD33 46 F DQ2 10 years IBS 
NA not available. SD patient codes refer to freshly isolated cells whereas JE patient codes 
were T-cell lines grown against FFIII and stored in liquid nitrogen for between 7-9 years. 
For the frozen cell lines, limited information was available. Length of time with coeliac 


















SD35 49 F DQ2 8 years osteoarthritis 
SD36 61 F DQ2 1 year 
dermatitis 
herpetiformis 
SD33 46 F DQ2 10 years IBS 
SD38 28 M DQ2 6 years nil 
SD39 46 F DQ2.5 6 month 
hypothyroid, recurrent 
miscarriages 
JE11 NA NA NA NA NA 
JE13 NA NA NA NA NA 
SD42 31 F DQ2/8 5 months type 1 DM 
SD45 66 F DQ2 17 years hypothyroid, IBS 
SD46 57 M DQ2 2 years SBBO 
SD48 38 M NA non-coeliac 
GORD, 
hypercholesterolaemia 
SD50 59 F DQ2 12 years 
psoriasis, meningioma 
resected 
SD51 26 F DQ8 9 years nil 
SD52 46 F DQ2 5 months nil 
SD56 69 F DQ2 7 years 
microscopic colitis, 
SBBO, IBS 
SD57 73 F DQ2 22 years 
microscopic colitis, 
hypothyroid, 
Barrett’s, IBS, eczema 
SD58 36 F DQ2 2 years IBS 
SD59 66 F DQ2 12 years type 1 DM 
SD61 39 F DQ2 2 years osteopenia 
SD62 24 F DQ5/6 non-coeliac IgA deficiency, IBS 
SD63 47 F DQ2 4 years SLE, recurrent GU 
SD64 63 F DQ2 25 years nil 
SD65 44 F DQ2 6 years SBBO 
SD66 56 F DQ2 5 months osteopenia, asthma 
SD68 65 F DQ2/8 6 years nil 
SD69 31 M DQ2 5 months GORD, hiatus hernia 
SD71 54 F DQ2 9 years nil 




SD73 57 F DQ2 4 months nil 
SD33T 48 F DQ2 12 years  IBS 
NA not available. SD patient codes refer to freshly isolated cells whereas JE patient codes were T-
cell lines grown against FFIII and stored in liquid nitrogen for between 7-9 years. For the frozen 
cell lines, limited information was available. Length of time with coeliac disease refers to the length 
of time from diagnosis to the small intestinal biopsies taken for the study. Patients in grey are non-
coeliac control patients. 
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3.5 Results 
3.5.1 Result of Frazer’s Fraction III studies 
Initially, T-cells were grown against Frazer’s Fraction III (FFIII), as a soluble gluten 
antigen that may possibly contain glutenins. ELISA plates coated with FFIII to assess 
serological response to the glutenin peptides in mice suggested that possibly these epitopes 
were not found in FFIII (see section 5.4). The results obtained from FFIII stimulation of 
coeliac small intestinal T-cells in proliferation assay are summarised in table 3.3, with 
individual patient results shown in tables 3.4-3.13. The stimulation index (SI) is calculated 
by dividing the mean counts per minute (CPM) of the candidate peptide by the value 
obtained for the corresponding control assay containing no antigen. A response of 2 or 
greater was considered to be positive, as in previous proliferation study literature (Molberg 
2001, Vader 2002a, Molberg 2003, Dewar 2006). 
The majority of T-cell lines tested against FFIII failed to produce a T-cell response against 
the positive control, let alone any candidate peptides. During this assay it was clear that the 
T-cells were not at their optimum with a poor stimulation with phytohaemaggluttinin 
(PHA), especially with the frozen T-cell lines, whereas the PBMCs were well stimulated by 
the PHA, as shown in tables 3.4-3.13. Unfortunately the PHA control was added in to 
screen for problems with the assay during the development of the assay and therefore not 
all tests contained PHA. 
Interferon-γ measurement in the culture supernatants was introduced as another assessment 
of immunostimulation towards the end of these assays. In the last patient SD33, see table 
3.13, there was a four-fold augmentation of the IFN-γ secretion indicating that the cell line 
was gluten-sensitive but no response to the candidate peptides.
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Table 3.3. Results of T-cell proliferation assays against Frazer’s Fraction III, high molecular weight glutenin04 721-735 (HMW glut04), low molecular weight glutenin 









T-cells + APC 
with 
Frazer’s Fraction III 























SD17 2 DQ2 98±42 202±206 2.06 260±207 2.60 115±47 1.17 136±44 1.37 
SD18 2 DQ2.5 169±21 149±11 1.10 135±18 0.69 129±18 0.76 262±127 1.55 
JE2 3 NA 126±3 95±56 0.75 132±12 1.05 155±10 1.23 121±9 0.96 
SD20 1 DQ2/8 365±87 476±169 1.33 192±51 0.52 331±116 0.91 1739±1413 4.7 
SD21 2 NA 237±27 243±33 1.02 179±37 0.76 202±33 0.85 273±74 1.15 
JE6 3 NA 327±127 754±110 2.3 247±161 0.76 319±223 0.98 305±250 0.93 
JE8 3 NA 6740±1671 2158±1224 0.32 7880±885 1.17 8616±1108 1.28 8051±611 1.19 
JE9 3 NA 139±17 167±17 1.2 180±15 1.29 173±24 1.66 171±18 1.23 
JE10 3 NA 229±4 309±108 1.23 333±74 1.45 365±35 1.6 326±21 1.43 
SD33 2 DQ2 145±18 862±182 5.94 145±12 1.00 112±15 0.77 102±9 0.70 
NA indicates those patients in whom HLA status was not tested. SD patient codes refer to freshly isolated cells whereas JE patient codes were T-cell lines grown 
against Frazer’s Fraction III (FFIII) and stored in liquid nitrogen for between 7-9 years. T-cells were isolated from small intestinal biopsies from patients with coeliac 
disease. The lymphocytes were isolated and cultured in the presence of interleukin-2 and weekly antigenic restimulation with FFIII. When 1.08x10
6
 cells were 
present, autologous irradiated peripheral blood mononuclear cells were pre-incubated with the relevant antigen to act as antigen-presenting cells and proliferation 
assays were set up to measure the T-cells proliferation response to various antigens. Results were calculated as the stimulation index; the mean incorporation of 





Table 3.4 Results of SD17 T-cell proliferation assays against Frazer’s Fraction III (FFIII), 
high molecular weight glutenin04 721-735 (HMW glut04), low molecular weight glutenin 
glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 
 Mean CPM ± 
SD 
SI Interferon-γ 
T-cells + APC 
no antigen 
98±42 1 NA 
T-cells alone 
with PHA 
289±71 2.94 NA 
APC alone 
with PHA 
NA NA NA 
T-cells + APC 
with Fraser’s 
Fraction III 
202±206 2.06 NA 
T-cells + APC 
with HMW 
glut04 
260±207 2.06 NA 
T-cells + APC 
with LMW 
glt156 
166±48 1.17 NA 




135±44 1.37 NA 
T-cell proliferation assay result for SD 17 T-cells (HLA DQ2). They spent 2 weeks in 
culture grown against Frazer’s Fraction III (FFIII). All tests were set up in triplicates with 
48 hour incubation with candidate peptides as well as control protein for FFIII and 
phytohaemaggluttinin, a potent lymphocyte stimulator. The mean is taken for the counts per 
minute after an overnight incubation with tritiated thymidine. Stimulation index (SI) has 
been calculated by dividing the mean CPM of the candidate peptide or protein by the value 
obtained for the assay containing no antigen. NA result not available 
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Table 3.5 Results of SD18 T-cell proliferation assays against Frazer’s Fraction III (FFIII), 
high molecular weight glutenin04 721-735 (HMW glut04), low molecular weight glutenin 
glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 
 Mean 





169±21 1 NA 
T-cells alone 
with PHA 
170±12 1 NA 
APC alone 
with PHA 


















262±127 0.75 NA 
T-cell proliferation assay result for SD18 T-cells (HLA DQ2.5) They spent 2 weeks in 
culture grown against Frazer’s Fraction III (FFIII). All tests were set up in triplicates with 
48 hour incubation with candidate peptides as well as control protein for FFIII and 
phytohaemaggluttinin, a potent lymphocyte stimulator. The mean is taken for the counts per 
minute after an overnight incubation with tritiated thymidine. Stimulation index (SI) has 
been calculated by dividing the mean CPM of the candidate peptide or protein by the value 
obtained for the assay containing no antigen. NA result not available 
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Table 3.6 Results of JE2 T-cell proliferation assays against Frazer’s Fraction III (FFIII), 
high molecular weight glutenin04 721-735 (HMW glut04), low molecular weight glutenin 
glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 






126±3 1 NA 
T-cells alone 
with PHA 
139±37 1.1 NA 
APC alone 
with PHA 


















121±9 0.96 NA 
T-cell proliferation assay result for JE2 T-cells (HLA DQ status not available). This was a 
frozen cell line which spent 3 weeks in culture grown against Frazer’s Fraction III (FFIII). 
All tests were set up in triplicates with 48 hour incubation with candidate peptides as well 
as control protein for FFIII and phytohaemaggluttinin, a potent lymphocyte stimulator. The 
mean is taken for the counts per minute after an overnight incubation with tritiated 
thymidine. Stimulation index (SI) has been calculated by dividing the mean CPM of the 
candidate peptide or protein by the value obtained for the assay containing no antigen. NA 
result not available 
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Table 3.7 Results of SD20 T-cell proliferation assays against Frazer’s Fraction III (FFIII), 
high molecular weight glutenin04 721-735 (HMW glut04), low molecular weight glutenin 
glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 
 Mean 





365±87 1 NA 
T-cells alone 
with PHA 
457±53 1.25 NA 
APC alone 
with PHA 


















1739±1413 4.76 NA 
T-cell proliferation assay result for SD20 T-cells (HLA DQ8). They spent a 1 week in 
culture grown against Frazer’s Fraction III (FFIII). All tests were set up in triplicates with 
48 hour incubation with candidate peptides as well as control protein for FFIII and 
phytohaemaggluttinin, a potent lymphocyte stimulator. The mean is taken for the counts per 
minute after an overnight incubation with tritiated thymidine. Stimulation index (SI) has 
been calculated by dividing the mean CPM of the candidate peptide or protein by the value 
obtained for the assay containing no antigen. NA result not available 
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Table 3.8 Results of SD21 T-cell proliferation assays against Frazer’s Fraction III (FFIII), 
high molecular weight glutenin04 721-735 (HMW glut04), low molecular weight glutenin 
glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 






237±27 1 NA 
T-cells alone 
with PHA 
236±123 1 NA 
APC alone 
with PHA 


















273±74 1.15 NA 
T-cell proliferation assay result for SD21 T-cells (HLA DQ status not available). They 
spent 2 weeks in culture grown against Frazer’s Fraction III (FFIII). All tests were set up in 
triplicates with 48 hour incubation with candidate peptides as well as control protein for 
FFIII and phytohaemaggluttinin, a potent lymphocyte stimulator. The mean is taken for the 
counts per minute after an overnight incubation with tritiated thymidine. Stimulation index 
(SI) has been calculated by dividing the mean CPM of the candidate peptide or protein by 
the value obtained for the assay containing no antigen. NA result not available 
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Table 3.9 Results of JE6 T-cell proliferation assays against Frazer’s Fraction III (FFIII), 
high molecular weight glutenin04 721-735 (HMW glut04), low molecular weight glutenin 
glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 






327±127 1 NA 
T-cells alone 
with PHA 
1150±101 3.51 NA 
APC alone 
with PHA 


















302±250 0.93 NA 
T-cell proliferation assay result for JE6 T-cells (HLA DQ status not available). This was a 
frozen cell line which spent 3 weeks in culture grown against Frazer’s Fraction III (FFIII). 
All tests were set up in triplicates with 48 hour incubation with candidate peptides as well 
as control protein for FFIII and phytohaemaggluttinin, a potent lymphocyte stimulator. The 
mean is taken for the counts per minute after an overnight incubation with tritiated 
thymidine. Stimulation index (SI) has been calculated by dividing the mean CPM of the 
candidate peptide or protein by the value obtained for the assay containing no antigen. NA 
result not available 
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Table 3.10 Results of JE8 T-cell proliferation assays against Frazer’s Fraction III (FFIII), 
high molecular weight glutenin04 721-735 (HMW glut04), low molecular weight glutenin 
glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 
 Mean 





6740±1671 1 NA 
T-cells alone 
with PHA 
3848 0.58 NA 
APC alone 
with PHA 


















8051±612 1.19 NA 
T-cell proliferation assay result for JE8 T-cells (HLA DQ status not available). This was a 
frozen cell line which spent 3 weeks in culture grown against Frazer’s Fraction III (FFIII). 
All tests were set up in triplicates with 48 hour incubation with candidate peptides as well 
as control protein for FFIII and phytohaemaggluttinin, a potent lymphocyte stimulator. 
Where there is no standard deviation result there were too few cells for triplicate assays and 
a single assay result was used. The mean is taken for the counts per minute after an 
overnight incubation with tritiated thymidine. Stimulation index (SI) has been calculated by 
dividing the mean CPM of the candidate peptide or protein by the value obtained for the 
assay containing no antigen. NA result not available 
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Table 3.11 Results of JE9 T-cell proliferation assays against Frazer’s Fraction III (FFIII), 
high molecular weight glutenin04 721-735 (HMW glut04), low molecular weight glutenin 
glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 
 Mean 





139±17 1 NA 
T-cells alone 
with PHA 
141±20 1.01 NA 
APC alone 
with PHA 


















171±18 1.23 NA 
T-cell proliferation assay result for JE9 T-cells (HLA DQ status not available). This was a 
frozen cell line which spent 3 weeks in culture grown against Frazer’s Fraction III (FFIII). 
All tests were set up in triplicates with 48 hour incubation with candidate peptides as well 
as control protein for FFIII and phytohaemaggluttinin, a potent lymphocyte stimulator. The 
mean is taken for the counts per minute after an overnight incubation with tritiated 
thymidine. Stimulation index (SI) has been calculated by dividing the mean CPM of the 
candidate peptide or protein by the value obtained for the assay containing no antigen. NA 
result not available 
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Table 3.12 Results of JE10 T-cell proliferation assays against Frazer’s Fraction III (FFIII), 
high molecular weight glutenin04 721-735 (HMW glut04), low molecular weight glutenin 
glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 






229±4 1 NA 
T-cells alone 
with PHA 
244±3 1.06 NA 
APC alone 
with PHA 


















326±21 1.42 NA 
T-cell proliferation assay result for JE10 T-cells (HLA DQ status not available). This was a 
frozen cell line which spent 3 weeks in culture grown against Frazer’s Fraction III (FFIII). 
All tests were set up in triplicates with 48 hour incubation with candidate peptides as well 
as control protein for FFIII and phytohaemaggluttinin, a potent lymphocyte stimulator. The 
mean is taken for the counts per minute after an overnight incubation with tritiated 
thymidine. Stimulation index (SI) has been calculated by dividing the mean CPM of the 
candidate peptide or protein by the value obtained for the assay containing no antigen. NA 
result not available 
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Table 3.13 Results of SD33 T-cell proliferation assays against Frazer’s Fraction III (FFIII), 
high molecular weight glutenin04 721-735 (HMW glut04), low molecular weight glutenin 
glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 
 Mean 







































120±9 0.89 2 
T-cell proliferation assay result for SD33 T-cells (HLA DQ2) They spent 2 weeks in 
culture grown against Frazer’s Fraction III (FFIII). All tests were set up in triplicates with 
48 hour incubation with candidate peptides as well as control protein for FFIII and 
phytohaemaggluttinin, a potent lymphocyte stimulator. The mean is taken for the counts per 
minute after an overnight incubation with tritiated thymidine. Stimulation index (SI) has 
been calculated by dividing the mean CPM of the candidate peptide or protein by the value 
obtained for the assay containing no antigen. NA result not available 
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3.5.2 Result of peptic-tryptic digest of whole gluten studies 
3.5.2.1  Results from coeliac patients 
The results from the Frazer’s Fraction III assays did not demonstrate gluten sensitivity, 
which may be due to poor T-cell survival. Therefore, an additional washing step was added 
after the biopsy was minced (see section 2.4.3) to minimise the amount of antigen still left 
in the culture. 
A peptic-tryptic digest of whole gluten was subsequently used as the antigen against which 
the T-cells were grown. This was felt to be more representative of the gluten peptide 
exposure of T-cells in the small intestine of coeliac patients. Interferon-γ (IFN-γ) 
concentrations were measured by ELISA and the net excess of interferon-γ secretion is 
shown. This was obtained by subtracting the value obtained in the negative control assay. A 
level of 0 indicates there was not an excess of interferon-γ in the test assay compared to the 
control. NA indicates those patients in whom supernatants could not be tested. The results 
of the proliferation assays, including IFN-γ concentrations, using these T-cells are shown in 
table 3.14, spread over 3 pages, with the results of the individual assays shown in tables 
3.15-3.42. 
Tables 3.15-3.42 show that these glutenin peptides are not major T-cell epitopes with only 
three of the cell lines, SD35, SD 38 and SD73, achieving positive stimulation indices (SIs). 
Unfortunately there is a lack of interferon-γ data for these patients. What is interesting is 
the difference in stimulation indices, SD35 has very high SI to both PT gluten and HMW 
glut04 while SD 38 and SD73 have more modest SIs towards all the peptides for SD38 and 
only HMW glut04 for SD73. 
It is also interesting that there is little rise in interferon-γ in SD38 in the LMW glt156 and 
dLMWglt156 compared to the PT gluten response despite similar values for the SI. There is 
also evidence in other patients, SD 39 and SD33T, for greater interferon-γ secretion 
towards HMW glut04 with a negative SI, suggesting high secretion of INF-γ from a few T-
cells. 
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The HLA status of the patients unfortunately was difficult to analyse as there were too few 
patients in this study to allow a proper assessment. However, the two heterzygotes, SD42 
and SD68, as well as SD51, the HLA DQ8 homozygote, did not seem to mount an immune 
response to these peptides. 
Certainly SD38 and SD73 were only a week in culture and therefore are more likely to be 
more representative of the mass T cell action in the gut. Other T cells lines with the same 
length of time in culture, SD 33 and SD 36, did not react to the HMW glut04 or LMW 
glt156 whether it was deamidated or not. It did not seem to matter the length of time of 
diagnosis nor the HLA DQ status in these patients. 
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Table 3.14 Results of T-cell proliferation assays against peptic-tryptic digest of whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 








T-cells + APC  
no antigen 
T-cells + APC 
with 
PT gluten 















































SD 36 1 DQ2 154±16 NA 507±85 3.29 NA 66±25 
0.4
3 




























33 8175±288 4.34 640 2649±312 
1.4
1 




JE 11 3 NA 189±43 0 717±42 3.8 13 224±36 
1.1
9 

















904±480 50 2124±261 2.56 110 459±44 
0.5
1 




SD45 2 DQ2 1028±69 10 2128±163 2.07 510 917±205 
0.8
9 




SD46 2 DQ2 128±48 0 329±63 2.56 430 126±36 
0.9
8 
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SD63 3 DQ2 422±54 0 
3608± 
432 
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T-cells + APC 
no antigen 
T-cells + APC 
with 
PT gluten 




































SD66 2 DQ2 255±25 0 617±50 2.42 180 299±23 1.17 0 257±13 1.01 0 261±23 1.02 0 
SD68 2 DQ2/8 310±49 0 3085±111 9.94 98 425±70 1.37 0 353±79 1.14 0 419±68 1.35 0 
SD69 2 DQ2 407±54 0 1095±167 2.69 400 462±31 1.13 0 288±38 0.71 0 364±28 0.9 0 
SD71 2 DQ2 218±48 0 468±16 2.15 130 236±31 1.09 0 223±13 1.02 0 237±19 1.09 0 
SD72 2 DQ2 961±38 NA 3737±234 3.89 NA 1088±156 1.13 NA 1028±281 1.07 NA 1068±138 1.11 NA 
SD73 1 DQ2 2091±88 0 6211±179 5.95 160 4433±839 2.12 18 3392±605 1.62 0 2992±1251 1.43 0 
SD33T 2 DQ2 135±18 13 714±182 5.3 78 135±12 1 53 120±6 0.89 13 120±9 0.89 2 
NA indicates those patients in whom HLA status was not tested. SD patient codes refer to freshly isolated cells whereas JE patient codes were T-cell lines 
grown against Frazer’s Fraction III (FFIII) and stored in liquid nitrogen for between 7-9 years. T-cells were isolated from small intestinal biopsies from 
patients with coeliac disease. The lymphocytes were isolated and cultured in the presence of interleukin-2 and weekly antigenic restimulation with peptic-
tryptic digest of gluten. When 1.08x10
6
 cells were present, autologous irradiated peripheral blood mononuclear cells were pre-incubated with the relevant 
antigen to act as antigen-presenting cells and proliferation assays were set up to measure the T-cells proliferation response to various antigens. Results 
were calculated as the stimulation index; the mean incorporation of tritiated thymidine expressed as counts per minute (CPM) for T-cells plus antigen-
presenting cells with antigen divided by the mean CPM for these cells without antigen.  
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Table 3.15 Results of SD35 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








515±8 1 NA 
T-cells alone 
with PHA 
18720±4836 35.8 NA 
APC alone 
with PHA 
5171±3290 10.05 NA 
T-cells + 
APC with PT 
gluten 













225±110 0.43 NA 
T-cell proliferation assay result for SD35 T-cells (HLA DQ2). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 




Table 3.16 Results of SD36 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 
 Mean 







154±16 1 NA 
T-cells alone 
with PHA 
4015±2540 26 NA 
APC alone 
with PHA 
2830±1178 18.97 NA 
T-cells + 
APC with PT 
gluten 













157±25 1.02 NA 
T-cell proliferation assay result for SD36 T-cells (HLA DQ2). These spent 1 week in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 




Table 3.17 Results of SD38 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








139±40 1 13 
T-cells alone 
with PHA 
2222±140 16.30 223 
APC alone 
with PHA 
345870±11290 249.55 1000 
T-cells + 
APC with PT 
gluten 













494±193 3.56 32 
T-cell proliferation assay result for SD38 T-cells (HLA DQ2). These spent 1 week in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells. 
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Table 3.18 Results of SD33 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








1776±69 1 13 
T-cells alone 
with PHA 
202468±32783 114.00 873 
APC alone 
with PHA 
40305±40465 22.69 253 
T-cells + 
APC with PT 
gluten 













1699±175 0.96 8 
T-cell proliferation assay result for SD33 T-cells (HLA DQ 2). These spent 1 week in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells. 
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Table 3.19 Results of SD39 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








1884±1667 1 33 
T-cells alone 
with PHA 
164541±42012 87.35 833 
APC alone 
with PHA 
25174±756 13.36 850 
T-cells + 
APC with PT 
gluten 













3440±158 1.83 27 
T-cell proliferation assay result for SD39 T-cells (HLA DQ2.5). These spent 3 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells. 
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Table 3.20 Results of JE11 T-cell proliferation assays against peptic-tryptic digest of whole 
gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low molecular 
weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








189±43 1 0 
T-cells alone 
with PHA 
7830±855 41.51 123 
APC alone 
with PHA 
15033±4073 79.69 >1000 
T-cells + 
APC with PT 
gluten 













248±9 1.31 1 
T-cell proliferation assay result for JE11 T-cells (HLA DQ status not available). This was a 
frozen cell line which spent 3 weeks in culture grown against peptic-tryptic digest of whole 
gluten (PT gluten). All tests were set up in triplicates with 48 hour incubation with 
candidate peptides as well as control protein for PT gluten and phytohaemaggluttinin 
(PHA), a potent lymphocyte stimulator. The mean is taken for the counts per minute after 
an overnight incubation with tritiated thymidine. Stimulation index (SI) has been calculated 
by dividing the mean CPM of the candidate peptide or protein by the value obtained for the 
assay containing no antigen. Interferon-γ was measured in the combined triplicate culture 
supernatants using an ELISA kit and the net secretion calculated by subtracting the 




Table 3.21 Results of JE13 T-cell proliferation assays against peptic-tryptic digest of whole 
gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low molecular 
weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 
 Mean 







70±36 1 NA 
T-cells alone 
with PHA 
4608±5097 66.25 NA 
APC alone 
with PHA 
8119±5732 116.74 NA 
T-cells + 
APC with PT 
gluten 













196±1 2.82 NA 
T-cell proliferation assay result for JE13 T-cells (HLA DQ status not available). This was a 
frozen cell line which spent 3 weeks in culture grown against peptic-tryptic digest of whole 
gluten (PT gluten). All tests were set up in triplicates with 48 hour incubation with 
candidate peptides as well as control protein for PT gluten and phytohaemaggluttinin 
(PHA), a potent lymphocyte stimulator. The mean is taken for the counts per minute after 
an overnight incubation with tritiated thymidine. Stimulation index (SI) has been calculated 
by dividing the mean CPM of the candidate peptide or protein by the value obtained for the 
assay containing no antigen. NA result not available as supernatants were not removed. 
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Table 3.22 Results of SD42 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








904±480 1 50 
T-cells alone 
with PHA 
9446±585 10.45 >1000 
APC alone 
with PHA 
50116±10985 55.45 >1000 
T-cells + 
APC with PT 
gluten 













535±35 0.59 35 
T-cell proliferation assay result for SD42 T-cells (HLA DQ2/8). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells. 
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Table 3.23 Results of SD45 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








1028±69 1 10 
T-cells alone 
with PHA 
58514±5803 56.92 >1000 
APC alone 
with PHA 
53149±10133 51.70 >1000 
T-cells + 
APC with PT 
gluten 













783±230 0.76 12 
T-cell proliferation assay result for SD45 T-cells (HLA DQ2). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells. 
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Table 3.24 Results of SD46 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 
 Mean 







128±48 1 0 
T-cells alone 
with PHA 
833±63 6.48 >1000 
APC alone 
with PHA 
823±66 6.04 >1000 
T-cells + 
APC with PT 
gluten 













139±13 1.08 0 
T-cell proliferation assay result for SD46 T-cells (HLA DQ 2). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells. 
  
118 
Table 3.25 Results of SD50 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








322±36 1 0 
T-cells alone 
with PHA 
17753±14960 55.13 810 
APC alone 
with PHA 
16207±4364 50.33 760 
T-cells + 
APC with PT 
gluten 













485±60 1.51 0 
T-cell proliferation assay result for SD50 T-cells (HLA DQ2). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells. 
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Table 3.26 Results of SD51 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








5776±1619 1 0 
T-cells alone 
with PHA 
35468±23010 6.14 230 
APC alone 
with PHA 
48525±71804 8.04 310 
T-cells + 
APC with PT 
gluten 













9406±3047 1.63 0 
T-cell proliferation assay result for SD51 T-cells (HLA DQ8). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells. 
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Table 3.27 Results of SD52 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








218±45 1 5 
T-cells alone 
with PHA 
1100±116 5.05 >1000 
APC alone 
with PHA 
19876±4477 91.24 >1000 
T-cells + 
APC with PT 
gluten 













335±292 1.54 14 
T-cell proliferation assay result for SD52 T-cells (HLA DQ2). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells. NA result not available 
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Table 3.28 Results of SD56 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








2117±420 1 12 
T-cells alone 
with PHA 
41904±10295 19.79 >1000 
APC alone 
with PHA 
71253±3749 33.65 >1000 
T-cells + 
APC with PT 
gluten 













2880±2 1.36 0 
T-cell proliferation assay result for SD56 T-cells (HLA DQ2). These spent 1 week in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells. NA result not available 
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Table 3.29 Results of SD57 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








14302±612 1 53 
T-cells alone 
with PHA 
83943±5363 5.86 598 
APC alone 
with PHA 
302189±50281 21.13 733 
T-cells + 
APC with PT 
gluten 













13873±1720 0.97 NA 
T-cell proliferation assay result for SD57 T-cells (HLA DQ2.6). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells. NA result not available 
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Table 3.30 Results of SD58 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








259±71 1 0 
T-cells alone 
with PHA 
10547±157 40.79 743 
APC alone 
with PHA 
45130±10159 174.52 693 
T-cells + 
APC with PT 
gluten 













224±83 0.86 0 
T-cell proliferation assay result for SD58 T-cells (HLA DQ 2). These 2 weeks in culture 
grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set up in 
triplicates with 48 hour incubation with candidate peptides as well as control protein for PT 
gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean is 
taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells.  
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Table 3.31 Results of SD59 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








2515±547 1 0 
T-cells alone 
with PHA 
91308±472 36.3 218 
APC alone 
with PHA 
35066±12589 13.94 398 
T-cells + 
APC with PT 
gluten 













1577±377 0.63 0 
T-cell proliferation assay result for SD59 T-cells (HLA DQ2). These spent 1 week in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells.  
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Table 3.32 Results of SD61 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








864±401 1 0 
T-cells alone 
with PHA 
14018±1218 16.22 >1000 
APC alone 
with PHA 
32833±2786 37.99 >1000 
T-cells + 
APC with PT 
gluten 













744±150 0.86 0 
T-cell proliferation assay result for SD61 T-cells (HLA DQ2). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells.  
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Table 3.33 Results of SD63 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 
 Mean 







422±54 1 0 
T-cells alone 
with PHA 
8310 19.72 >1000 
APC alone 
with PHA 
17264±12 40.96 505 
T-cells + 
APC with PT 
gluten 













704±219 1.67 0 
T-cell proliferation assay result for SD63 T-cells (HLA DQ2). These spent 3 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells.  
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Table 3.34 Results of SD64 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








702±81 1 0 
T-cells alone 
with PHA 
26995±1500 38.45 >1000 
APC alone 
with PHA 
49875±2720 71.05 >1000 
T-cells + 
APC with PT 
gluten 













917±216 1.31 0 
T-cell proliferation assay result for SD64 T-cells (HLA DQ2). These spent 1 week in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells.  
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Table 3.35 Results of SD65 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








810±154 1 0 
T-cells alone 
with PHA 
81832±9922 100.97 858 
APC alone 
with PHA 
81672±20254 100.76 997 
T-cells + 
APC with PT 
gluten 













1190±1083 1.47 0 
T-cell proliferation assay result for SD65 T-cells (HLA DQ). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells.  
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Table 3.36 Results of SD66 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








255±25 1 0 
T-cells alone 
with PHA 
18239±2495 71.56 876 
APC alone 
with PHA 
29389±4461 115.31 >1000 
T-cells + 
APC with PT 
gluten 













261±23 1.02 0 
T-cell proliferation assay result for SD66 T-cells (HLA DQ). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells.  
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Table 3.37 Results of SD68 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








310±49 1 0 
T-cells alone 
with PHA 
31704±4339 102.16 133 
APC alone 
with PHA 
73948±13077 238.29 983 
T-cells + 
APC with PT 
gluten 













419±68 1.35 0 
T-cell proliferation assay result for SD68 T-cells (HLA DQ2/8). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells.  
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Table 3.38 Results of SD69 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








407±54 1 0 
T-cells alone 
with PHA 
3893±604 21.97 >1000 
APC alone 
with PHA 
76782±7996 188.64 983 
T-cells + 
APC with PT 
gluten 













364±49 0.9 0 
T-cell proliferation assay result for SD69 T-cells (HLA DQ2). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells.  
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Table 3.39 Results of SD71 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








218±48 1 0 
T-cells alone 
with PHA 
4783±578 21.97 >1000 
APC alone 
with PHA 
26420±7066 121.38 158 
T-cells + 
APC with PT 
gluten 













237±19 1.09 0 
T-cell proliferation assay result for SD71 T-cells (HLA DQ2). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells.  
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Table 3.40 Results of SD72 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








961±38 1 NA 
T-cells alone 
with PHA 
53010±13343 55.19 NA 
APC alone 
with PHA 
124539±11049 129.65 NA 
T-cells + 
APC with PT 
gluten 













1068±138 1.11 NA 
T-cell proliferation assay result for SD72 T-cells (HLA DQ2). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells. NA result not available 
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Table 3.41 Results of SD73 T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 








2091±88 1 0 
T-cells alone 
with PHA 
22961±5938 10.99 >1000 
APC alone 
with PHA 
47381±15578 22.66 >1000 
T-cells + 
APC with PT 
gluten 













2992±1251 1.43 0 
T-cell proliferation assay result for SD73 T-cells (HLA DQ2.7). These spent 1 week in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells.  
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Table 3.42 Results of SD33T T-cell proliferation assays against peptic-tryptic digest of 
whole gluten (PT gluten), high molecular weight glutenin04 721-735 (HMW glut04), low 
molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated LMW glt156 44-59. 
 Mean 







135±18 1 13 
T-cells alone 
with PHA 
No PHA added 
APC alone 
with PHA 
No PHA added 
T-cells + 
APC with PT 
gluten 













120±9 0.89 2 
T-cell proliferation assay result for SD33T T-cells (HLA DQ2). These spent 2 weeks in 
culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests were set 
up in triplicates with 48 hour incubation with candidate peptides as well as control protein 
for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. The mean 
is taken for the counts per minute after an overnight incubation with tritiated thymidine. 
Stimulation index (SI) has been calculated by dividing the mean CPM of the candidate 
peptide or protein by the value obtained for the assay containing no antigen. Interferon-γ 
was measured in the combined triplicate culture supernatants using an ELISA kit and the 
net secretion calculated by subtracting the concentration of interferon-γ in wells containing 
ASM alone from the test protein or peptide wells. Unfortunately no PHA was added to the 
T-cell and APC control wells. 
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3.5.2.2  Result from non-coeliac patients 
A small number of patients who did not have a diagnosis of coeliac disease were also 
included as negative controls and the results are shown in tables 3.43, 3.44 and 3.45. 
Unfortunately the HLA status of one of the patients is missing and NA indicates that patient 
in whom HLA status or supernatants could not be tested. 
This study demonstrates that T-cells are not stimulated by peptic-tryptic gluten digest as 
well as the candidate glutenin peptides. Unfortunately due to ethical constraints more 






Table 3.43. Results of T-cell proliferation assays against peptic-tryptic digest of whole gluten (PT gluten), high molecular weight glutenin04 











T-cells + APC 
with 
PT gluten 





































































NA indicates that patient in whom HLA status was not tested. SD patient codes refer to freshly isolated cells. T-cells were isolated from 
small intestinal biopsies from patients without a diagnosis of coeliac disease. The lymphocytes were isolated and cultured in the presence of 
interleukin-2 and weekly antigenic restimulation with peptic-tryptic digest of gluten. When 1.08x10
6
 cells were present, autologous 
irradiated peripheral blood mononuclear cells were pre-incubated with the relevant antigen to act as antigen-presenting cells and 
proliferation assays were set up to measure the T-cells proliferation response to various antigens. Results were calculated as the stimulation 
index; the mean incorporation of tritiated thymidine expressed as counts per minute (CPM) for T-cells plus antigen-presenting cells with 
antigen divided by the mean CPM for these cells without antigen. 
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Table 3.44 Results of SD48, a non-coeliac patient, T-cell proliferation assays against 
peptic-tryptic digest of whole gluten (PT gluten), high molecular weight glutenin04 721-735 
(HMW glut04), low molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated 
LMW glt156 44-59. 








251±78 1 0 
T-cells alone 
with PHA 
4815±278 19.19 310 
APC alone 
with PHA 
45334±16638 180.68 >1000 
T-cells + 
APC with PT 
gluten 













302±31 1.2 0 
T-cell proliferation assay result for non-coeliac SD48 T-cells (HLA DQ status unknown) 
which were 1 week in culture grown against peptic-tryptic digest of whole gluten (PT 
gluten). All tests were set up in triplicates with 48 hour incubation with candidate peptides 
as well as control protein for PT gluten and phytohaemaggluttinin (PHA), a potent 
lymphocyte stimulator. The mean is taken for the counts per minute after an overnight 
incubation with tritiated thymidine. Stimulation index (SI) has been calculated by dividing 
the mean CPM of the candidate peptide or protein by the value obtained for the assay 
containing no antigen. Interferon-γ was measured in the combined triplicate culture 
supernatants using an ELISA kit and the net secretion calculated by subtracting the 
concentration of interferon-γ in wells containing ASM alone from the test protein or 
peptide wells.  
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Table 3.45 Results of SD62, a non-coeliac patient, T-cell proliferation assays against 
peptic-tryptic digest of whole gluten (PT gluten), high molecular weight glutenin04 721-735 
(HMW glut04), low molecular weight glutenin glt156 44-59 (LMW glt156) and deamidated 
LMW glt156 44-59. 








376±26 1 0 
T-cells alone 
with PHA 
1789±363 4.76 >1000 
APC alone 
with PHA 
43154±4725 114.87 >1000 
T-cells + 
APC with PT 
gluten 













527±58 1.4 0 
T-cell proliferation assay result for non-coeliac SD62 T-cells (HLA DQ5/6) which were 1 
week in culture grown against peptic-tryptic digest of whole gluten (PT gluten). All tests 
were set up in triplicates with 48 hour incubation with candidate peptides as well as control 
protein for PT gluten and phytohaemaggluttinin (PHA), a potent lymphocyte stimulator. 
The mean is taken for the counts per minute after an overnight incubation with tritiated 
thymidine. Stimulation index (SI) has been calculated by dividing the mean CPM of the 




3.5.3 Comparison of results from all three patient groups 
Figure 3.1 compares all the available results for the cells grown against FFFIII (tables 3.4-
3.15), PT gluten coeliac patients (tables 3.15-3.42) and non-coeliac patients (tables 3.44 
and 3.45). It demonstrates that the HMW glut04 peptide as well as the LMW glt156 
peptide, whether or not it is deamidated, is not immunostimulatory to non-coeliac patients' 
T-cells grown in vitro. Only one patient in the FFIII group mounted an immune response to 
the HMW glut04 pepitde and one other to the deamidated LMW glt156 peptide. 
T-cells grown against PT gluten are gluten-sensitive. However, the T-cells are not 
stimultaed by either of these glutenin peptides. This is evidenced by a lack of SI response 
as well as interferon-γ secretion into the culture medium. It does demonstrate a 
heterogenous T-cell response by each individual coeliac patient. 
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Figure 3.1 Stimulation Indices and Interferon-γ results for tables 3.3-3.45



















































































































































































































































Figure legend explained overleaf. 
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This figure is a summary of all the values for each individual experiment. Each dot 
represents a value for an experiment, the bar indicates the mean with standard deviation as 
the tails. Stimulation index is calculated by dividing the mean counts per minute (CPM) for 
the T-cells plus antigen-presenting cells (APC) by the CPM for the T-cells plus APC alone 
after tritiated thymidine is added to the assay and incubated overnight (section 2.4.5). 
Interferon-γ concentrations were measured using ELISA from supernatants collected prior 
to adding the tritiated thymidine to the experiment (section 2.5.1). PT gluten=peptic-tryptic 
digested gluten, HMW glut 04=high molecular weight glutenin04 721-735, LMW 
glt156=low molecular weight glutenin glt156 44-59, dLMW glt 156=deamidated LMW 
glt156 44-59, FFIII=Frazer’s Fraction III, ns=not significant, *** p<0.0005.  
Figure 3.1A compares the mean stimulation index from proliferation assays of duodenal T-
cells from coeliac patients grown in vitro against FFIII with the standard deviation shown 
as bars from tables 3.4-3.13. The mean stimulation index of T-cells with APC and no 
peptide is compared to the mean stimulation index of T-cells tested against positive control 
of FFIII and the candidate epitopes, HMW glut 04, LMW glt156 and LMT glt156 with 
standard deviation shown as the bars.  
Figure 3.1B compares the mean stimulation index from proliferation assays of duodenal T-
cells from coeliac patients grown in vitro against PT gluten from tables 3.15-3.42. The 
mean stimulation index of T-cells with APC and no peptide is compared to the mean 
stimulation index of T-cells tested against positive control of PT gluten and the candidate 
epitopes, HMW glut 04, LMW glt156 and LMT glt156 with the bars representing standard 
deviation.  
Figure 3.1C compares the mean interferon-γ secretion from each test condition from 
proliferation assays of duodenal T-cells from coeliac patients grown in vitro against PT 
gluten from tables 3.15-3.42. The mean interferon-γ secretion of T-cells with APC and no 
peptide is compared to the mean interferon-γ secretion of T-cells tested against positive 
control of PT gluten and the candidate epitopes, HMW glut 04, LMW glt156 and LMT 
glt156 with the standard deviation represented by the bars.  
Figure 3.1D compares the mean stimulation index from proliferation assays of duodenal T-
cells from non-coeliac control patients grown in vitro against PT gluten from tables 3.44 
and 3.45. The mean stimulation index of T-cells with APC and no peptide is compared to 
the mean stimulation index of T-cells tested against PT gluten and the candidate epitopes, 
HMW glut 04, LMW glt156 and LMT glt156 with the bars representing standard deviation. 
Figure 3.1E compares the mean interferon-γ secretion from each test condition from 
proliferation assays of duodenal T-cells from non-coeliac control patients grown in vitro 
against PT gluten from tables 3.44 and 3.45. The mean interferon-γ secretion of T-cells 
with APC and no peptide is compared to the mean interferon-γ secretion of T-cells tested 
against PT gluten and the candidate epitopes, HMW glut 04, LMW glt156 and LMT glt156 






At the start of this research, little was known on the immunostimulatory potential of 
glutenins and in particular, the disease-stimulating epitopes. The evidence available pointed 
to a region in the HMW protein (van de Wal 1999) found by a single HLA-DQ8 restricted 
T-cell clone in a child. Dewar et al (2006) demonstrated in 11/17 coeliac small intestinal T-
cell lines that there was evidence of T-cell activation against a mixture of chemically 
purified high molecular weight glutenin. Villous atrophy developed when this mixture of 
chemically purified HMW glutenin protein (Dewar 2006) or recombinant Dy10 and Dx5 
peptides (Ellis 2006) were instilled in the duodena of two coeliac patients demonstrating in 
vivo immunostimulation. There was less evidence for the immunostimulatory potential of 
LMW protein in adults with coeliac disease (Vader 2002a). During the course of this 
research, Tye-Din et al (2010) eloquently demonstrated that the HMW and LMW glutenin 
peptides tested on a large bank of peripheral blood lymphocytes taken from coeliac patients 
following a five-day oral gluten challenge failed to stimulate T-cells in the majority of 
HLA-DQ2 positive coeliac individuals. However, in a small minority of his patients, there 
was evidence of a marked T-cell response as assessed by enzyme-linked immunosorbent 
spot (ELISPOT). HMW glut04 peptide is contained in W24, one of the peptides tested by 
Tye-Din whereas the LMW glt156 peptide used in this study failed to elicit a response in 
Tye-Din’s screening phase and so was not tested further.  
High molecular weight glutenin protein takes 68 hours to deamidate in a laboratory setting 
therefore HMW glut04 was tested in its native form rather than deamidated. Some LMW 
glutenins can be deamidated and so it was thought preferable to test both the native form of 
LMW glt156, as well as deamidated peptide. 
The control patients were tested to ensure that the peptides were not immunostimulatory in 
non gluten-sensitive cell lines. More patients could have been tested; however, it was 
difficult to grow these cell lines without antigenic stimulation and it was difficult to obtain 
ethical approval for a large number of controls to be used. 
Cell lines grown against FFIII did not yield gluten-sensitive cells in the majority of those 
tested. There was only one cell line (SD17) in whom FFII sensitive cells showed a weak 
response to HMW glut04. Interestingly, SD20, an HLA-DQ2/DQ8 heterozygous patient, 
had a positive stimulation index towards deamidated LMW glt156 despite the fact that the 
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T-cells were not FFIII sensitive cells. There was not enough information to say if this was 
potentially an HLA-DQ8 epitope due to lack of HLA-DQ8 positive patients.  
All coeliac small intestinal T-cell lines grown against PT gluten demonstrated gluten 
sensitivity by positive stimulation index and at least a ten-fold rise in IFN-γ secretion, in the 
majority of those supernatants tested. However, only in a small minority of coeliac 
individuals tested was there any evidence of T-cell stimulation by HMW glut04, LMW 
glt156 or deamidated LMW glt156, that is in three, two and two out of twenty-eight 
individuals respectively. Interestingly, in the case of the one patient who had a positive 
stimulation index against LMW glt156 and deamidated LMW glt156 and for whom 
concentration of IFN-γ was known, there was less secretion of IFN-γ into the culture 
supernatant compared to that of PT gluten or HMW glut04.  
These results from small intestinal T-cell lines of coeliac individuals, agree with the 
findings of Tye-Din’s study (2010) from peripheral blood lymphocytes of coeliac 
individuals. In Tye-Din’s study however, the LMW peptides were not immunostimulatory 
towards HLA-DQ2 peripheral blood coeliac T-cells and therefore they did not go on to 
further assessment in their manuscript. In the present study, the majority of T-cells from the 
small intestine of the coeliac individuals tested fail to be stimulated by both HMW glut04 
and LMW glt156, whether or not it had been deamidated. There were not enough HLA-
DQ8 individuals, homozygous or heterozygous, recruited to this study to evaluate the 
earlier effect seen in a FFIII cell line. It would be interesting to repeat this study in such 
individuals although, due to the paucity of such individuals this may not be feasible. 
What this study does demonstrate is the heterogeneous response to different antigenic 
stimuli that adult coeliac patients have. Positive stimulation indices were seen in a small 
minority of patients. The group which underwent antigenic stimulation with PT gluten 
(SD38 and SD 73) seemed to respond to the glutenins early on, after a week of antigenic 
stimulation. This may be more representative of the mass T-cell gut action as the longer 
cells are in culture the more likely there is to be a clonal expansion of T-cell population 
which may not be naturally dominant. 
The paediatric literature (van der Wal 1999, Vader 2002) used a small group of HLA DQ8 
clones to test the immunostimulatory potential of both the HMW and LMW peptides tested 
in this study. In this study SD20 was the only HLA DQ2/8 heterozygote who demonstrated 
an immunostimulatory response towards the deamidated LMW glt156 peptide. The other 
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patients tested (SD17, SD 38 and SD73) were HLA DQ2 patients who demonstrated some 
response to the HMWglut04 peptide. 
The best response to both the HMW glut04 peptide as well as the LMW glt156 peptide was 
an HLA DQ2 patient, SD17, who had undergone 2 rounds of FFIII antigenic restimulation. 
This result was unlikely to be due to bacterial contamination as the other wells did not 
respond in the similar way; if bacteria were to come in contact with a plate it is highly 
unlikely that only 6 wells would be affected as bacteria are highly contagious in cell 
culture. This was a young patient with a reasonably new diagnosis of coeliac disease made 
4 months prior to recruitment. It may be that earlier in the disease more epitopes are able to 
elicit a T-cell response. This theory is supported by Vader’s work (2002a) that 
demonstrated that the paediatric clonal T-cell population responded differently to antigenic 
stimulation when compared to a smaller group of adult HLA DQ2 clonal T-cell population. 
This study lends more weight to the argument of epitope-spreading in children with 
epitope-focussing in adults. In children, the immune response is capable of reacting to any 
number of epitopes but that T-cell response will eventually focus on those peptides that 
combine strong HLA DQ binding with potent T-cell activity to reduce the number of 
epitopes to which adults will mount a response. By testing paediatric epitopes HMW glut04 
and LMW glt156 in an adult population these have been shown not to be major T-cell 
epitopes. However, perhaps if tested in HLA DQ8 adults or in a group of recently 
diagnosed coeliac population these epitopes may be more immunogenic than first thought. 
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Chapter 4: The role of glutenins in innate immunity 
 
 
4.1  Introduction and Aims 
Initial reports of organ culture of coeliac disease-affected small intestinal mucosa came 
from Trier and Browning in 1970. They showed that untreated coeliac mucosa, after only 
24 hours of organ culture in a gluten-free environment, reverted towards normal; the 
enterocytes became more columnar and less vacuolated. By 
3
H thymidine incorporation 
into crypt cells, they also demonstrated that untreated coeliac mucosa has an enhanced 
epithelial cell proliferation compared with normal mucosa, and that this proliferation 
returns to normal in patients treated with a gluten-free diet. This demonstrated that it was 
possible to study coeliac mucosa in vitro and differentiate it from normal mucosa. 
Falchuk et al (1974) published their first report of a series of experiments aimed at studying 
the pathogenesis of the mucosal abnormality in coeliac disease. They demonstrated that the 
mucosa of coeliac patients behaved differently in the presence of Frazer’s Fraction III by 
measuring changes in alkaline phosphatise activity, and found that these changes were 
specific for gluten. The inhibition of the rise in alkaline phosphatise activity with gluten 
was not present when casein was in the medium. However, there was some disagreement 
about the biochemical changes initially reported by Falchuk, with others not finding them 
so reproducible (Hauri 1978, Howdle 1981a, Fluge 1982). 
Howdle et al (1981b) modified this technique to use morphometric assessment as a reliable 
and reproducible means of studying coeliac disease. They measured the height of 
enterocytes (ECH) on small intestinal biopsies pre- and post-culture as well as measuring 
intra-epithelial lymphocytes (IELs) per 100 enterocytes and the crypt depth:villous height 
ratio. They were able to show that the reduction in ECH was specific for gluten and for 
coeliac mucosa. This modified model has been used to test the toxicity of various gluten 
sub-fractions (Ciclitira 1984, de Ritis 1988, Przemioslo 1995, Shidrawi 1995, Maiuri 1996, 
Biagi 1999, Beckett 1999, Martucci 2003, Mazzarella 2003, Maiuri 2003). 
Maiuri et al (2003) demonstrated that A-gliadin p31-43, a gluten peptide, could damage 
small intestinal biopsies in organ culture, via interleukin-15, despite not stimulating gluten-
sensitive T-cells (see section 1.10). It is thought that IL-15 activates IELs (Di Sabatino 
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2006, Mention 2003, Bergamashi 2008) and therefore can be seen as a link between the 
innate and adaptive immune response. Some gluten peptides can induce mucosal damage in 
coeliac disease through direct activation of the innate immune system. IL-15 is a protein 
mainly expressed by fibroblasts, epithelial cells, monocytes and dendritic cells. It is 
essential for the development of natural killer and T-cells (see section 1.4.1) and has a 
potent anti-apoptotic effect on these cells (Fehniger 2001, Budagian 2006). 
Refractory coeliac disease (RCD) is a rare complication of coeliac disease, see section 
1.7.1, where interleukin-15 seems to play an important role in disease pathogenesis. 
Mention et al (2003) found that IL-15 was overexpressed by enterocytes in both coeliac 
disease and RCD. More recently, Malamut et al (2010) found that when IL-15 was blocked 
by antibodies, the massive accumulation of intra-epithelial lymphocytes normally seen in 
RCD was reduced. The pathophysiology of refractory coeliac disease is poorly understood. 
This is due in part to the scarcity of patients. Even less is known about the effect of glutenin 
peptides in RCD. St Thomas Hospital is a tertiary referral centre for refractory coeliac 
patients for the South East of Britain and from further afield in the UK. It was hoped that 
this patient group could be used in the assessment of the role of glutenins in the innate 
immune response. The results from refractory coeliac disease duodenal biopsies have never 
been published in organ culture systems. The T-cells from the small intestine of RCD 
patients are known to be difficult to grow in vitro.This is due to their lack of antigenic 
stimulation by gluten as well as the immunosuppression treatment regimens, which patients 
are often on to help control their disease, to reduce the lymphocyte count. 
Results from T-cell proliferation studies (see Chapter 3) suggested that HMW glut04 and 
LMW glt156 were not major T-cell epitopes. They were unable to be tested in RCD patients 
as the T-cells were not able to be grown in vitro. These two glutenin peptides HMW glut04 
and LMW glt156, have not previously been used in small intestinal organ culture systems to 
assess their activation of the innate immune system.  
The aim of this study was to assess the innate immune system response towards two 
glutenin candidate epitopes, HMW glut04 and LMW glt156, in both coeliac disease and type 
2 refractory coeliac disease. Enterocyte cell height (ECH) was measured in formalin-fixed 
paraffin–embedded duodenal biopsy sections stained with haematoxylin and eosin and 
interleukin-15 secretion into the culture supernatants was assessed by high sensitivity 
ELISA. The null hypothesis in these experiments is that there is no clinically significant 
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histological change in the biopsies after overnight incubation with candidate epitopes, 
HMW glut04 and LMW glt156 glutenin peptides. 
4.2  Methods  
4.2.1  Small intestinal biopsy organ culture 
The methods used in this chapter were based on those reported by Przemioslo (1995) where 
biopsy viabiltity was assessed after delay in the organ culture system and length of time in 
the organ culture system. Pairs of small intestinal biopsies were set up, touching each other, 
in separate organ culture dishes containing either medium-only, ovalbumin as a negative 
control, PT gluten as a positive control, HMW glut04 or LMW glt156 as described in section 
2.3. Proteins (PT gluten and ovalbumin) were used at 1mg/ml concentration whereas the 
peptides (HMW glut04 and LMW glt156) were used at 200μg/ml. 
After overnight incubation the supernatants were collected, the biopsies were weighed, and 
fixed in formal saline as per section 2.6.1. After 48 hours in formal saline the biopsies were 
embedded in paraffin, see section 2.6.2. 
Secretory interleukin-15 in the organ culture supernatant was measured by ELISA, as per 
section 2.6.2, on a single day. 
4.2.2  Processing of formalin-fixed, paraffin-embedded small intestinal biopsies 
Tissue blocks were cut at 4μm thickness and baked on Super Frost sides at 60°C overnight 
(kindly done by Prof Novello’s team at University College Hospital, London). They were 
then de-waxed, stained with haematoxylin and eosin (H+E), to measure enterocyte cell 
height, or interleukin-15 immunohistochemistry as per sections 2.6.2, 2.6.3, 2.6.4, 2.6.5 and 
2.6.6. 
4.2.3  Microscopic examination of the slides 
The H+E stained slides were examined under blinded conditions using low power (x100) to 
identify the anatomy. These blinded conditions were unblended at the end of the 
measurement of the entire patient cohort. 
Where visible, three villi were selected in order to measure the enterocyte cell height ECH). 
Enterocytes were counted at the middle of the villi where there is the least amount of ECH 
variation. At each villi, 30 continuous enterocytes were measured at high power (x400) 
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using a graticule, giving a total of 90 ECH measurements for each section. This graticule 
required a coefficient of x1.92 correction to the measurements obtained.  
Where the biopsies were a Marsh 3, villi were not able to be identified however, the 
enterocyte layer was clear and the measurements were taken from the middle of the section. 
Measurements were not taken from any villi or epithelial layer at the edge of the section 
due to any artefact in the tissue handling or processing, as is standard among 
histopathologists. In damaged biopsies, the enterocyte layer was occasionally detached 
from the epithelium and this was stated in the results. 
4.2.4 Statistics 
In order to decide on relevant statistical tests the mean and median enterocyte cell height of 
each sample group were compared, see table 4.1 and 4.2. These tables include the Marsh 
grading (Oberhuber 1999) given by the gastrointestinal pathologist at St Thomas Hospital 
reporting the biopsy sent as part of routine investigations in these patients. They 
demonstrate that there is no clinically significant difference between the mean and median 
for each patient in the coeliac as well as type 2 refractory coeliac groups therefore normal 
distribution was assumed. 
GraphPad Prism 5.0 for Windows was used in the statistical analysis in this chapter. A one-
way repeated measurement ANOVA with Dunnett’s multiple comparison test was used to 






Table 4.1 Comparison of mean and median enterocyte cell height (microns) in coeliac population 
Patient 
(Marsh) 







































































































































































17.3 Biopsy destroyed 
Paired biopsies were left overnight in an organ culture system under five different conditions: medium-only, ovalbumin only as a 
negative peptide, peptic-tryptic digest of gluten (PT gluten) as a positive control, high molecular weight glutenin04 721-735 
(HMW glut04) and low molecular weight glutenin glt156 44-59 (LMW glt156). They were placed in formal saline for 48 hours 
before embedding in paraffin. Four micron sections were stained with haematoxylin and eosin and enterocyte cell height was 






Table 4.2 Comparison of mean and median enterocyte cell height (microns) in type 2 refractory coeliac population 
Patent 
(Marsh) 


































































































Paired biopsies were left overnight in an organ culture system under five different conditions: medium-only, ovalbumin only as a 
negative peptide, peptic-tryptic digest of gluten (PT gluten) as a positive control, high molecular weight glutenin04 721-735 
(HMW glut04) and low molecular weight glutenin glt156 44-59 (LMW glt156). They were placed in formal saline for 48 hours 
before embedding in paraffin. Four micron sections were stained with haematoxylin and eosin and enterocyte cell height was 




The rationale for choosing the peptides in this study has already been explained in section 
1.12. The following peptides were made commercially by GenScript (New Jersey, USA) 
with the minimum stimulating T-cell epitope in bold and the underlined glutamine residues 
a target for deamidation to glutamic acid:  
Amino acids 721-735 of HMW glutenin, HMW glutenin 04 (HMW glut04) 
        QGQQGYYPTSPQQSG 
Amino acids 44-59 of LMW glutenin LMW glutenin 156 (LMW glt156) 
        PPFSQQQQSPFSQQQQ 
As deamidation of peptides has been shown to occur by endogenous tissue 
transglutaminase in the mucosal tissue in culture (Molberg 2001), LMW glutenin glt156 
was not deamidated prior to addition in the organ culture system. 
 
4.4 Patients used in small intestinal biopsy organ culture studies 
Three different patient groups were used in this study. The first group consisted of nine 
coeliac patients who were undergoing endoscopy as part of their routine clinical work up 
who consented to the study. The demographic details of these patients are shown in table 
4.3. Interestingly, three of the patients, SM4, SM10 and SM15, also took part in the T-cell 
experiments in Chapter 3, known as SD20, SD50 and SD63. These are highlighted on the 
table with their Chapter 3 labels in brackets.  
Most of these patients had been diagnosed with coeliac disease and established on a gluten-
free diet for a number of years. The length of time patients had coeliac disease was taken as 
the time from their first diagnostic small intestinal biopsy. There was only one HLA DQ8 
positive patient in this cohort which is in keeping with prevalence of HLA DQ8 in the 
coeliac population. The ages span from 24 to 79 with the majority of patients agreeing to 
take part in the study being female.  
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Table 4.3 Coeliac disease patients in small intestinal organ culture studies 















SM4 (SD20) 24 F DQ8 3 years nil 





SM6 20 F DQ2 4 years 
PCOS, 
asthma 











SM12 61 M DQ2 4 years nil 
SM15 
(SD63) 




SM17 37 F DQ2 2 years nil 
Number in bracket relates to the patient number in Chapter 3 
 
As St Thomas Hospital is a referral centre for refractory coeliac disease, there was wealth 
of these patients available for assessment with no previously published organ culture 
studies. The second group in this study were therefore five patients who had a diagnosis of 
type 2 refractory coeliac disease and were undergoing endoscopic assessment every four 
months as part of their disease evaluation who consented to the study. The demographics 
for these patients are demonstrated in table 4.4. The length of time patients had coeliac 
disease was taken as the time from their first diagnostic small intestinal biopsy. The length 
of time patients had a diagnosis of type 2 RCD was taken as the time from first histological 
biopsy demonstrating Marsh 3 changes (section 1.5.2) intraepithelial lymphocyte T-cell 
receptor monoclonality demonstrated while on a gluten-free diet (section 1.6.1) and no 
other cause of villous atrophy identified. 
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As with RCD, they were of an older age range 53-75 and were more evenly matched for 
sex than the coeliac patients in table 4.1. There was only one HLA DQ8 patient in this 
study however, this is a little higher than would be expected by chance.  
Table 4.4 Type 2 refractory coeliac disease patients in small intestinal organ culture studies 







SM3 69 F DQ2 
CD 3 years 
RCD 1 year 
nil 
SM7 53 F DQ2 
CD 24 years 
RCD 6 years 
nil 
SM8 67 M DQ8 
CD 7 years 
RCD 3 years 
Depression, 
alcohol excess  
SM13 64 M DQ2 







SM16 75 F DQ2.5 
CD 8 years 
RCD 2 years 
RA, GORD 




The third group in this study was a non-coeliac control group of only two patients due to 
our available ethics. They were undergoing routine endoscopy as part of their clinical 
investigation and consented to the study. The purpose of this small group was to try to 
demonstrate that the candidate glutenin epitopes did not produce a toxic response in the 
small intestinal biopsies. 
Both patients had been screened with an IgA and IgG tissue transglutaminase antibody as 
well as IgA anti-endomysial antibody to exclude coeliac disease. The formal histology from 
the GI pathologists at St Thomas Hospital did not show any evidence of coeliac disease.  
The patient demographics in this group are shown in table 4.5. They are young patients 
with only one HLA DQ status available which was neither HLA DQ2 nor 8 positive. Both 
patients were young and both sexes were represented. 
 
 
Table 4.5 Non-coeliac disease patients in small intestinal organ culture studies 
Patients Age (years) Sex HLA status Diagnoses 
SM11 48 F NA 
Depression, vertigo, GORD, 
stillbirth 
SM14 30 M –ve IBS 




Appendix V contains photographs of some H+E slides analysed in the sections below. 
In organ culture biopsies it is not unusual to see “debris” on the luminal surface of the 
biopsy where dead enterocytes and inflammatory cells have sloughed off the biopsy. There 
is often a slight difference in histologic appearances in organ culture biopsies as there is 
often evidence of autolysis occurring. This is due to the delay in fixing the tissue. Whereas 
biopsies taken for histology in endoscopy are put immediately into formal saline, there is a 
delay of 18 hours in the organ culture sytem. Tables 4.6, 4.7 and 4.8 also contain the GI 
pathogists' assessment of the Marsh grading from the biopsies sent at the time of endoscopy 
which agreed with the organ culture system assessment of the medium-only biopsy 
specimens. 
Box plots are used in Figures 4.1, 4.2 and 4.3 to depict the spread of data from the repeated 
measurements of enterocyte cell height. The sample minimum and maximum values are 
whiskers extending from the box, the upper and lower quartiles make the box and median is 
shown as a line in the box. 
4.5.1  Results from the coeliac patients 
Every patient had a pair of biopsies in each experimental condition in the organ culture 
system; medium alone to act as the reference; ovalbumin, a neutral protein to act as 
negative control; peptic-tryptic digest of gluten as the positive control; the candidate 
glutenin peptides HMW glut04 and LMW glt156. 
Figure 4.1A-I demonstrate the results of enterocyte cell height (ECH) for each coeliac 
patient. There is often a significant difference seen between the medium-only group and the 
ovalbumin group which can be accounted for in biopsy size. The smaller biopsies were 
used in medium-only rather than the other experimental conditions. This explains why the 
ECH is often better in the ovalbumin group, although histopathologists consider a normal 
enterocyte height to be between 30 and 40 microns. Figure 4.1A is of a newly diagnosed 
coeliac patient hence the smaller ECH across all experimental conditions.  
There is a clear significant reduction in ECH in the PT gluten biopsies as well as both 
candidate glutenin epitopes seen across all the coeliac patients. In Figures 4.1B, F and H 
there is also T cell data from Chapter 3 demonstrating that in these three patients there was 
no T cell stimulation with the HMW glut04, LMW glt156 and deamidated LMW glt156 
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peptides. There is a significant reduction in the ECH in each of these three patients with 
both the HMW glut04 peptide and the LMW glt156 peptide. 
Unfortunately in Figure 4.1I patient SM17 LMW glt 156 biopsy was destroyed by the 
incubation and therefore ECH could not be determined. This was not as a result of bacterial 
contamination as the medium would not have remained the same colour, nor was it likely 
due to technique as the other biopsies would have also been destroyed. This further 
reinforces the idea that in vitro these glutenin peptides are certainly harmful to coeliac 
mucosa. 
Figure 4.2 demonstrates the combined results of all the coeliac patients. Overall it 
demonstrates, as expected, the PT gluten ECH is significantly reduced but that both the 
HMW glut04 and LMW glt156 ECH are also reduced significantly. This suggests that these 
peptides do trigger an immune response in the mucosa of coeliac patients.  
These biopsies were then stained for interleukin-15 (IL-15) on different sections using 
immunohistochemistry in order to see if this response involved IL-15. Unfortunately this 
staining was not successful after review by the histopathologist. Secretory IL-15 was 
measured in the organ culture medium which had been frozen at -20°C to enable all 
samples to be tested on the same day. The results are demonstrated in table 4.6 with the 
secretory IL-15 data expressed as picograms per milligram of tissue. The Marsh grading 
given by the GI histopathologists at St Thomas Hospital is given in brackets below the 
patient details. 
There is little IL-15 secreted into the organ culture medium as measured by high sensitivity 
ELISA.  
There was only one patient who was HLA DQ8, SM4, and this patient did not appear to 
behave any differently to the other patients in this study. 
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Results of overnight incubation of a pair of coeliac duodenal biopsies in organ culture 
system with medium-only (med), ovalbumin (oval), a peptic-tryptic digest of gluten (PT 
gluten) and the candidate glutenin epitopes HMW glut04 (high molecular weight glutenin04 
721-735) and LMW glt156 (low molecular weight glutenin glt156 44-59). The biopsy 
morphology was preserved in formal saline for 48 hours and embedded in paraffin wax, 
after which they were cut 4μm thick, dewaxed and stained with haematoxylin and eosin. At 
x400 magnification the enterocyte cell height from mid-villus was counted for 30 
continuous enterocytes in three different villi. The median, interquartile range and 
maximum and minimum values are represented in the graphs above. Each graph, A-I, is a 
different patient. Median values are compared to medium-only to see if there is any 
difference. ns=not significant, * p<0.05, ** p<0.005, *** p<0.001.  
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Combined results for each coeliac patient from Figure 4.1 enterocyte cell height 
measurements after overnight incubation of a pair of coeliac duodenal biopsies in organ 
culture system with medium-only (med), ovalbumin (oval), a peptic-tryptic digest of gluten 
(PT gluten) and the candidate glutenin epitopes HMW glut04 (high molecular weight 
glutenin04 721-735) and LMW glt156 (low molecular weight glutenin glt156 44-59). The 
biopsy morphology was preserved in formal saline for 48 hours and embedded in paraffin 
wax, after which they were cut 4μm thick, dewaxed and stained with haematoxylin and 
eosin. At x400 magnification the enterocyte cell height from mid-villus was counted for 30 
continuous enterocytes in three different villi. The median, interquartile range and 
maximum and minimum values are represented in the graphs above. Median values are 
compared to medium-only to see if there is any difference. ns=not significant, * p<0.05, ** 
p<0.005, *** p<0.001.  
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Table 4.6 Interleukin-15: ELISA quantification of secretory interleukin-15 results in coeliac patients 
Patient 
(Marsh) 
Medium Ovalbumin PT gluten HMW glut04 LMW glt156 
ELISA (pg/mg) ELISA (pg/mg) ELISA (pg/mg) ELISA (pg/mg) ELISA (pg/mg) 
SM2 
(3b) 




0.02 0.00 0.00 0.04 0.06 
SM5 (1-
2) 
0.01 0.00 0.02 3.54 0.06 
SM6 
(3a) 
0.04 0.03 0.08 0.05 0.06 




0.03 0.07 0.11 0.03 0.03 
SM12 
(0) 




0.01 0.01 0.02 0.03 0.02 
Paired biopsies were left overnight in an organ culture system under five different conditions: medium-only, ovalbumin only as a 
negative peptide, peptic-tryptic digest of gluten (PT gluten) as a positive control, high molecular weight glutenin04 721-735 
(HMW glut04) and low molecular weight glutenin glt156 44-59 (LMW glt156). Secretory IL-15 was measured with a commercial 
high sensitivity ELISA kit from the culture supernatants.  
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4.5.2  Results from the type 2 refractory coeliac disease patients 
Every patient had a pair of biopsies in each experimental condition in the organ culture 
system; medium alone to act as the reference; ovalbumin, a neutral protein to act as 
negative control; peptic-tryptic digest of gluten as the positive control; the candidate 
glutenin peptides HMW glut04 and LMW glt156. 
Refractory coeliac disease biopsy specimens shown in Figure 4.3A-E demonstrate a similar 
trend as the coeliac patients in Figure 4.1. There is a difference between the ovalbumin 
group and the medium-only group which can be accounted for by biopsy size: the smaller 
biopsies being used in the medium-only group. They all show decreased ECH in the PT 
gluten group as well as both HMW glut04 and LMW glt156 groups. Unfortunately the 
biopsy specimens for SM3 in PT gluten and HMW glt04 were destroyed and therefore 
unable to measure ECH. 
Figure 4.4 shows the combined ECH for each patient under each experimental condition. It 
summarises that there is an overall significant difference between the ECH in the medium-
only group and the ECH in the PT gluten, HMW glut04 and LMW glt156 groups. 
Both these figures demonstrate that there is a toxic process happening in vitro in the 
mucosa of type 2 refractory coeliac disease despite their treatment with azathioprine 
(2.5mg/kg) and 20mg prednisolone. 
Unfortunately, the IL-15 immunohistochemistry was reviewed by histopathologist, Prof 
Novelli, who suggested it be removed from this study. Secretory IL-15 was measured by 
high sensitivity ELISA from the biopsy culture supernatants, the results expressed as 
picograms per milligram of tissue. The results of these experiments are shown in table 4.7 
demonstrating there was little IL-15 secreted into the culture supernatants. 
There was only one patient who was HLA DQ8, SM8, and this patient did not appear to 
behave any differently to the other patients in this study. 
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Enterocyte cell height measurements after overnight incubation of a pair of type 2 
refractory coeliac duodenal biopsies in organ culture system with medium-only (med), 
ovalbumin (oval), a peptic-tryptic digest of gluten (PT gluten) and the candidate glutenin 
epitopes HMW glut04 (high molecular weight glutenin04 721-735) and LMW glt156 (low 
molecular weight glutenin glt156 44-59). The biopsy morphology was preserved in formal 
saline for 48 hours and embedded in paraffin wax, after which they were cut 4μm thick, 
dewaxed and stained with haematoxylin and eosin. At x400 magnification the enterocyte 
cell height from mid-villus was counted for 30 continuous enterocytes in three different 
villi. The median, interquartile range and maximum and minimum values are represented in 
the graphs above. Each graph, A-E, is a different patient. Median values are compared to 


























































Combined results of enterocyte cell height measurements for each type 2 refractory coeliac 
patient from Figure 4.3 after overnight incubation of a pair of coeliac duodenal biopsies in 
organ culture system with medium-only (med), ovalbumin (oval), a peptic-tryptic digest of 
gluten (PT gluten) and the candidate glutenin epitopes HMW glut04 (high molecular 
weight glutenin04 721-735) and LMW glt156 (low molecular weight glutenin glt156 44-59). 
The biopsy morphology was preserved in formal saline for 48 hours and embedded in 
paraffin wax, after which they were cut 4μm thick, dewaxed and stained with haematoxylin 
and eosin. At x400 magnification the enterocyte cell height from mid-villus was counted 
for 30 continuous enterocytes in three different villi. The median, interquartile range and 
maximum and minimum values are represented in the graphs above. Median values are 
compared to medium-only to see if there is any difference. ns=not significant, * p<0.05, ** 





Table 4.7 Interleukin-15: ELISA quantification of secretory interleukin-15 results in type 2 refractory coeliac patients 
Patient 
(Marsh) 
Medium Ovalbumin PT gluten HMW glut04 LMW glt156 
ELISA (pg/mg) ELISA (pg/mg) ELISA (pg/mg) ELISA (pg/mg) ELISA (pg/mg) 
SM3 
(3b) 
0.00 0.02 0.09 0.01 0.03 
SM7 (0)  0.01 0.07 0.10 0.63 0.3 
SM8 
(3b) 
0.00 0.03 0.01 0.63 0.3 
SM13 
(0) 
0.06 0.03 0.03 0.05 0.03 
SM16 
(0) 
0.06 0.06 0.06 0.06 0.02 
Paired biopsies were left overnight in an organ culture system under five different conditions: medium-only, ovalbumin only as a 
negative peptide, peptic-tryptic digest of gluten (PT gluten) as a positive control, high molecular weight glutenin04 721-735 
(HMW glut04) and low molecular weight glutenin glt156 44-59 (LMW glt156). Secretory IL-15 was measured with a commercial 
high sensitivity ELISA kit from the culture supernatants.  
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4.5.3  Results from the non-coeliac patients 
Figure 4.5A and B demonstrate that the ECH is increased after overnight incubation with 
PT gluten or the candidate peptides, HMW glut04 and LMW glt156. In Figure 4.5C, where 
results from both patients are combined, there is no effect on the ECH with either of the 
candidate peptides. There is an amelioration of ECH in the biopsies incubated with PT 
gluten. 
In table 4.8, when these biopsies were assessed for IL-15 production there is again little 
secretion of IL-15 into the culture medium. The IL-15 immunohistochemistry when 
reviewed by histopathologist, Prof Novelli, was removed from this study. 
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Enterocyte cell height measurements after overnight incubation of a pair of non-coeliac 
duodenal biopsies in organ culture system with medium-only (med), ovalbumin (oval), a 
peptic-tryptic digest of gluten (PT gluten) and the candidate glutenin epitopes HMW glut04 
(high molecular weight glutenin04 721-735) and LMW glt156 (low molecular weight 
glutenin glt156 44-59). The biopsy morphology was preserved in formal saline for 48 hours 
and embedded in paraffin wax, after which they were cut 4μm thick, dewaxed and stained 
with haematoxylin and eosin. At x400 magnification the enterocyte cell height from mid-
villus was counted for 30 continuous enterocytes in three different villi. The median, 
interquartile range and maximum and minimum values are represented in the graphs above. 
Graphs A and B represent different patients with graph C combining the results of both 
patients. Median values are compared to medium-only to see if there is any difference. 






Table 4.8 Interleukin-15: ELISA quantification of secretory interleukin-15 results in non-coeliac patients 
Patient 
(Marsh) 
Medium Ovalbumin PT gluten HMW glut04 LMW glt156 
ELISA (pg/mg) ELISA (pg/mg) ELISA (pg/mg) ELISA (pg/mg) ELISA (pg/mg) 
SM11 (0) 0.04 0.06 0.04 0.02 0.03 
SM14 (0) 0.01 0.01 0.02 0.03 0.02 
Paired biopsies were left overnight in an organ culture system under five different conditions: medium-only, ovalbumin only as a 
negative peptide, peptic-tryptic digest of gluten (PT gluten) as a positive control, high molecular weight glutenin04 721-735 
(HMW glut04) and low molecular weight glutenin glt156 44-59 (LMW glt156). Secretory IL-15 was measured with a commercial 




As a method to assess the immunostimulatory potential of various proteins or peptides, the 
organ culture system benefits from having many more cells present than in a pure T-cell 
assay, it is closer to in vivo studies, and is less invasive than the latter. This system has 
fallen out of favour in recent times as it is time-consuming and requires rapid setting into 
the organ culture chamber to prevent damage to the biopsies. However, it is a good method 
to examine the innate immune response in coeliac disease. Maiuri et al (2003) 
demonstrated the toxicity of A-gliadin peptide 31-43 in coeliac disease patients using this 
method after T-cell proliferation assays failed to demonstrate immunostimulatory potential 
of this peptide. 
There is no published data on the effects of glutenin peptides on the innate immune 
response as measured by the organ culture system. Previous studies have suggested that 
glutenins are not major T-cell epitopes (Tye-Din 2010, Molberg 2003, Vader 2002a) as 
well as this thesis in Chapter 3. However, in vivo studies point to a huge response by HLA-
DQ2 positive coeliac individuals’ small intestines when instilled with either a purified 
mixture of high molecular weight glutenin peptide or recombinant Dy10 and Dx5 fractions 
(Dewar 2006, Ellis 2006). The HMW glut04 peptide is contained within the Dy10 HMW 
glutenin subunit. 
In this study non-coeliac patients were included in order to demonstrate that these glutenin 
peptides were not toxic to all patient groups. They demonstrate that they do not have a 
significant reduction in enterocyte cell height after overnight incubation with both the 
HMW glut04 and LMW glt156 peptides. Unfortunately there were only a few patients in 
this group due to ethical constraints. 
What this study demonstrates is that there is a significant reduction in enterocyte cell height 
compared to medium alone or ovalbumin in coeliac as well as refractory coeliac individuals 
when exposed to the HMW and LMW glutenin peptides tested. Reduction in enterocyte cell 
height is the earliest damage that can be seen in the coeliac small intestine and from 
Howdle’s work (1981b) has been shown to predict coeliac toxicity. Of interest, three 
patients, SM4, SM10 and SM15, who had no T-cell response to these glutenin peptides, 
have a marked response in reduction of enterocyte cell height. This suggests that these 
glutenin candidate peptides exert their effect on coeliac mucosa independent of T-cells. It is 
not surprising therefore, that there was no difference seen in the two HLA DQ8 positive 
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patients, SM4 and SM 8, as the HLA molecule is key to the presentation of antigen to T 
cells. The changes seen in these studies are not necessarily as a result of damage from T-
cell activation.  
It is not surprising that the level of secretory interleukin-15 measured by ELISA was low as 
the majority of Il-15 is membrane bound. It is also a tightly regulated hormone as very low 
concentrations can have significant effects in vivo. There was also tissue present containing 
target cells for the IL-15 which may well have reacted to the IL-15 secreted rather than 
letting it spill into the supernantant. Perhaps the measurement of IL-15 expression in these 
biopsies should have included mRNA expression as it may have been a more accurate way 
of detecting any subtle changes in very low concentrations. 
St Thomas Hospital is privileged to have a number of refractory coeliac patients which had 
not previously been used in this type of study. Little is known about the pathophysiology of 
this rare complication of coeliac disease however, IL-15 is known to play an important role. 
Interestingly, the type 2 refractory coeliac group appear to be gluten-sensitive in the organ 
culture system. This is something that is not thought to be important in clinical practice. In 
the type 2 refractory group, the major complication is an enteropathy associated T-cell 
lymphoma derived from the intra-epithelial compartment (Spencer 1989, Cellier 2000). It is 
possible that the intraepithelial response to peptides triggers the initial response in coeliac 
patients rather than the gluten peptides in the lamina propria being deamidated and 
presented to the gluten-sensitive T-cells. 
This study suggests that these glutenin proteins, very different structures to gliadin proteins, 
may be the first trigger in small intestinal response seen in coeliac disease. The next step in 
the immune response towards gluten peptides is likely to be the T-cells' response to the 








5.1 Introduction and aims 
Gluten-free foods are permitted by law to contain gluten in small amounts. This level in 
Europe is regulated by Codex Standard. The latest guideline (Codex Stan 118-1979) was 
amended in 2008 to reduce the permissible gluten content in these foods. The change was 
ratified in January 2009 and manufacturers had until January 2012 to comply. Any food 
labelled as “gluten-free” must contain less than 20mg/kg of gluten and any food labelled as 
“very low gluten” may contain between 21-100mg/kg. 
This latest amendment also recommends the use of the “R5 Mendez” enzyme-linked 
immunosorbent assay (ELISA) method to measure gluten content in foods (Valdés 2003). 
There are inherent problems with this method of gluten quantification. The antibody used 
detects a pentapeptide, QQPFP, found in rye secalins but also commonly found in wheat 
gliadins and barley hordeins. However, it fails to measure the glutenin fraction found in 
wheat, and similar proteins in rye and barley. It also does not measure oat avenins which 
are immunostimulatory in a minority of coeliac individuals. In order to compensate for the 
lack of detection of glutenins, the quantity of gliadin measured is multiplied by a factor of 
2: gluten=2(gliadin). This can inaccurately estimate total gluten content. Between wheat 
varieties there is a difference in the ratio of gliadins to glutenins present. High pressure 
liquid chromatography has demonstrated that the ratio of glutenin to gliadin varies between 
0.2 to 5.8 times in wheat starch samples (Wieser 2003). If measured using individual 
antibodies to a subunit of HMW glutenin, Dy10, as well as antibodies to the 
immunodominant HLQ-DQ2 α-gliadin epitope, the values obtained for total gluten content 
were significantly different to the value that would be obtained by multiplying the gliadin 
value by 2, in a number of gluten-free foods (Ellis 2008b). Therefore, there is a need for a 
better test to measure gluten content in foods and especially processed foods. The R5 
Mendez method can be even more inacurate when measuring processed foods. 
Tests for the measurement of gluten in foods must be sensitive enough to detect the lower 
limit of gluten (20mg/kg) as well as be able to detect hydrolysates present after food 
processing. The findings of Ellis et al (2008b) suggest that both gliadins and glutenins 
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should be involved in the quantification of gluten. A potential assay which would meet 
these needs is a “cocktail ELISA”, although this has not yet been designed, due to lack of 
suitable glutenin monoclonal antibodies. The principle of a “cocktail ELISA” is to use a 
mix of several antibodies as the primary detection antibodies, such as antibodies to a 
gliadin peptide, HMWG and LMWG peptides. The resultant value would be closer to the 
true value of the gluten content in the food. This assay could be further developed into a 
competition ELISA required to measure hydrolysates in foods. 
However, monoclonal antibodies are difficult to produce. The process involves immunising 
animals with the peptide of interest and assessing the serological response. The animals that 
display a serological response are culled and the spleens removed. Spleens contain a 
mixture of T-cells, B-cells, dendritic cells and macrophages. The splenocytes that are B-
cells are capable of producing antibodies. However, they are difficult to grow alone. Fused 
with an immortal cell line, such as mouse myeloma cells, they can produce antibody-
secreting cell lines, known as hybridomas. Mice are the ideal vector to use as their small 
size means that less antigen is required in order to generate an immune response. In this 
study, mice were on a gluten-free diet to avoid the previously observed oral tolerance of 
gluten when inoculated with glutenin peptides (Ellis 1989). 
One of the main problems encountered in monoclonal antibody work is generating a 
sufficient immune response to stimulate antibody production in B-lymphocytes to obtain 
viable hydridoma cell cultures. Injected peptides have to be sufficiently immunogenic for 
this purpose. Peptides are generally by themselves too small to elicit an immune response. 
A number of methods have been used to increase the size of the immunogen either by 
conjugation to a carrier molecule or by the use of multiple antigen peptides (MAP). 
Conjugation to a larger carrier molecule can enhance immunogenicity, although this can 
lead to cross-reactivity and a diversion of antibody production which may need to be 
screened out later. The choice of carrier protein for conjugation is therefore important. 
Examples of candidate carrier proteins include purified tuberculin protein derivative (PPD), 
ovalbumin, bovine serum albumin, keyhole limpet haemocyanine and tetanus toxiod. 
Peptides in this study were conjugated to purified tuberculin protein derivative (PPD), 
using methodology that has been used to raise monoclonal antibodies to a toxic gliadin 
peptide (Ellis 1998). Another group has also managed to raise monoclonal antibodies to a 
number of gluten epitopes using tetanus toxoid conjugation (Mitea 2008). 
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Multiple antigenic peptides have a central core of branched poly-lysine residues with 
peptides of interest attached (Posnet 1989). There are several different types of MAPs 
based on the size of peptide used. Peptides shorter than 16 amino acids have eight branches 
whereas longer peptides can elicit a response with four branches. This format ensures the 
antigen is nearly pure due to the majority of the molecule consisting of the peptide (Tam 
1996). Serological responses using MAPs are enhanced compared to immunisation with 
conjugated peptides (McLean 1991). Several groups managed to raise monoclonal 
antibodies using the MAP format for the immunogen; however, the numbers of hybridomas 
seen was small and an even smaller percentage of these were actively secreting antibody 
(Kamo 1992, Brown 2000).  
To increase the immunological response, an adjuvant was used which also controlled a 
slower release of antigen into the mouse. Freund’s adjuvant is the most common adjuvant 
used for research. It is a water-in-oil emulsion prepared with non-metabolisable oils; 
complete Freund’s adjuvant (CFA) contains killed Mycobacterium Tuberculosis whereas 
incomplete Freund’s adjuvant (IFA) does not. Freund’s is one of the best adjuvants for 
stimulating strong and prolonged immune responses. However, the principle disadvantage 
of Freund’s adjuvant is that it can evoke very aggressive and persistent granulomas in the 
mouse. To minimise these side effects the primary injection is done in CFA with all 
subsequent injections in IFA. 
Chapter 4 demonstrates that both HMW glut04 and LMW glt156 peptides stimulated the 
innate immune system which then caused damage to coeliac disease small intestinal 
biopsies in vitro. At present there is no direct measurement of glutenin in gluten estimation 
using the “R5 Mendez” ELISA method. The aim of this particular study was to raise 
monoclonal antibodies towards HMW glut04 and LMW glt156 peptides using Balb-C mice 
in order to facilitate the measurement of glutenin component of foods by ELISA. This 
would allow a more accurate measurement of total gluten in foods, with the quantification 





Both HMW glut04 and LMW glt156 immunisation schedules ran in parallel to each other. 
Mice were immunised in groups of three using the protocol as described in section 2.7. 
These three mice were used to allow for variation in the immune response and for any 
adverse reactions to the Freund’s adjuvant potentially requiring culling. If the peptide used 
was conjugated to PPD, a BCG immunisation was carried out 2 weeks prior to 
immunisation with peptide in order to sensitise the mouse to PPD. The first injection was in 
complete Freund’s adjuvant (CFA) and a month later the second one was in incomplete 
Freund’s adjuvant (IFA). A tail bleed was performed 10-14 days after the IFA injection to 
assess the serological response (see section 2.7.4). 
The ELISA methodology used in this study was an established method already successfully 
running in the department. Initially the serum responses were screened on ELISA plates 
coated with Frazer’s Fraction III, a soluble peptic-tryptic digest fraction of gluten (see 
sections 1.9.1 and 2.7.4). However, due to unexpected reduced responses they were 
subsequently tested on peptic-tryptic digest of industrial gluten and recombinant peptic-
tryptic digested Dy10, a HMW glutenin subunit containing HMW glut04, or LMW glutenin 
MAP. Negative control serum was obtained from Balb-C mice at the time of cull, having 
previously been immunised with HLA DQ8 immunodominant peptide and found not to 
have mounted a serological response. The resultant optical density from the serum was 
multiplied by a factor of 2 in order to have a cut-off value for negative serum response. 
Positive control for HMW glut04 was serum of mice previously successfully immunised 
with recombinant HMW Dy10 by Dewar (2009) as part of his MD thesis. The HMW Dy10 
contains the HMWglut04 peptide being tested here. There was no positive control serum 
for the LMW glutenin peptide on test as none was available. 
Mice that demonstrated a good serological response, at least 1:6400 titre on ELISA (Ellis 
1989), were given an intravenous injection of peptide (50μg dissolved in 100μl 0.9% 
saline), between 2 and 10 weeks after the tail bleed as per home office regulations. They 
were culled using cervical dislocation three to five days later where the spleen was 
dissected and blood was collected (see section 2.7.6).  
A comparison of immunisation schedules for the different methods used in other papers 
mentioned in this chapter is summarised in table 5.1. Most of the other authors use a more 
aggressive intraperitoneal injection rather than the subcutaneous route for adjuvant 
174 
 
immunisation. The number of injections used to immunise mice using adjuvant also ranges 
from 4 (Spaenij-Dekking 2004) to 9 (Kamo 1992), as opposed to the 2 used in this schedule. 
Brown (2002) also uses 4 injections as an intravenous "booster" rather than the one used in 
this study. 
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MAP multiple antigen peptide, PPD purified tuberculin protein derivative, TTd tetanus 
toxoid, KLH keyhole limpet haemocyanin, sc subcutaneous, ip intraperitoneal, im 
intramuscular, ic intracutaneous, CFA complete Freund's adjuvant, IFA incomplete 





The high and low molecular weight glutenin peptides used for this study were chosen as a 
result of studies published prior to the start of this research, covered in section 1.12. Van de 
Wal (1999) demonstrated a region within the HMWG protein, HMW glut04, with higher 
activity using T-cell clones from a single patient. The peptide configuration with the second 
highest activity was used as this was the more stable peptide to make, according to protein 
chemists from GenScript (New Jersey, USA). The peptide used in MAP had to be changed 
as the chemists from Cambridge Peptides (Birmingham, UK) considered the original 
peptide, QGQQGYYPTSPQQSG, would form ring structures in MAP format and would be 
difficult to make. The peptide QPGQGQQGYYPTSPQ was used as a compromise, having 
the 5
th
 highest activity in van de Wal’s work. The LMW glt156 peptide used is known to 
stimulate 4 out of 16 T-cell clones in children (Vader 2002a). 
Cambridge Peptides supplied the multiple antigenic peptides while GenScript provided the 
peptides which were then conjugated to purified protein derivative from Statens Serum 
Institut (Copenhagen, Denmark). 
The bold amino acids are the minimum B-cell stimulatory epitopes while the underlined 
amino acids are the minimum T-cell stimulatory epitopes in humans (Mitea 2008). 
Multiple antigenic peptide of HMW glut04    (QPGQGQQGYYPTSPQ) x8 
Multiple antigenic peptide of LMW glt156    (PPFSQQQQSPFSQQQQ) x8 
Amino acids 721-735 of HMW glutenin, HMW glutenin 04 (HMW glut04) conjugated to 
purified tuberculin protein derivative    QGQQGYYPTSPQQSG 
Amino acids 44-59 of LMW glutenin LMW glutenin 156 (LMW glt156) conjugated to 






5.4.1 High molecular weight peptide immunisation: screening results 
Table 5.2 shows the serological responses as obtained from the tail bleeds (see section 
2.7.5) in the first three mice immunised with HMW glut04 as multiple antigen peptide 
(MAP) at a dose of 300μg per mouse. Initially the serological response was assessed on an 
ELISA plate coated with Frazer’s Fraction III (25μg/ml in carbonate buffer). As the titres 
were unexpectedly lower than anticipated, the same serum was tested on plates coated with 
a peptic-tryptic digest (PT) of the recombinant HMW Dy10 subunit which contained the 
peptide HMW glut04. This demonstrated an augmentation in the titre of antibody detected 
in all the mice.  
As all three mice had a positive result on PT Dy10 coating antigen ELISA. These three 
mice were immunised for hybridoma formation (see section 5.4.3, 2.7.6, 2.7.7, 2.7.8 and 
2.7.9). 
Due to poor hybridoma formation (see section 5.4.3), a further two mice were immunised 
with HMW glut04 MAP rather than three. This was due to a reduced litter size from the 
female Balb-C mouse and the need for parallel experiments with the LMW glt156 MAP 
immunisation. Sera were tested with both PT Dy10 and PT gluten to see if there was any 




Table 5.2 ELISA screening of serological response to high molecular weight glutenin 04 721-735 




















































FFIII Frazer’s fraction III, PPD purified proten derivative, (PT) Dy10 (peptic-tryptic digest 
of) recombinant Dy10 HMW glutenin subunit containing HMW glut04. Adult Balb-C 
mice, on a gluten-free diet, were inoculated with MAP format immunogen suspended in 
complete Freund’s adjuvant and a month later inoculated with MAP format immunogen 
suspended in incomplete Freund’s adjuvant. Tail bleed taken 14 days after incomplete 
Freund’s adjuvant subcutaneous injection with immunogen in MAP format and tested on 
both FFIII and PT Dy10 HMW subunit as coating antigen for ELISA. A positive result was 




Table 5.3 ELISA screening of serological response to high molecular weight glutenin 04 
721-735 (HMW glut04) multiple antigenic peptide immunisations in Balb-C mice numbers 


















































MAP multiple antigen peptide, PPD purified protein derivative, (PT) Dy10 (peptic-tryptic 
digest of) recombinant Dy10 HMW glutenin subunit containing HMW glut04, PT gluten 
peptic-tryptic digest of industrial gluten. Adult Balb-C mice, on a gluten-free diet, were 
inoculated with MAP format immunogen suspended in complete Freund’s adjuvant and a 
month later inoculated with MAP format immunogen suspended in incomplete Freund’s 
adjuvant. Tail bleed taken 14 days after incomplete Freund’s adjuvant subcutaneous 
injection with immunogen in MAP format and tested on both PT gluten and PT Dy10 
HMW subunit as coating antigen for ELISA. A positive result was considered a titre greater 
than 1:6400 therefore none of the results from the inoculated mice were considered to be 
positive. 
 
As the results with the MAP immunogen immunisations were disappointing, further 
immunisation was undertaken using HMW glut04 peptide conjugated to purified tuberculin 
protein derivative (PPD). The method had previously produced successful antibodies in this 
laboratory (Ellis 1993, 1994b, 1998). This required the immune system to be sensitised to 
the tuberculin protein with BCG vaccination two weeks prior to the scheduled 
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immunisation with CFA (see section 2.7.3). The results of these immunisations are shown 
in table 5.4. 
Table 5.4 ELISA screening of serological response to high molecular weight glutenin 04 
721-735 (HMW glut04) purified tuberculin protein derivative (PPD) conjugate 




















































PPD purified tuberculin protein derivative, (PT) Dy10 (peptic-tryptic digest of) 
recombinant Dy10 HMW glutenin subunit containing HMW glut04, PT gluten peptic-
tryptic digest of industrial gluten. Adult Balb-C mice, on a gluten-free diet, were inoculated 
with MAP format immunogen suspended in complete Freund’s adjuvant and a month later 
inoculated with MAP format immunogen suspended in incomplete Freund’s adjuvant. Tail 
bleed taken 14 days after incomplete Freund’s adjuvant subcutaneous injection with 
immunogen in PPD-conjugate format and tested on both PT gluten and PT Dy10 HMW 
subunit as coating antigen for ELISA. A positive result was considered a titre greater than 
1:6400 therefore none of the results from the inoculated mice were considered to be 
positive. 
 
None of these results were considered to be positive therefore, further mice pairs were 




Table 5.5 ELISA screening of serological response to high molecular weight glutenin 04 
721-735 (HMW glut04) purified tuberculin protein derivative (PPD) conjugate 




















































PPD purified tuberculin protein derivative, (PT) Dy10 (peptic-tryptic digest of) 
recombinant Dy10 HMW glutenin subunit containing HMW glut04, PT gluten peptic-
tryptic digest of industrial gluten. Adult Balb-C mice, on a gluten-free diet, were inoculated 
with PPD-conjugated immunogen suspended in complete Freund’s adjuvant and a month 
later inoculated with PPD-conjugated immunogen suspended in incomplete Freund’s 
adjuvant. Tail bleed taken 14 days after incomplete Freund’s adjuvant subcutaneous 
injection with immunogen in PPD-conjugate format and tested on both PT gluten and PT 
Dy10 HMW subunit as coating antigen for ELISA. A positive result was considered a titre 
greater than 1:6400 therefore none of the results from the inoculated mice were considered 
to be positive. 
Unfortunately there was a wild mouse infestation in the animal house during this 
experiment and therefore all subsequent experiments had to be abandoned. In conclusion, 
none of these results were positive.  
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5.4.2 Low molecular weight peptide immunisation screening results 
In parallel with the HMW immunisation schedule (section 5.4.1), Balb-C mice were also 
being immunised with LMW glt156 as the immunogen. The first immunogens, as for the 
HMW glut04 peptides, were in MAP format. Table 5.6 shows the serological response as 
obtained from the tail bleed (see section 2.7.4) in the first three mice immunised with LMW 
glt156 as multiple antigen peptide (MAP) at a dose of 300μg per mouse. Initially the 
serological response was assessed on an ELISA plate coated with Frazer’s Fraction III 
(25μg/ml in carbonate buffer) but as the titres were unexpectedly lower than anticipated the 
same serum was tested on plates coated with the MAP LMW peptide (50μg/ml in 60% 
ethanol) as there was no other LMW glutenin protein available.  
 
Table 5.6 ELISA screening of serological response to low molecular weight glutenin 156 








































LMW glt156 MAP low molecular weight glutenin156 multiple antigenic peptide, FFIII 
Frazer’s fraction III. . Adult Balb-C mice, on a gluten-free diet, were inoculated with MAP 
format immunogen suspended in complete Freund’s adjuvant and a month later inoculated 
with MAP format immunogen suspended in incomplete Freund's adjuvant. Tail bleed taken 
14 days after incomplete Freund’s adjuvant subcutaneous injection with immunogen in 
MAP format and tested on both FFIII and LMW glt156 MAP as coating antigen for ELISA. A 
positive result was considered a titre greater than 1:6400 and highlighted in grey. 
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The initial result on FFIII coating plate suggested there was a good serological response to 
the LMW glt156 MAP immunogen. As mouse 6 had died prior to the tail bleed it was felt 
that a dose of 300 μg in a mouse may be too toxic. Both mouse 4 and mouse 5 that survived 
went on to subsequent immunisation for hybridoma formation (see section 5.4.3). The 
serological response to subsequent immunisations with LMW glt156 MAP were repeated 
with half the dose of MAP and the results displayed in table 5.7. 
 
Table 5.7 ELISA screening of serological response to reduced dose low molecular weight 
glutenin 156 44-59 (LMW glt156) multiple antigenic peptide (MAP) immunisations in 





































300μg LMW glt156 
MAP 50μg/ml 
1:400 
LMW glt156 MAP low molecular weight glutenin156 multiple antigenic peptide. Adult 
Balb-C mice, on a gluten-free diet, were inoculated with MAP format immunogen 
suspended in complete Freund’s adjuvant and a month later inoculated with MAP format 
immunogen suspended in incomplete Freund's adjuvant. Tail bleed taken 14 days after 
incomplete Freund’s adjuvant subcutaneous injection with immunogen in MAP format and 
tested on LMW glt156 MAP as coating antigen for ELISA, FFIII was not used as it was felt at 
the time not to add any further value. A positive result was considered a titre greater than 
1:6400 and highlighted in grey. 
 
These results suggested that even at half the dose of immunogen the LMW glt156 was 
capable of evoking a good serological response with a further mouse dying soon after the 
tail bleed prior to subsequent immunisation for hybridoma formation (see section 5.4.3). 
Three further Balb-C mice were immunised with LMW glt156 MAP immunogen as initial 
hybridoma formation experiments failed to produce a hybridoma colony that secreted the 
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desired monoclonal IgG antibodyto LMW glt156 peptide (see section 5.4.3). The 
serological responses to these immunisations are shown in table 5.8. 
Table 5.8 ELISA screening of serological response to reduced dose low molecular weight 
glutenin 156 44-59 (LMW glt156) multiple antigenic peptide (MAP) immunisations in 


















































LMW glt156 MAP low molecular weight glutenin156 multiple antigenic peptide, PT gluten 
peptic-tryptic digest of whole gluten; un-interpretable means that there is no decrease in 
optical density with the doubling dilutions. Adult Balb-C mice, on a gluten-free diet, were 
inoculated with MAP format immunogen suspended in complete Freund’s adjuvant and a 
month later inoculated with MAP format immunogen suspended in incomplete Freund’s 
adjuvant. Tail bleed taken 14 days after incomplete Freund’s adjuvant subcutaneous 
injection with immunogen in PPD-conjugate format and tested on both PT gluten and 
LMW glt156 MAP as coating antigen for ELISA. A positive result was considered a titre 
greater than 1:6400 therefore none of the results from the inoculated mice were considered 
to be positive. 
 
Unfortunately mouse 14 had to be culled after the first injection with CFA as it developed 
granulomas. The serologic repsonse of mice 12 and 13 were difficult to interpret since there 
was no decrease in optical denisty on ELISA plates. A possible explanation for this could 
be that the branches of the LMW glt156 peptide in the MAP format trapped the antibodies 
thereby not allowing successful washing of unbound antibody off the plate. It should be 
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noted that the MAP was two years old at the time of testing the mouse sera for serological 
response. Hence it is possible that the structure of the MAP was compromised, or lost, 
causing problems in interpretation of ELISA results. 
As the results with the MAP immunogen form were disappointing, further immunisation 
was undertaken using LMW glt156 peptide conjugated to PPD. This required the immune 
system to be sensitised to the tuberculin protein with BCG vaccination 2 weeks prior to the 
scheduled immunisation with CFA (see section 2.7.3). The results of these immunisations 
are shown in table 5.9 
Table 5.9 ELISA screening of serological response to low molecular weight glutenin glt156 
44-59 (LMW glt156) tuberculin-purified protein derivative (PPD) conjugate immunisations 






















































LMW glt156 PPD conjugate low molecular weight glutenin 156 purified tuberculin protein 
conjugate, PT gluten peptic-tryptic digest of whole gluten; un-interpretable means that there 
is no decrease in optical density with the doubling dilutions.Adult Balb-C mice, on a 
gluten-free diet, were inoculated with PPD-conjugated immunogen suspended in complete 
Freund’s adjuvant and a month later inoculated with PPD-conjugated immunogen 
suspended in incomplete Freund’s adjuvant. Tail bleed taken 14 days after incomplete 
Freund’s adjuvant subcutaneous injection with immunogen in PPD-conjugate format and 
tested on both PT gluten and LMW glt156 MAP as coating antigen for ELISA. A positive 
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result was considered a titre greater than 1:6400 therefore none of the results from the 
inoculated mice were considered to be positive.  
There were similar issues with the optical density measured which failed to decrease 
despite doubling dilution of the sample. For these subsequent experiments washing was 
done by hand with 4 washes to try to overcome this problem in case it was due to poor 
washing technique with a multi-channel pipette. This suggested this might indeed be a 
systemic problem in the ELISA experiment. However, it was also encountered in 
subsequent experiments shown in table 5.10. 
Table 5.10 ELISA screening of serological response to low molecular weight glutenin 
glt156 44-59 (LMW glt156) tuberculin-purified protein derivative (PPD) conjugate 












































LMW glt156 PPD conjugate low molecular weight glutenin 156 purified tuberculin protein 
conjugate, PT gluten peptic-tryptic digest of whole gluten; un-interpretable means that there 
is no decrease in optical density with the doubling dilutions. Mice, on a gluten-free diet, 
were inoculated with PPD-conjugated immunogen suspended in complete Freund’s 
adjuvant and a month later inoculated with PPD-conjugated immunogen suspended in 
incomplete Freund’s adjuvant. Tail bleed taken 14 days after incomplete Freund’s adjuvant 
subcutaneous injection with immunogen in PPD-conjugate format and tested on both PT 
gluten and LMW glt156 MAP as coating antigen for ELISA. A result of 1:6400 was 




Unfortunately there was a wild mouse infestation in the animal house and therefore all 
subsequent experiments had to be abandoned. The results from mouse 20 and mouse 21 
were uninterpretable. 
5.4.3 Result of hybridoma formation  
Fusion experiments were undertaken between 2 and 10 weeks after the tail bleeds (see 
sections 2.7.6, 2.7.7 and 2.7.8) for mice numbers 1-4, 8 and 9 (see sections 5.4.1 and 5.4.2). 
All of these mice were immunised with MAP immunogen formats. The resultant 
hybridomas were maintained in culture (see section 2.7.8) and screened for antibody 
production by ELISA (see section 2.7.9). Unfortunately, mouse number 5 developed a 
lymphoma, a recognised complication of inbreeding to produce the strain of Balb-C, and 
had to be culled before any hybridoma fusions could be attempted. The results of the 
hybridoma fusion experiments are shown in table 5.11 with photographs depicting a 
hybridoma colony in HT medium in figure 5.1. 


































0/96 negative negative 
The intravenous injection for this experiment used high molecular weight glutenin 04 721-
735 (HMW glut04) peptide and low molecular weight glutenin glt156 44-59 (LMW glt156) 
peptide (50 μg in 100μl 0.9% saline). After fusion, the wells were inspected weekly to 
screen for any hybridoma formation. Once the hybridomas were identified, 100μl of the 
medium was removed, added to 20μl HEPES and screened for antibody secretion with PT 
Dy10 3.8μg/ml as the coating antigen for HMW glutenin antibodies and PT gluten 25μg/ml 
as the coating antigen for LMW glutenin antibodies. A result was considered positive if the 
optical density of the sample was at least twice the optical density of HT medium alone. A 
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sample was weakly positive if the optical density was one and a half time the optical 
density of HT medium.  
 
These results suggest that there is no IgG or IgM antibody formation against either 
candidate glutenin peptide. Mouse 8 had a very low titre of IgM towards the LMW glt156 
peptide however this would not have been enough to precipitate and collect for 
incorporation into an ELISA for the measurement of gluten. 
Figure 5.1 Photographs of hybridoma colony and dead splenocytes and myeloma cells in 
cell culture 
    
Dead splenocytes and myeloma cells   Large hybridoma colony 
 
5.5  Discussion 
This research group has previously successfully made monoclonal antibodies to various 
gliadin peptides (Ellis 1993, 1994b, 1998). However, they experienced considerable 
difficulties obtaining a serological response in mice to high molecular weight glutenin 
peptide by conjugating the peptide to purified tuberculin protein (PPD) (Ellis personal 
communication). This may have been in part due to the small size of peptide being used 
(Šuligoj 2011) despite conjugation to PPD. Peptide biochemists from the Cambridge MRC 
Research Laboratory, who first developed the technique of monoclonal antibody formation, 
suggested a trial of multiple antigenic peptides (MAP) as the immunogen, as at the time the 
evidence suggested an improved serological response (Brown 2000, Waldron 2002). 
However, these studies demonstrated a relatively poor hybridoma formation compared to 
our previous hydridoma production using PPD conjugates (Ellis personal communication). 
This seems to have been borne out in the present MAP immunisation experiments where 
initially a good serological response was achieved but very few hybridoma colonies were 
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seen. Those hybridomas which were produced failed to secrete IgG class antibodies, 
required for the stability of commercial ELISA tests. 
A single researcher performed all the mouse and the ELISA experiments using the same 
reagents and methodology. The only difference in these MAP format immunisations was 
the time. Initial mouse experiments with mice 1-9 were done with MAPs that were fresh at 
the start of the thesis. Subsequent experiments were done towards the end of the thesis with 
MAPs that were two years old. It was noted that these MAPs formatted peptides were a 
little more sticky than they had been in initial experiments. Little is known about the 
stability of MAP-formatted glutenin peptides. It may be that the stability of MAP peptides 
were affected and this is why there were good serological responses seen in mice 1-9 which 
were not see in subsequent mice immunisations with MAP-format peptides. 
Having tried different methodology using MAP-formatted peptides which did not raise 
monoclonal antibodies against both HMW glut04 and LMW glt156, immunisations with 
PPD-conjugated HMW glut04 and LMW glt156 peptides were attempted. The past 
attempts in the group had failed to raise monoclonal antibodies using PPD conjugated 
smaller glutenin peptides. It was felt that some of these difficulties could be overcome by 
increasing the peptide length to try to improve its antigenicity. This was not the case as 
bourne out by these experiments. 
Unfortunately there was a wild mouse infestation in the mouse facility. In every room there 
are a number of mice kept as health screening mice. They are culled every few months to 
screen for infections. While the health screening mice did not reveal any evidence of 
infection it is possible that the mice used in this study were contaminated. This may have 
meant that the immune response was directed towards the pathogen rather than the glutenin 
peptides. 
It is clear that the LMW glt156 in the MAP format is harmful to mice at high dose, with two 
out of the three mice immunised dying. Mice 1 to 3 as well as 6 to 9 demonstrated higher 
serological responses as measured by ELISA compared to mice 1 to 3 which were 
immunised with HMW glut04 MAP. Perhaps the lower dose used was too low to obtain a 
serological response. It is not clear why LMW glt156 should be harmful to mice. 
Another difficulty encountered in the attempt to raise monoclonal antibodies to LMW glt156 
was the lack of a good testing antigen. For HMW glut04 screening there was Dy10 HMW 
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subunit available containing HMW glut04 peptide, as well as positive mouse sera against 
this protein to use as a positive control. For screening LMW glt156 there was no similar 
coating antigen or mouse serum available. Autran et al (1987) demonstrated that the 
percentage of LMW glutenins in two different stains of durum wheat varied from 18% to 
27%. The coating antigen for the ELISA plates was PT gluten from industrial gluten: the 
percentage content of LMW glutenins is unknown. As this study shows, if the percentage 
LMW glutenin was low, the resultant signal from the ELISA could also be low. 
Antibody production requires T-cells to be primed and interact with B-cells. Vasconcelos et 
al (2004) demonstrated that the immunogenicity of B-cell epitopes in MAP format can be 
augmented by the combination of a universal T-cell epitope in tandem. The known B and 
T-cell epitopes in these glutenin peptides are human, not necessarily mouse epitopes, and 
are unlikely to contain a universal T-cell epitope. However, another group has successfully 
raised monoclonal antibodies to both these glutenin peptides used in this study (Mitea 
2008). Their methodology (Spaenij-Dekking 2004) differs considerably to the one used in 
this study, with much greater number of immunisations, at different sites. Brown et al 
(2000), who raised IgG class antibodies against JS30 (a vitamin K protein which is highly 
immunogenic) with MAP format, also differed in the methodology used. They used a total 
of 5 intracutaneous and intraperitoneal injections and had 4 intravenous "booster" injections 
to gain a small number of IgG secreting hybridomas. However, both methodologies were 
discarded as they would fail to pass through an animal ethics committee in the UK. Animal 
experiments in the UK are bound by the 3Rs; Reduction in the number of animals used, 
Refinement of techniques to minimise discomfort and Replacement of animals with in vitro 
models, where possible. Both studies (Spaenij-Dekking 2004 and Brown 2000) were 
performed outside the UK, so workers were not bound by the same Home Office rules for 
use of animals in experiments.  
Monoclonal antibodies raised in ascites have been banned and the number of injections has 
been limited to two by the Home Office. On this basis Kamo’s methods (1992, see table 
5.1) would not be approved in the UK due to the use of ascites as well as the large number 
of IFA immunisations.  
The use of Freund’s adjuvants in the present experiments was strongly discouraged, 
however available alternatives, such as TiterMax™, are only allowed for a single 
subcutaneous injection by King’s College London present animal ethics committee; this 
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may not be enough to generate an IgG class of antibody (product literature). As for the 
purposes of this thesis this class of antibody is required to generate stable ELISA reagents 
rather than IgM class antibodies the alternatives would not serve. 
Future directions could target different approaches. If MAP format was to be used then a 
universal T-cell epitope, such as tetanus toxoid, could be used in tandem with the peptide. 
At present this methodology has been used to improve the serological response in the 
development of vaccines. The use of TiterMax™ instead of Freund’s adjuvant, keeping the 
same protocol, may improve the serologic response seen, but may be difficult to pass the 
animal ethics committee. These two changes would mean the severity of the animal project 
would remain as “mild”. Another option could include increasing the severity of the project 
to “moderate” and increasing the number of IFA injections, although this is likely to be met 
with opposition in the Animal Ethics Committee at King’s College London, and the UK 
Home Office.  
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Chapter 6: General discussion and future directions 
 
 
6.1  General discussion 
Research into the immunostimulatory potential of glutenin proteins has been hampered in 
the past by problems obtaining pure glutenin samples. Glutenin reactive T-cell clones were 
isolated (van de Wal 1999, Vader 2002a). With improved extraction methods (Wieser 
2003), Dewar et al (2006) were able to demonstrate, with a mixture of chemically purified 
high molecular weight (HMW) glutenin subunits Dx5, Bx7, By9 and Dy10, T-cell 
stimulation in 11 out of 17 lines. Recombinant proteins Dy10 and Dx5 were tested by 
various groups using T-cell lines, Molberg (2003), Ellis (2006), and they found that in a 
minority of lines these proteins were immunostimulatory. Dewar et al (2006) as well as 
Ellis et al (2006) carried out in vivo studies instilling their HMW glutenin subunits, 
chemically purified or recombinant, into the duodena of coeliac patients and found a 
dramatic flattening of the duodenal mucosa starting an hour after the subunits were infused. 
These studies suggested that HMW glutenins were immunostimulatory in coeliac patients, 
although the exact disease-stimulating epitope remains to be characterised. 
The evidence for the immunostimulatory potential of low molecular weight (LMW) 
glutenin proteins was even less well established. Vader et al (2002a) tested novel T-cell 
epitopes in children, using T-cell clones, and found that a small number of clones extracted 
from a few coeliac individuals responded to two LMW glutenin peptides. These peptides, 
however, failed to stimulate the T-cell clones isolated from adult coeliac individuals.  
In demonstrating that the children do not react to the same epitopes as adults, Vader's work, 
in 2002(a) started a debate in coeliac research over the possibility that children and adult 
coeliac individuals respond to different epitopes. A theory has evolved that the range of 
immunostimulatory epitopes to which coeliac individuals will mount a response is reduced 
as they age, perhaps due to the focussing of the immune system to these epitopes. In my 
own thesis, the earlier in culture a sample was tested, the more immunostimulatory it was 
likely to be. Furthermore, the newly diagnosed coeliacs were more likely to have an 
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immunostimulatory T-cell response. Both these findings are consistent with the "epitope 
spreading and focussing" argument. 
Tye-Din et al (2010) further suggested that both HMW and LMW glutenin peptides were 
not immunostimulatory to T-cells from the majority of HLA-DQ2 positive coeliac 
individuals tested. This was a large study measuring peripheral blood lymphocyte 
interferon-γ secretion from coeliac individuals who had undergone a five-day gluten 
challenge. 
In this thesis, the results presented in Chapter 3 agree with those in Tye-Din's manuscript 
(2010) suggesting that glutenins are not major T-cell epitopes. T-cell responses are 
enhanced by deamidation of glutamine to glutamic acid in key QXP motifs (Vader 2002b). 
In both the HMW and LMW proteins, there are very few of these motifs present and none 
in the HMW glut04 and LMW glt156 peptides tested. This may explain why T-cells in the 
majority of coeliac patients tested failed to mount a response to these peptides. 
While the evidence was lacking for the HMW glut04 and LMW glt156 glutenin epitopes to 
be major T-cell epitopes, the results presented in Chapter 4 demonstrated that these 
peptides are capable of inflicting damage to the mucosa of not only individuals with coeliac 
disease but also type 2 refractory coeliac disease. This is the first study of its kind using the 
organ culture system to assess the coeliac toxicity of glutenin peptides in both coeliac 
disease and type 2 refractory coeliac disease. Exactly what is initiating the mucosal damage 
is unclear, however, Maiuri’s work (2003) highlighted the role of interleukin-15 in 
potentially triggering the innate immune response. My own work investigates this further.  
Chapter 4 demonstrates a process happening in the mucosa leading to a reduction in 
enterocyte cell height. It is likely to be independant of a T-cell response as three of the 
coeliac patients in Chapter 4 (SM4, SM10, SM15) failed to mount a T-cell response in 
Chapter 3 (SD20, SD50, SD63). This must be happening at the mucosal level. 
A-gliadin 31-43, the "innate peptide", has an unusual QQQXXXXQQ motif, where XXXX 
represent any amino acids, not commonly found in the known immunostimulatory gliadin 
epitopes, but found in the LMW glt156 peptide tested and the HMW glutenin subunits. In 
HMW glutenins there is a repeating sequence of QQGYY motifs. These amino acid 
sequences, as well as the lack of QXP motifs to favor deamidation, may well explain why 
the T-cells do not mount an immune response. 
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Zimmer et al (2010) found that in enterocytes there was delayed endocytic vesicle 
trafficking and maturation with A-gliadin 31-49 compared to other gliadin pepides. The 
group found that the "innate peptide" was present in endosomes in the luminal surface of 
the enterocytes rather than the basolateral surface, required for antigen-presentation to T-
cells. They suggest that A-gliadin 31-49 is not presented to T-cells in the lamina propria 
which explains why there is no T-cell response. However, another possible explanation 
could be that it is the failure to migrate through the enterocyte that causes up-regulation of 
IL-15. The peptide structure may well be the cause for the failure of endosomes to migrate 
through the enterocytes. This in turn may cause stress to the enterocytes which could 
express MICA on its surface via IL-15 and the enterocyte releases granzyme and perforin 
from exosomes which ultimately lead to its destruction. This may explain the enterocyte 
cell height changes seen with the glutenin peptides in Chapter 4. 
Chapter 4 further supports the idea that the immune response in the mucosa of coeliac 
disease is not just an adaptive one but also involves the innate immune system. Previous 
studies (Sturgess 1994, Fraser 2003) suggest that the activation of an immune response in 
coeliac disease occurs within the first hour of gluten ingestion. This would favour the 
innate response being the initial gut mucosal response in coeliac disease with the T-cell 
response occurring some time later and helping maintain the damage seen on histology. It 
also demonstrates that when assessing the immune response towards candidate epitopes, a 
T-cell response alone is insufficient to say that no damage will occur to the mucosa of 
coeliac individuals. 
Following on from this discovery, there was increasing evidence that glutenins should be 
included when assessing the gluten content in foods for individuals with coeliac disease. 
This thesis further supports the need to measure both gliadins and glutenins in the 
measurement of total gluten content in foods for individuals with coeliac disease. At 
present the way in which gluten is measured does not include a measurement of glutenins, 
the amounts of which is known to vary among different wheat cultivars and particularly in 
processed foods. Current assays are using monoclonal antibodies to measure a pentapeptide 
found in rye. By measuring different gluten components, HMW, LMW glutenins and 
gliadins, more accurate gluten measurement can be achieved. Unfortunately, due to the 
stricter experimental animal health regulations in the UK compared to other institutions this 
has made progress in this area difficult. In particular, the difficulties the regulations cause 
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6.2  Future directions 
6.2.1 Monoclonal antibodies production 
Because of the stringent regulatory experimental animal health regime alluded to above, 
monoclonal antibody production in the UK is unlikely to be competitive against its 
European counterparts. However, a number of alternative possibilities may be found to deal 
with that situation. Multiple antigenic peptides appear to work better when a universal T-
cell epitope, such as tetanus toxoid, is made in tandem with the B-cell epitope peptide. This 
strategy is currently being evaluated in vaccine design. The use of a different adjuvant such 
as TiterMax™ to replace Freund’s adjuvants might offer some benefit but as the 
manufacturer cannot guarantee an IgG response after a single injection this would need a 
change in protocol from “mild” to “moderate” in the animal licence. Incomplete Freund’s 
adjuvant could also be used in this case with an increased number of immunisations. 
6.2.2 The role of glutenins in the pathogenesis of coeliac disease 
The role of glutenins in the pathogenesis of coeliac disease should be investigated further. 
A number of interesting points were raised by this thesis and further investigational 
strategies are suggested below: 
1. Improving the organ culture experiments: This thesis has demonstrated the importance of 
testing candidate epitopes with both a T-cell response as well as an innate immune system 
response. Messenger RNA (mRNA) expression in the biopsies may be a better way to 
measure the IL-15 activation. Labelled monoclonal antibodies for HMW glut04 and LMW 
glt156 could be used with electron microscopy to see if the peptides are found in early 
endosomes rather than the late endosomes found in the transport of most gliadins. By 
combining the  IL-15 mRNA data with the electron microscopy data, this may help 
pinpoint the immune pathway involved in the villous atrophy seen on the biopsy 
specimens. Using Luminex multiplex assays for the analysis of the culture supernatants 
may increase the understanding of the cytokines secreted. However, because there is tissue 
present that contain many receptors, it may not be beneficial to clarify the precise 
pathogenic mechanisms involved. 
2. The role of HLA DQ8: Most coeliac epitope studies do not include HLA DQ8 patients as 
they are less common than HLA DQ2 patients. Mazzarella (2003) demonstrated that these 
patients have a different immunodominant epitope to HLA DQ2 patients. Vader (2002a) 
196 
 
and van de Wal (1999) both tested HLA DQ8 positive patients with demonstrating T-cell 
stimulation against HMW glut04 and LMW glt156 peptides. Very little is known on the 
disease course of these patients. The immunodominant HLA DQ8 epitope is not as 
immunostimulatory as the HLA DQ2 immunodominant epitope. This could suggest a more 
“benign” form of coeliac disease. Larger studies with this patient group are required in any 
epitope immunostimulatory testing. This may require participation between different 
hospitals and clinicians in the country to obtain sufficient results. It would also necessitate 
the HLA DQ status to be tested in every coeliac patient which, at present, is not routinely 
undertaken. This may change if the EPSGHAN diagnostic criteria are changed in the 
paediatric cohort as currently proposed.  
3. Further investigation of epitope focussing: Little is known about the potential change in 
epitope response in adults at initial diagnosis and then several years later, or those who 
were diagnosed early in life versus later in their adult life. Another potential study would be 
to study the epitope response of those patients in their first 6 months of diagnosis in their 
teenage years or twenties as opposed to those diagnosed in later life. The latter is becoming 
more common and it is these patients that are more likely to develop refractory coeliac 
disease. A longitudinal study including both small intestinal T-cell lines and organ culture 
systems looking at newly-diagnosed coeliac patients, young and older, over many years 
would be of benefit as little is published on the "epitope focussing" theory. It should 
include glutenin epitopes as well as the better understood gliadin epitopes to see what 
happens to the immune response at the beginning of a disease and further into it. 
4. The effect of glutenin epitopes on dendritic cells in coeliac disease: Very little is known 
about the role of dendritic cells in coeliac disease. A recent study suggested that the 
phenotype of dendritic cells was controlled by the concentration of tissue transglutaminase 
2 in the lamina propria (Dalleywater 2012). At low concentrations the dendritic cells acted 
more like sentinels sampling the antigens available but at higher concentrations these 
became much better at presenting antigen to the T-cells. We know that these glutenin 
epitopes are not major T cell epitopes but their effect on tissue transglutaminase 
concentrations as well as their role in dendritic cells would be interesting to discover. 
5. in vivo testing in coeliac patients: While in vitro testing is helpful to investigate further 
the immunostimulatory potential of any epitope these are artificially created conditions. In 
the 1980s Ciclitira et al used a Quinton Hydraulic capsule to take biopsies while instilling 
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into the duodenum of coeliac patients candidate toxic proteins and helped characterise 
further the coeliac disease epitope toxicity of α, β, γ and ω fractions of wheat gliadin. With 
the advances in immunology testing this could give real time immunological processes 
which could be sampled. However, the disadvantages are that it is an invasive technique 
which requires skilled clinicians and the Quinton capsule is no longer being made and 
repaired. While there are still a few of these in circulation it will not be long before this 
technique dies out. 
6. The role of glutenins in IBS: Jabri in a recent conference (International Coeliac Disease 
Symposium, Oslo 2011) suggested that in order to develop coeliac disease both the innate 
immune response and the adaptive immune response had to be triggered. If it was just the 
innate response being triggered then IBS-type symptoms on gluten ingestion were 
experienced. Gluten is a potentially toxic molecule to humans as with its high proline 
content human proteases find it difficult to cleave these proteins into smaller peptides. The 
larger the peptide size, the more likely it is to trigger an immune response. Gluten 
sensitivity is a common complaint amongst irritable bowel syndrome (IBS) sufferers, 
although they do not develop the villous atrophy seen in coeliac disease. This thesis 
demonstrates that HMW and LMW glutenin peptides are capable of generating an immune 
response in not only coeliac disease but also refractory coeliac disease. It would be 
interesting to put gluten-sensitive IBS patient biopsies in the organ culture system to 
determine if the triggering of the innate immune reponse by glutenin peptides may be 
observed. 
Some of these potential research projects would be difficult to implement. The Quinton 
capsule technology and experience is dwindling. It is also more invasive than an upper GI 
endoscopy and no longer routinely used in the diagnosis of coeliac disease. This makes 
patient recruitment difficult. Due to the paucity of HLA DQ8 coeliac patients, a multicentre 
research group would need to be established. This can be costly in time and resources and 
is unlikely to be easily attainable in a short time period. However, the changes occuring in 
the paediatric diagnosis may fascilitate this research in the future. 
Comparison of the immune repsonse to these glutenin peptides in gluten-senstive IBS 
against coeliac disease would be interesting. The most useful investigation strategy would 
be the combination of mRNA IL-15 measurement in organ culture biopsies after overnight 
incubation with the candidate peptides as well as the monoclonal antibody staining and 
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electron microscopy of the enterocytes. Commercially-made monoclonal antibodies may 
fascilitate this potential study. This research could help highlight further areas of interesting 
research as little is known about the enterocyte interaction with intra-epithelial cells in 
coeliac disease. This is likely to be the focus of coeliac immunology research groups in the 
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Appendix II: Materials 
 
T Cell Studies 
Autologous Plasma Culture Medium (50ml) 
 5ml autologous, heat inactivated serum 
 0.5ml HEPES (N-2-hydroxyethylpiperazine-N-2ethane sulphonic acid) buffer 
(H0887, Sigma) 
 0.5ml amphotericin B (0.25mg/ml, P11-001, PAA) 
 50µg Plasmocin (25μg/ml, ant-mpt, Source BioScience) (for prevention of 
mycoplasma infection) 
 44ml RPMI1640 medium with L-glutamine (E15-840, PAA) 
 
Organ Culture Medium (10ml) 
 8ml RPMI 1640 (E15-840, PAA) 
 0.1ml HEPES (H0887, Sigma) 
 0.1ml Amphotericin B (PAA) 
 10ul Plasmocin (Source BioScience) 






Formal saline (100ml) 
 0.9g sodium chloride (S9888, Sigma) 
 90 ml distilled water 
 10ml formaldehyde (BDH10113, VWR) 
 
1% v/v acid alcohol (100ml) 
 70 ml 74 OP ethanol 
 29ml distilled water 




Carbonate buffer (100ml) pH 9.6 
 159mg sodium carbonate (S2127, Sigma) 
 293mg sodium bicarbonate (S5761, Sigma) 
 100ml distilled water 
Double strength antibiotic medium (50ml) 
 46.5ml RPMI 1640 (PAA) 
 2ml Penicillin/Streptomycin (5,000u penicillin, 5,000g streptomycin/ml, 15070063, 
Invitrogen) 
 0.5ml Gentamicin (10mg/ml, 15710, Invitrogen) 
 1ml Amphotericin (PAA) 
 
Single strength antibiotic medium (50ml) 
 48.25ml RPMI 1640 (PAA) 
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 1ml Penicillin/Streptomycin (5000u/5000µl/m,  Invitrogen) 
 250µl Gentamicin (10mg/ml, Invitrogen) 
 0.5ml Amphotericin B (PAA) 
 
HAT medium (100ml) 
 20ml Foetal calf serum (A15-101, PAA) 
 2ml HAT (H0262, Sigma) 
 1ml Amphotericin B (PAA) 
 50µl Plasmocin (Source BioScience) 
 77ml RPMI 1640 (PAA) 
 
HT medium (100ml) 
 20ml Foetal cal serum (PAA) 
 2ml HT (H0137, Sigma) 
 1ml amphotericin B (PAA) 
 50µl plasmocin (Source BioScience) 
 77ml RPMI 1640 (PAA) 
 
Saturated ammonium sulfate solution 
 761g ammonium sulfate (A4915, Sigma) 




Appendix III: Reagents and Equipment addresses of suppliers 
 
Amersham Biosciences UK Ltd, Amersham Place, Little Chalfont, Buckinghamshire HP7 
9NA, UK 
Axis-Shield PoC, Kjelsasveien 161, Oslo, N-0884. Norway 
BDH Chemical Ltd, see VWR 
Bio-Equip, 304B Sanhang Mansion, 139 Pinjiang Road, Shanghai, 200032, P.R. China 
Bio-Optica, via San Faustino 58, I-20134 Milano, Italy 
Cambridge Peptides Ltd, 1 Phillip Victor Road, Birmingham, West Midlands, B20 2QB, 
UK 
Clin-Tech Ltd, Unit G, Perrham Works, Merrow Lane, Guilford, Surrey, GU4 7BN, UK 
Fisher Scientific UK Ltd, Bishop Meadow Road, Loughborough, Leicestershire LE11 5RG, 
UK 
GenScript USA Inc., 860 Centennial Ave, Piscataway, NJ 08854, USA 
Harlan Teklad, Shaws Farm, Blackthorn, Bicester, Oxfordshire, OX25 1TP, UK 
Health Protection Agency Culture Collections, Centre for Emergency Preparedness and 
Response, Porton Down, Salisbury SP4 0JG, UK 
Invitrogen Ltd, 3 Fountain Drive, Inchinnan Business Park, Paisley PA4 9RF, UK 
LEO Laboratories Ltd, Longwick Road, Princes Risborough, Buckinhamshire, HP27 9RR, 
UK 
MP Biomedicals, Inc. Rue Geiler de Kayserberg, Illkirch, 67402, France. 
Nunc A/S, Kamstrupvej 90, Postbox 280 DK-4000 Roskilde, Denmark 
PAA Laboratories, PAA-Strasse 1, 4061 Pashing, Austria 
PerkinElmer, Chalfont Road, Seer Green, Buckinghamshire HP9 2FX, UK 
231 
 
R&D Systems Inc, 614 McKinley Place NE, Minneapolis, MN 55413, USA 
Receptor Technologies Ltd, 23 Cross Street, Leamington Spa CV32 4PX, UK 
Scientific Laboratory Supplies Ltd (SLS), Orchard House, The Square, Hessle, East Riding 
of Yorkshire, HU13 0AE, UK 
Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorset BH12 4QH, UK 
Source BioScience UK Ltd, 1 Orchard Place, Nottingham Business Park, Nottingham, NG8 
6PX, UK 
Statens Serum Institut (SSI), 5Artillerivej, 2300 Coperhagen S, Denmark 
VWR International-Jencons Ltd, Hunter Boulevard, Magna Park, Lutterworth, 
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Appendix V: Photographs of some H+E 
stained slides from Chapter 4 
 
Duodenal biopsies were set in organ culture chambers 
for overnight incubation with various antigens before 
fixing in 10% formal saline and embedding in paraffin. 
They were then satined with H+E. 
Coeliac patients 
SM4: Coeliac patient HLA DQ8 with coeliac disease 
for 3 years. 
Medium-only magnification x2.5 
 




Peptic-tryptic digest of gluten 1mg.ml magnification x5 
 
HMW glut 04 200μg/ml magnification x5 
 














PT gluten 1mg/ml magnification x2.5 
 
HMW glut04 200μg/ml magnification x2.5 
 




SM6: Coeliac patient HLA DQ2 with coeliac disease 
for 4 years 
Medium-only magnification x1.07
 





PT gluten 1mg/ml magnification x2.5
 
HMW glut04 200μg/ml magnification x2.5 
 















PT gluten 1mg/ml magnification x2.5 
 
HMW glut04 200μg/ml magnification x5 
 




SM10: coeliac patient HLA DQ2 12 year history of 
coeliac disease 
Medium-only magnification x2.5 
 





PT gluten 1mg/ml magnification x2.5 
 
HMW glut04 200μg/ml magnification x2.5 
 




Type 2 refractory coeliac patients 
SM7: Type 2 refractory coeliac disease HLA DQ2 
coeliac disease for 24 years, RCD for 6 years 
Medium-only magnification x2.5 
 





PT gluten 1mg/ml magnification x2.5 
 
HMW glut04 200μg/ml magnification x2.5 
 




SM8: Refractory coeliac patient HLA DQ8 coeliac 
disease for 7 years and reftactory coeliac disease for 3 
years 
Medium-only magnification x2.5 
 





PT gluten 1mg/ml magnification x2.5 
 
HMW glut04 200μg/ml magnification x2.5 
 




Control group of non-coeliac patients 
SM14: investigation of IBS not HLA DQ2 or 8 positive 
Medium-only magnification x2.5
 





PT gluten 1mg/ml magnification x2.5 
 
HMW glut04 200μg/ml magnification x2.5 
 
LMW glt156 200μg/ml magnification x2.5 
 
